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Thesis Summary 
Thesis title 
Abdominal Aortic Aneurysms; Identification by Self-Examination and Analysis of 
Variation in Matrix Metalloproteinases with Peak Wall Stress. 
Introduction 
Abdominal aortic aneurysms (AAAs) cause 5,000 deaths a year in the UK.  Self-
examination for AAAs may provide an economic and practical solution.  Matrix 
metalloproteinase (MMP) concentration is elevated and levels of their natural 
inhibitors - Tissue Inhibitors of Matrix Metalloproteinases (TIMPs) are reduced at sites 
of AAA rupture.  Finite element analysis (FEA) of AAAs can define the area of peak 
wall stress area, the most likely site of rupture in engineering terms. 
Study 1 
Aim: To assess the effectiveness of self-examination for detection of AAAs compared 
to ultrasound measurement.  The psychological consequences were also evaluated. 
6,888(65%) of 10,591 male patients aged ≥65 years who were invited to participate, 
joined the study. 
The sensitivity of self-examination for all AAAs (≥3cm) was 37% and for clinically 
significant AAAs (≥5cm) was 49%. Specificities were 80% and 79% respectively. 
The psychological consequences of screening were assessed with the HAD (Hospital 
Anxiety and Depression) scale.  There was no clinical anxiety or depression but there 
was a statistically significant reduction in both domains on completion.  
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Self-examination for AAAs cannot be recommended as an effective screening tool. 
Study 2 
Aim: To assess the tissue concentration of MMPs & TIMPs in AAAs at the site of 
peak wall stress. 
22 patients undergoing elective AAA repair had FEA performed on their CT scans, 
identifying the peak stress site.  Biopsies from this site and the arteriotomy site were 
stored at -80°C, and tested for MMP & TIMP concentrations with an enzyme linked 
immunosorbent assay (ELISA). 
No significant difference was found between the 2 sites for MMP2, 8, 9, TIMP1 or 2.  
These findings suggest either that the peak stress and rupture sites are geographically 
different, or that the event of rupture is temporally related to a fundamental 
biochemical change. 
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1. Introduction 
1.1. Abdominal Aortic Aneurysms 
For many years Albert Einstein suffered with abdominal pain.  He eventually 
presented to Rudolph Nissen, then attending surgeon at Brooklyn Jewish Hospital, 
who diagnosed an abdominal aortic aneurysm.  Surgery was carried out in December 
1948 to wrap the anterior portion of the aneurysm in cellophane (it was thought too 
dangerous to mobilise the posterior aorta).  Einstein was discharged 3 weeks later and 
returned to work 6 weeks after this.  
In the early hours of Monday 18
th
 April 1955, six and a half years later, he died in 
Princeton Hospital after refusing further surgery, and is quoted as saying: “I want to go 
when I want.  It is tasteless to prolong life artificially.  I have done my share, it is time 
to go. I will do it elegantly.”(Cohen and Graver, 1990)  Thus ended the life of the 
greatest scientist of our time. 
1.1.1. Definition 
An abdominal aortic aneurysm (AAA) is a permanent, localised dilatation of all 3 
layers of the arterial wall in the abdominal aorta to at least 3cm. 
The word aneurysm is taken from the Greek term aneurysma – meaning a widening.  
In 1975, McGregor et al proposed a definition of an abdominal aortic aneurysm as an 
aorta with infra-renal diameter of at least 3cm(McGregor et al., 1975).  A later report 
by the Society for Vascular Surgery and the International Society for Cardiovascular 
Surgery Ad Hoc Committee on Standards in Reporting proposed as a criterion that the 
infra-renal diameter should be 1.5 times the expected normal diameter.  However the 
MD Thesis  MST Heng 25 
same report recognised that normal arterial diameter was variable, and determined by 
factors such as gender, age, and body habitus, and therefore a more practical definition 
was taken to be a 50% dilatation as compared to the adjacent normal portion of the 
same artery (Johnston et al., 1991).  Thus there is no definite consensus on the 
definition of abdominal aortic aneurysm; however conventionally, infrarenal aortic 
diameters of 3cm or more are diagnosed AAAs.   
Arterial dilatation below 50% is termed ectasia, and diffuse arterial enlargement of 
more than 50% above normal termed arteriomegaly.  If there is dilatation but it does 
not affect all 3 layers of the arterial wall, then it is termed a pseudoaneurysm.  Most 
aneurysms are fusiform – that is the entire circumference of the artery is affected, but 
where there is a localised bulge, this is called a saccular aneurysm.  Finally an 
inflammatory aneurysm has extensive perianeurysmal and retroperitoneal fibrosis, 
with dense adhesions to surrounding organs. 
1.1.2. Significance 
AAAs are significant because of their propensity to rupture.  They accounted for 
almost 5,000 deaths in England and Wales in 2005, over 95% of which were in people 
aged 65 and over (Office for National Statistics, 2005).  AAAs are commonly 
asymptomatic, and rupture is often the first indication of their presence.  Rupture is 
generally a catastrophic event associated with a highly significant overall mortality of 
between 65 – 85% (Kniemeyer et al., 2000, Thompson, 2003).  Indeed, about 50% of 
patients die before arrival in theatre(Scott et al., 1991, Wilmink et al., 1999). Ruptured 
AAAs are responsible for 1.5% of deaths in men aged 55 and above, and are the 
thirteenth most common cause of death in the Western world (Hak E et al., 1996). 
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1.1.2.1. Historic Significance 
Arterial aneurysms have been known since ancient times.  One of the earliest texts 
containing a description was the Ebers Papyrus, a 20 metre long internal medical 
reference, written 2000 years before Christ.  It described the association of aneurysms 
with trauma to the peripheries.  
The Ebers Papyrus was primarily an internal medical reference, and consisted of a list 
of some 876 prescriptions and remedies for ailments such as wounds, stomach 
complaints, gynaecological problems and skin irritations. Prescriptions were made up 
in proportions according to fractions which were based on parts of the eye of Horus, 
ranging from 1/64 to 1/2.  It also contained anatomical and physiological references 
Interestingly, and for some unknown reason, the scribe who wrote it did not finish the 
papyrus, and ended in mid sentence. 
Galen, a second century Greek surgeon who worked with gladiators and experimented 
widely on animals, described an aneurysm as a localised pulsatile swelling that 
disappeared on pressure and wrote “if an aneurysm be wounded, the blood spouted out 
with so much violence that it can scarcely be arrested.” 
Andreas Veaslius, a 16th century anatomist, first described an aneurysm of the 
abdominal aorta. 
In 1949, Rudolph Nissen stimulated periarterial fibrosis by wrapping cellophane 
around the symptomatic AAA of Albert Enstein, which eventually ruptured after 6 
years. 
Mr DeBakey treated a 70 year old King Edward VIII in 1965 for an abdominal aortic 
aneurysm.  “In an operation lasting little more than an hour, DeBakey cut out the 
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swollen part of the aorta--normally less than an inch in diameter at this point in the 
body, but now the size of a large grapefruit--and replaced it with a 4-inch length of 
knitted Dacron tubing.” The Duke of Windsor recovered without incident and lived 
until 1972, when he died of throat cancer aged 78. 
1.1.3. Epidemiology 
AAAs are predominantly a disease of the elderly male, with an incidence of between 
1.3% and 8.9% (Lederle et al., 2000, Lindholt et al., 2000c, Singh et al., 2001, 
Vardulaki et al., 2000), increasing with age to peak incidence at 80 years of age.   The 
disease is 4-5 times less common in women (Collin J et al., 1988) and also tends to 
start later at about 65 years of age.  A recent study of 10,000 men and 7,500 women 
with a history of cardiovascular disease or a family history of AAA found an incidence 
of AAA of 3.9% in these men and 0.7% in these women (DeRubertis et al., 2007).  
One of the most important risk factors for AAA is smoking, and it is postulated that 
the sex ratios will be less marked in the future due to the increasing incidence of 
smoking in women (Lederle et al., 2001, Singh et al., 2001).  It is also less common in 
Negro men with a 2.5 fold less incidence, and in Asian men (Spark et al., 2001). 
The incidence of AAAs is increasing as demonstrated by the 20-fold increase in the 
age-standardised death rate over the last 4 decades (Fowkes FGR et al., 1989), and a 
Swedish necropsy study revealed a clear increase in prevalence over this time 
(Bengtsson H et al., 1992).  An inverse relationship has also been shown between the 
decreasing prevalence of peripheral vascular disease and the increasing prevalence of 
AAAs (Coggon D et al., 1996). 
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1.1.4. Aetiology 
There are a numerous causes of arterial dilatation, but specific causes of AAAs such as 
connective tissue disorders (Marfan’s syndrome & Ehlers-Danlos type IV), 
inflammatory diseases (Takayasu’s & Behcet disease), acute infections (brucellosis & 
salmonellosis), chronic infections (tuberculosis), and trauma, cause a relatively small 
proportion of AAAs.  Most abdominal aortic aneurysms are called non-specific 
(Johnston et al., 1991). 
Severe atherosclerotic disease is seen affecting the aortic wall in most AAAs, therefore 
atherosclerosis was considered to be an important aetiological factor (Reed et al., 
1992).  However, this view has been challenged due to the difficulty in consolidating 
atherosclerotic occlusive disease with atherosclerotic dilatational disease (Tilson, 
1992, Xu et al., 2001).  It is likely that atherosclerosis is an associated factor rather 
than an instigating factor.  Atherosclerosis is primarily a disease of the intima, whereas 
aneurysmal disease primarily affects the medial layer of the artery.  Epidemiologically, 
patients with atherosclerotic occlusive disease present at an average age of 55 years, 
contrasting with an average age of 70 for aneurysmal disease (Millis et al., 1992).  It 
has also been suggested that patients with aneurysms tend to be taller and thinner than 
patients with occlusive disease, and may have generalised arteriomegaly (Tilson and 
Chau, 1981).  Various differences have been demonstrated between levels of protease 
inhibitors in occlusive and aneurysmal disease suggesting the divergent evolution of 
atherosclerotic plaque towards one or the other (Defawe et al., 2003).  
More recent evidence points to flow limitation inhibiting aneurysm dilatation and 
progression, with the suggestion therefore that atherosclerosis forms as a result of a 
change in luminal flow in AAAs rather than being an initiating factor (Hoshina et al., 
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2003).  Finally if the main causative factor in AAA formation was atherosclerosis, then 
some correlation would be expected between atherosclerotic severity and AAA 
development.  The Tromso study examined carotid, femoral and coronary 
artherosclerosis and compared this to AAA diameter, with no dose-response 
relationship seen, forming the conclusion that there was no evidence to support the 
case for atherosclerosis being a causal event in AAA formation (Johnsen et al.). 
Other contributing causes are wall stress, vibratory forces, and enzymatic imbalance 
(Millis et al., 1992). 
Arterial rupture is associated with connective tissue disorders such as Marfan’s 
Syndrome and Ehlers-Danlos type IV disease.  Marfan’s syndrome is associated with 
aortic dissection, and rupture rather than true aneurysms.  A genetic defect results in 
the production of a defective fibrillin glycoprotein, which forms a network in the extra-
cellular matrix for the deposition of elastin.  These networks are particularly abundant 
in the aortic media where weakness may result in aortic valve incompetence, and may 
predispose to intimal tearing, initiating an intramural haematoma, cleaving the layer of 
the media to produce an aortic dissection, occasionally proceeding from the root of the 
aorta to the iliac arteries, and eventual rupture.  This is the eventual cause of death in 
30-45% of individuals with Marfan’s.  In Ehlers-Danlos Syndrome type IV, defective 
type III collagen is produced which predisposes to spontaneous rupture of large 
arteries and intestines.  Ehlers-Danlos Syndrome type IV is a heterogenous group of 
disorders where 3 possible mutations affect the synthesis of type III collagen.  These 
can affect the rate of synthesis of the pro a1 chain; secretion of type III procollagen; 
and the synthesis of structurally abnormal type III collagen (Cotran RS et al., 1994). 
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1.1.4.1. Risk Factors 
Risk factors for AAA may be linked to AAA development, progression and rupture 
(Nordon et al.).  Smoking has been found to affect at least 2 of these stages.  Other risk 
factors for AAA include male sex, age, hypertension, chronic obstructive pulmonary 
disease, hyperlipidaemia, and family history of AAA (Lederle et al., 2001, Singh et al., 
2001, Vardulaki et al., 2000, Brady et al., 2004, Thompson et al., 2002). 
Smoking 
Strong associations have been shown between tobacco smoking and the development 
of aneurysms (Vardulaki et al., 2000, Brown and Powell, 1999, Blanchard et al., 2000, 
Lindholt et al., 2001a).  In fact the prevalence of AAAs in smokers is 4 times that of 
life-long non-smokers (Vardulaki et al., 2000).  This might be perhaps attributed to 
elevating the general risk of atherosclerosis, but a report has also shown that the 
relative risk of developing an AAA in chronic smokers is 3 times higher than for 
developing coronary heart disease and 5 times higher than for developing 
cerebrovascular disease (Lederle et al., 2003).  Smoking has therefore been cited as the 
single most important risk factor for the development and progression of aortic 
aneurysms (Sakalihasan et al., 2005).  AAA progression is also greater in current 
smokers than non-smokers (2.83mm per year vs 2.53mm per year, respectively)(Brady 
et al., 2004).  However the exact mechanism by which tobacco smoking promotes 
aneurysm formation is unknown, and continues to be investigated (Buckley et al., 
2004). 
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Family history 
The familial clustering of AAA was first reported in 1977 (Clifton, 1977), and patients 
with a positive family history have the highest risk of AAA formation.  A Canadian 
study found that siblings of AAA patient had 8 times the incidence of AAA compared 
to the siblings of their spouses (Ogata et al., 2005).  The incidence in first degree 
relatives has been shown at 15-19%, compared to 1-3% in unrelated patients 
(Kuivaniemi et al., 2003).  This same study demonstrated two inheritance modes, with 
72% of families being autosomal recessive, and 25% being autosomal dominant.  A 
suggestion has been made for a candidate gene on chromosome 19 (Shibamura et al., 
2004).  Despite the genetic inheritance, this clustering is also thought to be due in 
some part to environmental factors (Powell, 2003). 
With no clear evidence and conflicting studies on candidate-gene associations, 
genome-wide association studies were thought to be the way forward in finding the 
genetic component of AAA development (Sandford et al., 2007). This has revealed a 
single nucleotide polymorphism on chromosome 9p21 associated with AAA 
(Helgadottir et al., 2008).  Further studies are awaited (Aneurysm Consortium, 2008). 
Hyperlipidaemia 
The association between lipid level and AAAs remains unclear.  Studies have reported 
increased risk of AAA with increased serum cholesterol (Iribarren et al., 2007), but 
also the protective effect of increased serum HDL (Pleumeekers et al., 1995).  
Lowering of serum cholesterol levels with statins has been suggested to delay AAA 
formation, in a retrospective analysis of the Dutch AAA screening database (Schouten 
et al., 2006), however the Tromsø cohort study found that statin therapy increased the 
risk of AAA formation (Forsdahl et al., 2009).    
MD Thesis  MST Heng 32 
1.1.5. Presentation 
Most abdominal aortic aneurysms are asymptomatic and exist until found incidentally 
on routine examination or imaging – for example in ultrasound examination of the 
abdomen – or until the aneurysm ruptures. 
The most common symptom is abdominal pain, mostly epigastric but very variable, 
constant, boring or throbbing in character, and classically radiating to the back.  The 
location of the aneurysm can cause compression of adjacent structures, thereby causing 
symptoms such as weight loss due to relative gastric outlet obstruction secondary to 
duodenal compression.  Other presentations are flank and groin pain perhaps due to 
ureteric compression. 
Thrombus within the aneurysm can cause symptoms by distal embolisation, for 
example, acute lower limb ischaemia, or blue toe syndrome.  As most AAAs are 
asymptomatic it is no surprise that in the 1960s only about 50% presented at an 
asymptomatic stage.  However with improved imaging, and perhaps more accessible 
healthcare, about 80% are now diagnosed in the asymptomatic stage (Millis et al., 
1992). 
On examination, an AAA is palpated as an expansile mass midway between the 
umbilicus and the xiphisternum.   Occasionally a pulsatile mass is felt in this area due 
to transmitted aortic pulsation, overlaying mass, or perhaps due to the slight built of 
the patient. 
MD Thesis  MST Heng 33 
1.1.6. Investigations 
Physical examination 
Physical examination has been the main method of AAA detection for centuries, 
however it can very be inaccurate with sensitivities quoted from 29% in AAAs from 3-
3.9cm, through 50% in AAAs from 4-4.9cm, up to 76% in AAAs above 5cm in 
diameter (Lederle and Simel, 1999).  It often over-estimates size by 20% compared to 
intra-operative measurement (Brewster et al., 1977).   
Radiographs 
Lateral spine radiographs can be useful in the 75% of patients with some calcification 
in the aorta.  It does however involve a dose of radiation, and skilled interpretation by 
a radiologist.   
Ultrasonography 
Ultrasonography was reported to be reliable and useful as far back as 1977, and 
comments at that time related to the fact that it would under-estimate AAA size due to 
the difficultly in delineating the external wall.  Although this problem still exists to 
some extent, it is much improved due to improvements in technology particularly 
resolution and grey-scale displays, and does not present much of a problem to a skilled 
ultrasonographer.  Ultrasound examination does not involve radiation, is quick and 
painless and widely acceptable.  The ultrasonographer in most cases also can report it 
instantly.  The main problems with this technique include bowel gas and excessive 
obesity – both of which can prevent adequate visualisation of the aneurysm. 
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Aortography 
Aortography involves the use of radio-opaque dye, and radiation, is an invasive 
technique and requires time-consuming radiology reporting.  The radio-opaque dye is 
also nephrotoxic, although some centres use carbon dioxide angiography.  It is of value 
in operation planning, but as it demonstrates mainly the lumen of the AAA, it is 
limited in determining AAA size based on external wall dimensions, as both intra-
luminal thrombus and aneurysm wall thickness may hinder the acquisition of external 
dimensions.   
Computerised tomography 
CT imaging is more expensive than plain radiographs or ultrasonography, but provides 
detailed information regarding aneurysm geometry, internal and external diameters, 
thrombus, and relationships to neighbouring structures including the renal arteries.  
The information obtained can be reprocessed to form 3-D images, and can help to plan 
endovascular procedures. 
Magnetic resonance angiography 
This involves the use of gadolinium as contrast, but no xrays, and can be a problem in 
claustrophobic patients as it is commonly performed in a tunnel configuration.  It 
provides excellent soft tissue definition, and does not have a problem with penetrating 
bone, therefore giving particularly good images of the iliac arteries.  The scans are 
more expensive than CT scans, but these are increasingly being used in the planning 
stage prior to endovascular AAA repair. 
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1.1.7. Histology 
1.1.7.1. Structure of an artery 
The walls of large and medium sized arteries have 3 discernable layers – the intima, 
media, and adventitia.  Smaller arteries also have these layers but they tend to merge 
and are less discrete. 
The intima is the thin inner layer of the artery, and its main function is to facilitate the 
smooth, friction-free passage of blood in the arterial lumen.  It therefore mainly 
consists of flat endothelial cells.  These cells lie on a basement membrane and just 
beneath this is a layer of elastic fibres – the internal elastic lamina.  This is clearly seen 
in muscular arteries, but less clearly seen in elastic arteries like the aorta.  The other 
functions of the intima are to be watertight, but selectively permeable, and to withstand 
the shearing, tangential forces experienced by the walls with systolic flow.  The 
endothelium also modulates vascular tone via the synthesis and release of factors such 
as nitric oxide, prostacyclin, endothelin, and angiotensin II.  It is also responsible for 
the production and release of various growth factors, and cytokines.  The oxidation of 
low density lipoprotein (LDL) also occurs here.  
Depending on the position of the artery within the circulatory circuit, the media has 
different characteristics.  Large proximal arteries, have elastic characteristics which 
enable them to firstly withstand the systolic pressure wave without rupturing, and 
secondly to conserve the potential energy and retransmit this at the end of systole.  The 
distal arteries (about 1cm in diameter), have a more muscular aspect, controlled by the 
autonomic nervous system, which helps to control the preferential supply of blood 
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depending on conditions such as fright or flight, when blood is diverted to the 
musculature, and diverted from the gut. 
In an elastic artery – i.e. the aorta, the media is thick and consists of sheets of elastin 
fibres concentrically arranged throughout the thickness of the media (about 28-32 
layers in the infrarenal aorta).  The fibres are arranged circumferentially to best 
counteract the pulsatile blood flow.  Return of the artery to its un-stretched state during 
diastole results in a pressure of 60-80mm Hg within the larger vessels.  These medial 
elastic fibres take most of the stress applied to the arterial wall at physiological 
pressures (McMillan et al., 1997, Clark and Glagov, 1985).  Interposed within these 
elastin layers are smooth muscle cells and collagen fibre bundles.   
In a muscular artery (figure 1, below), the media is composed almost entirely of 
smooth muscle, which are arranged circumferentially at right angles to the long axis of 
the vessel.  In large muscular arteries there may be 30 or more smooth muscle layers, 
which can decrease to 2 or 3 layers in a small peripheral artery.  These arteries are 
therefore highly contractile.  A few fine elastic fibres are scattered amongst the smooth 
muscle cells, but are not arranged into sheets.  These are most numerous in the larger 
of these vessels, where they have continued from an elastic artery.    
The adventitia is composed largely of collagen, which takes the load when extra-
physiological pressures are experienced in the vessel (McMillan et al., 1997).  The 
adventitia of larger vessels also contains the vasa vasorum, small blood vessels from 
which small nutrient branches penetrate into the media.  In smaller vessels oxygen 
simply diffuses through the thinner walls to supply the media (Stevens and Lowe, 
1992b).  The adventitia is demarcated from the media in arteries by a condensation of 
elastic fibres that forms the variably distinct external elastic lamina. 
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 A medium sized artery wall (Kangasneime and Opas, 1997) Figure 1.
1.1.7.2. The Extracellular Matrix 
The extracellular matrix (ECM) is a complex structural network that provides cell and 
tissue support, helps form different tissue compartments, and provides a surface for 
molecular sieving and cellular regulation.  Extracellular barriers are formed by 
elements of the matrix; 
 Basement membrane: separating parenchyma & stroma 
 Interstitial stroma: separating blood vessels and lymphatics from organ 
parenchyma. 
The components of the ECM include the fibrous proteins, proteoglycans, and several 
glycopeptides. 
The 4 major proteins that form fibrils in the extracellular matrix are; 
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 Collagen; 
 Fibrillin; 
 Elastin; 
 Fibronectin. 
The ECM is normally impermeable to cells, but focal penetration can occur during 
healing, remodelling, inflammation, and neoplastic development.  Continual 
mechanical stresses require the maintenance of structural integrity and physical 
properties to prevent weakening of the vessel wall.  The processes that can be affected 
in order for permeability to occur are; 
 Cell/basement membrane attachment via cell surface receptors 
 Excess cellular secretion of proteolytic enzymes or the reduction of inhibitors 
 Tumour cell migration into the area modified by proteolysis. 
The degradation of the ECM is an essential step in the process of tumour metastases.  
ECM degradation is also a feature of some benign conditions including the 
arthropathies, vascular aneurysms, and atherosclerosis. 
1.1.7.3. Collagen 
The collagens type I – XI are a family of closely related proteins concerned with 
providing tensile strength to tissues.  They are the most abundant of the extracellular 
proteins, and are constructed of precursor proteins ( chains, of which there are more 
than 20 different types) wound together to form rigid linear triple helix structures in 
long filaments.  They are produced by fibroblasts  
MD Thesis  MST Heng 39 
Collagen type I-III are the main forms of fibrillar collagen.  This is formed from 3 
polypeptide ( chains), which are initially secreted with both carboxyl (COOH) and 
amino (NH2) terminals to prevent the formation of collagen in cells. These chains form 
a triple helix (procollagen), and cleavage of the carboxyl and amino extensions results 
in the functional mid regions (tropocollagen), which can now form long filaments 
(collagen microfibres).  Microfibres form fibres (figure 2 below) and fibres form 
bundles by tight cross-linking lysine residues between molecules.  Collagen molecules 
are 300nm long and are arranged with a 67nm overlap between adjacent molecules.  
The main forms of fibrillar collagen maintaining structural integrity in arterial vessel 
walls are types I and III (Melrose et al., 1998), but tensile characteristics are mainly 
due to type III collagen (Menashi et al., 1987).  
Type I collagen is found primarily in the adventitial layer and to a lesser extent in the 
medial layer of arteries, and consists of large, well-structured fibres providing 
structural integrity (Millis et al., 1992). 
Type III collagen, the predominant collagen in blood vessels, and is finer, more 
distensible then type I collagen, and forms a banded collagen fibre.  It is found mainly 
in the medial layer of arteries.  It also occasionally forms reticulin, thin fibres of type 
III collagen which form a mesh or scaffold for other components of the extracellular 
matrix. 
Type IV collagen is the predominant collagen seen in the basement membrane of 
blood vessels, and it forms a meshwork rather than fibrils.  
Finally type VIII collagen is seen in the endothelium of vessels. 
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Collagen is a highly stable protein, but it is in a continuous state of synthetic and 
degradative flux. 
 
 
 Collagen (www.SigmaAldrich.com) Figure 2.
1.1.7.4. Fibrillin 
The glycoprotein fibrillin is one of the components of elastin-associated microfibrils 
(EAMF), which are ubiquitous connective tissue structures, thought to act as a scaffold 
for elastin deposition, and to mediate adhesion between different components of the 
extracellular matrix.  It has been noted to decrease with moderate age in human aorta 
(Godfrey et al., 1993).   
1.1.7.5. Elastin 
Elastin (figure 3, below) is the main component of elastic fibres (which it forms with 
fibrillin) and has a random coil structure in a relaxed state that can stretch, but reforms 
in a different coil shape when relaxed again. This hydrophobic protein is produced by 
fibroblasts, and covalently linked molecules form fibres or sheets of elastin.  As elastin 
is secreted, fibrillin microfibrils organise it so as to form distinct fibres between the 
microfibrils (Stevens and Lowe, 1992a).  The half-life of elastin is 40-70 years, and it 
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is not synthesized in adults, which accounts for the reduction in elastin often seen with 
age.    
It is a major structural component of the abdominal aorta, mainly contained in the 
medial layer.  It is one of the most durable proteins of the extracellular matrix and 
requires the presence of specific proteinases (eg certain MMPs) for dissolution. 
 
 
 Elastin – relaxed and stretched states (Alberts et al., 2002) Figure 3.
1.1.7.6. Fibronectin 
This is a glycoprotein with the ability to bind a variety of substances including 
collagen, heparin, and specific fibronectin receptor proteins in cell membranes.  It can 
exist in a plasma protein form, a protein form that can transiently attach to many 
different cells, and an insoluble fibril form, with disulphide bond cross-links, which 
can form part of the extracellular matrix(Stevens and Lowe, 1992a). 
MD Thesis  MST Heng 42 
1.1.7.7. The abdominal aorta 
The abdominal aorta is the continuation of the thoracic aorta, emerging from the 
diaphragmatic aortic hiatus, in front of the 12
th
 thoracic vertebra, descending anterior 
to the lumbar vertebral bodies to the 4
th
 lumbar vertebra where it bifurcates into the 2 
common iliac arteries (Snell RS, 1992).  It is about 12-15cm in length, with support 
from the vertebrae posteriorly, the renal arteries superiorly (and to a lesser extent the 
suprarenal arteries and aortic hiatus of the diaphragm), anteriorly, the 3 visceral 
branches (celiac, superior and inferior mesenteric arteries), and the aortic bifurcation 
inferiorly.  In addition there is some support from the surrounding tissue/organ matrix.   
The normal diameter of the abdominal aorta varies with age, sex and bodyweight, and 
decreases rapidly from its entry into the abdomen at the aortic opening of the 
diaphragm progressively to the bifurcation to become the iliac arteries, due to the size 
of its branches.  Studies from cadavers have reported superior diameters between 9-
14mm, and inferior diameters between 8-12mm, with little differences between the 
sexes (Borley 2005).  In elderly men the diameter is between 15 and 24mm 
(Liddington and Heather, 1992).  The average diameter of the aorta is taken to be 
about 2cm in an average 65 year old man.  Following on from the definition of an 
aneurysm – at least 50% larger in diameter compared to normal segments – a size of 
3cm is taken as the minimum diameter of an aneurysm.  This would be expected to be 
smaller in women, and therefore a lower threshold may be applied.   
1.1.7.8. Structure of the abdominal aorta 
As with other arteries, the abdominal aorta has 3 main layers, with the main strength of 
the vessel coming from the medial layer.  This is composed of around 30 layers of 
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circumferentially arranged elastin fibres, together with collagen and smooth muscle – 
occasionally referred to as a lamellar unit.  These help the aorta to withstand the 
pulsatile nature of systolic blood close to the left ventricle, and also help to retain the 
energy contained in the blood flow, transferring kinetic energy from the blood flow to 
potential energy in elastin fibres and back again to the blood flow.  There is also some 
support from the external elastic lamina within the adventitial layer of the aorta, but 
hardly any support from the internal elastic lamina in the intimal layer.  Allowing the 
aorta to dilate or pulsate with systolic pulsation also enables the aorta to better 
withstand the systolic pressures of the blood transmitted within it as a rigid lumen 
would have to be stronger to withstand the same pressures.  However the strength of a 
normal healthy aorta has in-built redundancy, with wall strength much greater than 
required.    
The main mechanical properties of the aorta including its visco-elastic properties are 
determined by elastic and fibrillar collagens within the medial and adventitial layers.   
Elastin and collagen are arranged within the aortic wall to convey resistance to stretch.  
Most of the load at physiological pressures is taken up by the elastin within the medial 
layer of the arterial wall, and elastic deformation is seen, with the return to the pre-
stretched state after each pressure cycle (McMillan et al., 1997, Clark and Glagov, 
1985) 
Aortic wall also has to withstand wall shear stresses – the stresses that occur due to the 
flow of blood along the vessel wall.  2 main features ameliorate this stress, the smooth 
internal layer of the vessel – the intima, and the laminar flow of blood through the 
vessel.  This allows blood flowing through the middle of the lumen to flow more 
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quickly than blood along the periphery of the vessel – blood acting as its own 
lubricant. 
The blood supply to the medial layer of the aorta is via small vasa vasorum penetrating 
the adventitial layer(Millis et al., 1992). 
1.1.7.9. Abdominal aortic aneurysm 
The normal abdominal aorta dilates with age, and is the commonest site for an 
aneurysm. 
The normal histological architecture of the aorta is lost in aneurysms, with 
characteristic destructive remodelling of the elastic media, and outer aortic wall.  The 
media has scattered smooth muscle cells, fragments of collagen and elastin fibres, and 
thickened, less pliable type 1 collagen replaces the normal adventitial collagen (Millis 
et al., 1992).  In addition, the intimal layer is replaced by debris, with mural thrombus, 
cholesterol and calcified lipid. 
Investigations have emphasized disease mechanisms involving chronic wall 
inflammation, and the progressive degradation of fibrillar matrix proteins (Dobrin and 
Mrkvicka, 1994, Shah, 1997). 
Elastin content has been shown to decrease through a decrease in elastin cross-
links(decrease in high performance liquid chromatography (HPLC) demonstrated 
desmosines & isodesmosines).  The number of collagen cross-links seems to increase 
(HPLC demonstrated pyridinoline collagen cross-links), but the tissue content of 
collagen as demonstrated by characteristic amino acids 4-hydroxyproline, and 5-
hydroxylysine was shown to decrease, suggesting that old collagen accumulates cross-
links whilst new collagen biosynthesis is defective or reduced(Carmo et al., 2002). 
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Medial neovascularisation is more common in aneurismal aortas than in normal aorta 
or aortas involved in occlusive disease.  Furthermore this seems to correlate with areas 
of elastin degradation and chronic inflammation (Holmes et al., 1995). 
A study analysing the histological features of aneurysms, took biopsies from 21 small 
(4-5.5cm) and 45 larger aneurysms.  The histological feature most associated with 
enlarging diameter was a higher density of inflammatory cells in the adventitia.  This 
inflammation was non-specific with mostly macrophages and B lymphocytes.  Fibrosis 
of the adventitia provided compensatory thickening of the aortic wall as the aneurysm 
diameter increased (Freestone et al., 1995).   
It has been noted that the average number of lamellar units in human aorta is 28, which 
is far fewer than seen in other mammals.  In addition the number of vasa vasorum 
supplying the medial layer is less than expected from comparison of similar thickness 
arterial wall in comparable mammals.  It has been postulated that this results in greater 
tension per lamellar unit, and relative arterial wall ischaemia, with a propensity for 
degeneration and aneurysm formation (Zatina et al., 1984).  Porcine studies suggest a 
critical value of less than 40 lamellar units (porcine normal = 75) and an average 
tension of greater than 3 times normal (porcine) (4087 dyn/cm= 40mN/cm) lead to 
aneurysm formation.  Aneurysm formation was directly proportional to tension per 
unit and inversely proportional to number of lamellar units present(Zatina et al., 1984). 
Elastin associated microfibrils (EAMF) are ubiquitous connective tissue structures, 
thought to provide tensile strength and flexibility to numerous tissues by providing a 
framework for elastin deposition.  One of the components of EAMF is fibrillin, and a 
study looking at EAMF in normal human aorta by identifying fibrillin through 
immunohistochemical methods and mRNA levels, found decreasing levels with 
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increasing age in organ donor patients from 11 months to 44 years (Godfrey et al., 
1993). 
1.1.7.10. Thrombus 
The role of thrombus in AAA is uncertain, although in general the development of 
abdominal aortic aneurysms is associated with a mural thrombus, and it is seen in 75% 
of AAAs.  In contrast to arterial occlusive disease, blood flow is maintained in 
aneurysms leading to a constant remodelling of the thrombus and its components.  
Thrombus diameter has been potentially linked to the change diameter of aneurysms, 
through correlation with circulating plasmin-2-anti-plasmin (Lindholt et al., 2001b), 
together with plasma markers of fibrin formation and degradation (Yamazumi et al., 
1998).  A rapid increase in relative intraluminal thrombus (ILT) volume may be a 
better predictor of AAA rupture than AAA diameter (Stenbaek et al., 2000).   
Opinion varies regarding the effect of thrombus on aneurysm wall stress and strength 
and thus on aneurysm rupture potential.  Earlier studies showed that ILT decreased the 
peak stress by up to 30% (Inzoli et al., 1993), and other studies suggested that 
thrombus was mechanically protective (Vorp et al., 1996a), reducing mechanical stress 
transmitted to the arterial wall through a diffusing or blanketing mechanism (Mower et 
al., 1997, Wang et al., 2002).  However the failure to reduce the transmission of 
pressure and pressure transmission by a different mechanism have also been 
demonstrated (Schurink GW et al., 2000).  Wall stress is influenced by many factors 
including AAA diameter, length, wall thickness, luminal pressure, thrombus thickness, 
volume ratio, surface area ratio, elastic modulus and homogenicity. Of equal 
importance to AAA wall stress is AAA wall strength.  It has been demonstrated that 
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ILT reduces wall tensile strength, which is postulated to be due to a hypoxic 
environment, compensatory inflammation and local proteolytic activity (Vorp and 
Vande Geest, 2005).  Local hypoxia of the arterial media has been observed, with 
increased medial neovascularisation and inflammation (Vorp et al., 2001).  More 
recent work has provided a constitutive model for ILT derived from biaxial testing but 
clearly the impact of ILT rupture risk is a complex one and further work is required on 
AAA (Vande Geest et al., 2006b). 
ILT is also a source of proteases, with enrichment of MMP9 (gelatinase B) in the 
thrombus (Sakalihasan et al., 1996).  Polymorphonuclear neutrophils (PMN) within 
this, trap and store MMP9, which may represent another important role for ILT in 
AAA development and progression (Fontaine et al., 2002).  In addition, ILT contains 
plasminogen and its activator (u-PA), which in turn could result in local generation of 
plasmin, an MMP activator. 
1.1.7.11. Atherosclerotic plaque 
Inzoli (Inzoli et al., 1993) demonstrated calcified atherosclerotic plaque to be 
associated with elevated stress concentrations and an elevation in peak wall stress.  
This is presumably due to the higher stiffness of the plaque in comparison to the 
adjacent ‘normal’(without plaque) aneurysmal tissue, and the abrupt change in tissue 
characteristics at the boundary. 
1.1.8. Pathophysiology of AAA 
The primary abnormality in the formation of abdominal aortic aneurysms is alteration 
of the connective tissue in the vessel wall, namely the loss of elastin and smooth 
muscle cells from the medial layer of the artery, together with fragmentation of elastic 
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fibres (Powell, 1990, Baxter et al., 1992, Sakalihasan et al., 1993). This loss of elastic 
fibres seems to be an early event in aneurysm formation (Dobrin and Mrkvicka, 1994).  
White et al agreed, but they thought that the primary layer involved was the adventitia 
(White et al., 1993). 
The previously accepted hypothesis associated with these aneurysmal changes in the 
medial layer was postulated to be atherosclerotic related degeneration.  The intimal 
atherosclerotic plaque was thought to impair the medial blood supply resulting in 
muscle and elastin loss.  It was suggested (Mower et al., 1993), that vasa vasorum and 
other blood vessels in regions of increased stress may tend to be compressed and not 
provide nutrition to the vessel wall.  However this could apply to stress due to 
atherosclerotic plaque or to wall stress due to intraluminal pressure. 
Other evidence suggests that the loss of elastin is primarily due to an increase in 
proteolytic capacity.  Specifically, increased elastolytic activity has been observed in 
aneurysmal aortic wall compared to normal aorta (Busuttil et al., 1982), and in 
ruptured versus non-ruptured AAA regardless of size (Cohen et al., 1987). The matrix 
metalloproteinases are an important group of proteases with elastase activity amongst 
others, and they will be discussed in detail later.  This proteolytic process is hastened 
by the prostaglandins and proteolytic enzymes from infiltrating leucocytes, which also 
secrete growth factors stimulating angiogenesis and chemotaxis within the arterial 
wall.  Elastin loss leads to other components of the aortic wall being subjected to 
greater forces, and the tensile strength of the vessel is decreased.  The natural 
compensatory response is the laying down of extra excessive adventitial collagen, and 
thickening of the aortic wall.  The disruption of the extracellular matrix is associated 
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with a widespread inflammatory infiltrate (Koch AE et al., 1990), and decreased 
proteoglycan synthesis (Tamarina NA et al., 1998).    
In AAA, medial elastin loss results in arterial wall strength being dependant upon 
adventitial collagen and therefore final rupture occurs due to failure of this collagen 
layer (Dobrin and Mrkvicka, 1994).  Indeed increased collagen turnover has been 
demonstrated in human AAA (Satta et al., 1995), possibly consistent with the 
demonstration of collagen repair processes in animal models (Huffman et al., 2000).  
An imbalance in collagen homeostasis could lead to a catabolic state and aneurysm 
rupture. 
Vine and Powell demonstrated significantly increased gelatinase activity in the luminal 
aspect of the aortic media compared to control aorta.  Interestingly collagenase and 
stromelysin could be detected in homogenates of aneurysmal aorta (n=10), but rarely 
in atherosclerotic aorta (n=10) and never in control aorta (n=6), and collagenase 
activity was highest in the adventitial aspect of the aortic media (Vine and Powell, 
1991).   
1.1.8.1. Natural History 
Expansion 
The natural history of large abdominal aortic aneurysm is gradual expansion, which 
can lead to rupture (Vardulaki et al., 1998). 
An expension rate of 0.4cm/yr in untreated AAA until rupture was reported 
(Cronenwett et al., 1990).  A similar expansion rate of 0.33cm/yr was reported by the 
(UK Small Aneurysm Trial Participants, 1998b), in patients with AAA diameter 4.0-
5.5cm under surveillance.  (Vega de Ceniga et al., 2006) reported an expansion rate of 
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0.21cm/yr in AAAs 3-3.9cm in diameter and a rate of 0.47cm/yr in AAAs 4-4.9cmm 
in diameter.  Of the smaller group (3-3.9cm), they estimated that 2.4% of patients 
would reach 5cm within 2 years, and 17.6% within 5 years.  Of the larger group (4-
4.9cm) 55.8% would reach 5cm within 2 years, and 81.6% within 5 years.  They also 
admitted however that aneurysm growth wasn’t necessarily uniform with 25% of the 
smaller group and 18% of the larger group experiencing no expansion (0cm) at all 
during the mean follow-up time of 3.5 years.  This finding is in line with work by 
(Brady et al., 2004) which showed an AAA growth pattern characterised by growth 
spurts, stasis and aneurysm regression in 6.4% of cases. 
Rupture 
(Cronenwett et al., 1985) followed up a homogenous group of 67 patients with AAAs 
(diameter 2 to 7 cm) selected for conservative management for a mean time period of 
36 months, and found an annual rupture rate of 6%. 
Small aneurysms (4.0-5.5cm diameter) were found to have a 1% annual rupture risk 
(UK Small Aneurysm Trial Participants, 1998b), and AAAs at least 5.5cm in diameter 
(median 6.3cm, IQR 6-7cm) had an annual rupture risk of 9% (172 patients observed 
in the no-treatment arm of EVAR II had 23 ruptures over a median 3.3 year follow 
up)(EVAR trial participants, 2005a).  The overall annual risk of rupture in AAA with 
diameters > 6cm is estimated at 25% (Brown and Powell, 1999).  Independent factors 
associated with aneurysm rupture were found to be; female sex (3 to 1), larger initial 
AAA diameter, lower FEV1, current smoking status, and higher mean blood pressure.  
AAA repair is generally recommended when maximum diameter approaches / exceeds 
5-5.5cm.  At this size, the annual rupture risk is estimated to be 5%, thus roughly 
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equating to the mortality associated with open surgical repair (Dryjski et al., 1994).  
However studies have shown that this is often unreliable (Darling et al., 1977, 
Geroulakos and Nicolaides, 1992), and indeed small aneurysms have been shown to 
rupture (Choksy et al., 1999, Hall et al., 2000) and some large AAAs may not rupture 
given the life expectancy of certain patients (Darling et al., 1977).  The present 
situation is therefore not ideal and more accurate patient specific assessments of 
rupture risk are continuously being evaluated (Vorp, 2007). 
An autopsy study (Darling et al., 1977) at the Massachusetts General Hospital analysed 
24,000 consecutive, non-specific autopsies performed over a 23-year period (1952-
1975).  473 non-resected AAAs were found, of which 118 were ruptured.  Of 265 
AAAs 5cm in diameter, 34 had ruptured (12.8%), and of 194 AAAs >5cm, 78 had 
ruptured (40%). In addition 14 had no size recorded, and 6 (43%) of these had 
ruptured.  Interestingly they found that aneurysms of diameter between 4.1cm and 
7.0cm had a similar rupture rate of about 25% (4.1-5.0cm 23.4%, n=64; 5.1-7.0cm 
25.3%, n=83).  Aneurysms of diameter 7.1-10.0cm had a rupture rate of about 45%, 
and aneurysms with a diameter of more than 10.0cm, had a mortality rate by aortic 
haemorrhage of 60%.  It could however be postulated that measuring the size of these 
AAAs post rupture may have lead to an incorrectly low measurement for the diameter, 
however the repost suggested by the authors was that the AAA size during a surgical 
procedure after proximal aortic clamping was rarely less than the diastolic size (2-
4mm)(which they put down to calcification of the aortic wall).   
By retrospectively going through the patient notes, it was possible to ascertain survival 
times after onset of symptoms consistent with AAA rupture (severe back pain, acute 
abdominal pain, or collapse).  46% died within 6hrs, 57% within 24hrs, but 25% 
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survived longer than 6 days, and 6% survived longer than 6 wks (total group n=118, of 
which 14 length of survival not determined). 
Also of interest, there was no clear predilection for the site of rupture, but anterior and 
posterior surfaces seemed to experience the same number of events (18% each), and 
left and right, also about the same number (36% and 30% respectively).  However if 
the circumference of the AAA was split into thirds, the anterior third (roughly 
correlating with ruptures that may rupture into the peritoneum), would only account 
for 18% of ruptures (Darling et al., 1977). 
1.1.8.2. Progression of an aneurysm 
Hydraulic stress 
The angle of the aortic bifurcation varies widely, particularly in the elderly, and there 
has been speculation that the relationship between aortic size and shape is a possible 
causative factor in the development of AAA (Newman et al., 1971).  This is possibly 
because of reflected pressure waves, which occurs at junctions between vessels.  
Animal and post-mortem studies, have demonstrated that the magnitude of the wave 
was proportional to the diameter of the proximal aorta and inversely proportional to 
the diameter of the iliac vessels (Gosling et al., 1971). In this way the wave increased 
in intensity as the aneurysm increased in size.  This continued succession of waves 
increasing in magnitude with time would potentially result in progressive dilatation of 
the aortic wall.  (Shah et al., 1978) found no evidence to support the theory of distal 
aortic intimal trauma through pressure oscillations and turbulence associated with 
change in vessel diameter at the aortic bifurcation.  A ‘water hammer’ theory of direct 
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tangential lateral aortic wall stress has also been proposed where a retrograde, reflected 
wave hits an advancing, antegrade wave (Blakemore and Voorhees, 1954b). 
Vibratory forces 
Turbulent flow generated distal to the renal arteries was also proposed as a reason for 
aneurysm initiation.  This turbulent flow results in low frequency vibrations in the 
vessel wall (200 cycles per second), and this was demonstrated to be damaging to the 
medial layer of the artery in an experimental setting (Roach, 1963). 
Wall stress 
The law of Laplace states that wall tension is directly proportional to intraluminal 
radius and pressure in a perfect sphere with infinitely thin walls (Laplace, 1806). Using 
this principle, and applying it to the imperfect situation of an AAA, it would be 
reasonable to associate increased wall stress with increased rates of AAA expansion.    
1.1.9. AAA management 
1.1.9.1. Historical treatments 
Ligation 
The first AAA ligation was performed by Astley Cooper, a student of John Hunter.  He 
found that applying ligatures to proximal or distal ends alone was ineffective, but that 
ligating both proximal and distal sides of the aneurysm was better.  Not surprisingly 
however, the extremities were vulnerable to ischaemic damage. 
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Embolization with intraluminal wire 
In 1864 Moore inserted and left lengths of silver wire in a thoracic aneurysm to induce 
clot formation.  Corradi (1879) passed galvanic current through this wire, and this 
combined technique was adapted by various investigators including Blakemore & 
King (1938) who devised an accurate means of electrothermic coagulation.  A deposit 
of protein coagulum formed on wire, which stimulated clot production throughout the 
aneurysm.  Power demonstrated the same method in AAAs (1921). 
Periarterial fibrosis with cellophane 
The stimulation of periarterial fibrosis was attempted by using cellophane or other 
types of plastic film.  First developed by Harrison and Chandy (1943) to an aneurysm 
of the subclavian artery, then applied by Poppe and De Oliviera (1946) to syphilitic 
thoracic aneurysms, both with some success, but the method was very unpredictable.  
Rea introduced this technique to AAAs (1948), wrapping cellophane around the neck 
and anteriolateral surfaces of the AAA, and it was used by Nissen (1949) to treat the 
symptomatic AAA of Albert Enstein, who eventually ruptured after 6 years. 
Endoaneurysmorrhaphy (obliterative / restorative / reconstructive) 
Rudolph Matas, a New Orleans surgeon revived endoaneurysmorrhaphy (which simply 
means suturing of the inside of the aneurysm whilst in place) in 1888, when he treated 
a plantation worker (Manual Harris) who had sustained a traumatic brachial artery 
aneurysm after being shot with buckshot.  Proximal ligation or amputation was the 
usual treatment for false aneurysms at that time.  After initial intermittent compression 
therapy for 3 weeks, proximal then distal ligation, the aneurysm had not improved. 
“Being loath to subject a young strong man to amputation,” Matas eventually decided 
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to follow Antyllus’ procedure.  He opened the aneurysm, with an Esmarch tourniquet 
in place, and carried out intima-to-intima approximation of the 3 feeding vessels in the 
aneurysm with fine silk sutures. Harris subsequently did well, and was still in manual 
plantation occupation 10 years later.  This was Matas’ first obliterative 
endoaneurysmorrhaphy.  This form of endoaneurysmorrhaphy still precluded 
application to situations where the artery in question was necessary to prevent 
ischaemia. 
Matas also devised restorative endoaneurysmorrhaphy which he used for saccular 
aneurysms, and reconstructive endoaneurysmorrhaphy where he excised the diseased 
portion, and created a tunnel through the remaining normal portion.  Both of these 
allowed the artery to continue working, and allowed application to the aorta or other 
major arteries. 
Jose Goyanes (Madrid 1906) ligated popliteal aneurysms, then mobilised the adjacent 
popliteal vein which was used as an interposition graft via an end-to-end anastomosis.  
Alexis Carrel (1873-1948) was awarded the Nobel Prize in 1912 by formulating a 
technique in animals of replacing a segment of aorta with artery or vein.  Charles 
DuBost (1951) was the first to successfully replace aorta with freeze dried homograft 
(Dubost et al., 1952).  In 1953, Voorhees used a new synthetic fibre fabric graft called 
Vinyon-N (Blakemore and Voorhees, 1954a).  This proved to be a major innovation 
over the unreliable homograft, and heralded the start of the modern era of aneurysm 
repair. 
King Edward VIII was treated for an abdominal aortic aneurysm by DeBakey.  “In an 
operation lasting little more than an hour, DeBakey cut out the swollen part of the 
aorta--normally less than an inch in diameter at this point in the body, but now the size 
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of a large grapefruit--and replaced it with a 4-inch length of knitted Dacron tubing.” 
The Duke of Windsor recovered without incident and lived until 1972, when he died of 
throat cancer at age 78.  
The principle of relining rather than excising the diseased portion of aorta, led to 
endoaneurysmorrhaphy with intraluminal graft placement.  This was popularised by 
Creech and DeBakey. 
1.1.9.1. Medical management 
The medical management of AAA includes medical therapy to treat conditions that can 
contribute to aneurysm growth (eg hypertension, smoking, hyperlipidaemia) and 
medical therapy to treat conditions that can affect the health of patients and the risk of 
intervention for AAA (eg diabetes, heart failure, ischaemic heart disease).  
Some studies have demonstrated theoretical methods of reducing or decreasing the rate 
of aneurysm expansion, including by the use of Doxycycline, MMP inhibitors, and 
statins. 
Statins 
Hydroxymethylglutaryl-Coenzyme A reductase inhibitors (statins) are known to have 
pleiotrophic effects in addition to their lipid lowering function.  They have been shown 
to reduce aortic diameter and the number of AAAs in mice (Steinmetz et al., 2005).  
Retrospective analysis of the Dutch AAA screening database also suggests that statins 
delay AAA growth (Schouten et al., 2006).  An observational study of conservatively 
managed medium-sized AAA patients treated with or without statins also demonstrates 
reduced growth at 2 years and reduced AAA rupture rate at 4 years in those treated 
with statins (Sukhija et al., 2006).  Analysis of AAA tissue samples in patients treated 
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pre-operatively has shown a decrease in tissue MMP9 giving a possible mechanism to 
its protective effect on AAA development and progression (Evans et al., 2007).  In 
contrast however, the Tromsø cohort study suggested that statin therapy increased the 
risk of AAA formation (Forsdahl et al., 2009). 
1.1.9.2. Endovascular Aneurysm Repair (EVAR) 
1.1.9.2.1. The history of EVAR 
In 1992, Laborde in collaboration with Parodi reported a feasibility study of “intra-
luminal bypass of AAA” in 8 dogs.  An artificial aneurysm was created in each dog 
with Dacron, and a Dacron tube graft with integrated balloon expandable stents at both 
ends was inserted trans-femorally and expanded within the artificial aneurysm.  Early 
occlusion was seen in 2 dogs due to torsion of the graft, but 6 remained patent for 6 
months, with 4 showing kinking resulting from shrinkage of the artificial aneurysm.  
Trans-luminal bypass of AAA was concluded as possible in a dog model (Laborde et 
al., 1992).   
Parodi carried out the first endovascular abdominal aortic aneurysm repair by using 
balloon expandable stents sutured to the ends of a tubular knitted Dacron graft.  The 
friction seals established at the ends fixed the ends of the graft to the AAA wall and 
excluded the aneurysm from the circulation.  His study reported the treatment in 5 
patients, but recognised that further study and development were necessary before 
widespread use was possible (Parodi et al., 1991). 
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1.1.9.2.2. The aim of EVAR 
Endovascular AAA repair (EVAR) attempts to isolate the aneurysmal aortic segment 
from the circulation by deploying a covered stent-graft, which is inserted in a narrow 
deployment system via the femoral artery.  Once the aneurysmal segment is isolated 
then the aneurysm is depressurised and thus should not increase in size or have any 
propensity to rupture.   
1.1.9.2.3. The EVAR procedure 
EVAR is commonly carried out in a sterile operating theatre with radiological 
facilities.  This may be within the theatre suite or in a suitably equipped radiology 
department.  General or regional anaesthesia is administered with or without 
prophylactic antibiotics and a surgeon carries out vascular cut down to allow access to 
one or both femoral arteries, and achieves control of the vessel(s).  Occasionally the 
brachial artery can be used if access to the femoral arteries is difficult.  An 
endovascular catheter is then introduced and an on-table angiography carried out to 
establish and locate the desired landing zones for the stent-graft.  The deployment 
system with the appropriate pre-ordered stent-graft is then introduced under 
fluoroscopic guidance, and once in position, is deployed, again under close 
fluoroscopic scrutiny.  Further limbs of the stent-graft are inserted and deployed as 
necessary (eg for a bifurcated graft).  Completion angiography is performed to exclude 
primary type 1 endoleaks (see below).  The femoral artery/arteries are then repaired 
surgically and the incision closed. 
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1.1.9.3. Operative intervention 
1.1.9.3.1. Open AAA repair 
Current guidelines suggest that elective repair of AAA be offered at a diameter of 
5.5cm or above to patients in reasonable health (Brewster et al., 2003, Dryjski et al., 
1994).  Open surgery, consisting reconstructive aneurysmorrhaphy, with the insertion 
of an in-line synthetic vascular graft is associated with a mortality rate of 4-5% (Katz 
et al., 1992), but many patients have extensive or advanced co-morbid conditions, and 
will have mortality rates in excessive of the above quoted.  It is common practice to 
have a short period of high dependency nursing following surgery due to the high-risk 
nature of the surgery, and the general frailty of the patients involved. 
The average length of hospital stay following open AAA repair was 11 days (UK 
Small Aneurysm Trial Participants, 1998a).  The only factors associated with a longer 
length of hospital stay was lung function (positive association) and pre-operative 
physical function (negative association). 
1.1.9.4. Conservative management 
Some patients with significant co-morbidities are considered to be too high risk to 
undergo elective surgery, and are therefore managed conservatively.  In a series of 52 
such patients, 40% were dead at 1 yr, 75% were dead at 5 yrs, and all had died by 10 
yrs.  The cumulative percentage of ruptures increased as patients survived longer with 
43% dying of rupture in the first year, 46% at 5 yrs and 52% at 10 yrs.  There was 
significant association between rupture and size, in the 5-7cm AAA group 
approximately 50% of patients died of rupture whilst in the >10cm AAA group, 93% 
died of rupture (Darling et al., 1977). 
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1.2. Screening & Abdominal Aortic Aneurysms 
1.2.1. Principles of screening 
Screening has the aim of intervening at an early stage in disease, where significant 
improvement can be achieved, in order to prevent undesirable normal disease 
progression.  It thus seeks to improve the quantity and quality of life of the screening 
programme’s participants. 
Several standards are required to support the introduction of a screening programme 
(Wilson and Jungner, 1968, Gavin et al., 2007); 
 The disease should be an important health problem 
 The natural history of the disease should be reasonably understood 
 There should be a recognisable pre-disease or early disease stage 
 There should be an effective, safe, and acceptable test 
 The treatment should improve outcome and there should be additional 
improvement with treatment at the pre-disease or early disease stage 
 There should be evidence of reduction in mortality and morbidity in 
participants 
 The benefit from the screening programme should outweigh possible physical 
and psychological harm from the programme itself, diagnostic tests, and 
treatment 
 Costs and facilities needed have to be considered in context of other resource 
needs. 
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The health and well being of patients is perhaps the most important consideration of 
any screening programme.  Patients may be subjected to substantial physical and 
psychological harm from the most well intentioned screening programme.  Raising the 
possibility of a disease that had not been previously considered by the participants may 
induce significant anxiety, which may be prolonged by the time lag between test and 
final result. 
Diagnostic tests may be both invasive and traumatic (eg colonoscopy or fine needle 
aspiration (FNA) biopsy), thus careful consideration of the risk / benefit profile should 
be mandatory. 
The management of disease positive subjects needs specific consideration.  A 
proportion of such patients will merit urgent treatment, which may be associated with 
substantial morbidity, occasional mortality, and perhaps a prolonged incapacitated 
recovery period.  A second group of disease positive patients may not have sufficiently 
advanced disease to warrant treatment, but require continuous surveillance, which may 
be associated with its own specific problems i.e. anxiety / quality of life impairment 
(Lindholt et al., 2000a).  Finally there is a group of disease positive patients that are 
unsuitable for intervention, in whom diagnosis raises the permanent spectre of an 
untreatable disease.  Ideally, such patients should be excluded prior to commencement 
of the screening process, however precise selection of patients beyond a general target 
group can be extremely difficult. 
1.2.2. The case for AAA screening 
AAAs affect 5% of men aged 65 to 74 years old (Ashton et al., 2002) and are generally 
asymptomatic until they rupture or leak.  AAA rupture is associated with an 80% 
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overall mortality (Scott et al., 1995), accounting for 6800 deaths / year in the UK 
(Vardulaki et al., 2000).  In addition 4-5% of sudden death is due to ruptured AAA 
(O'Sullivan, 1996).  In contrast, elective AAA repair is associated with a 5-7% 30-day 
mortality (Bayly et al., 2001, EVAR trial participants, 2005b, National confidential 
enquiry into patient outcome and death, 2005).  
The main case for AAA screening therefore, lies with the fact that emergency AAA 
repair is dramatically more dangerous in terms of mortality and morbidity compared to 
elective AAA repair.  An AAA screening programme would result in the detection of 
AAAs at an asymptomatic stage when elective surgery is an option.   
The other main argument for an AAA screening programme is that AAAs are easily 
and reliably detected given the appropriate staff and equipment, utilising a test that is 
non-invasive and widely acceptable to patients. 
1.2.3. Problems with AAA screening 
Problems with AAA screening pertain to effects on the psychological health of all 
screening participants – in particular anxiety; 
 Healthy participants - between being invited to the programme (this raising the 
possibility that they have an AAA) and to having the test (patients can be 
informed straight away if they do not have an aneurysm) 
 Participants found to have an asymptomatic AAA < 5.5cm in diameter – 
undergoing lengthy surveillance of their aneurysm before potentially 
undergoing intervention 
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 Participants found to have a large (>5.5cm diameter) or symptomatic AAA 
having to await investigations before undergoing major surgery to repair their 
AAA.  
 Participants found to have a large >5.5cm AAA who are unfit to undergo 
elective repair and are thus burdened with the permanent spectre of an 
untreatable, unpredictable and potentially lethal disease. 
There are also substantial resource implications; 
 The screening programme involves the need for skilled ultrasonographers or 
vascular technologists, and ultrasound machines.  The test is relatively quick 
and simple, and the teams can be mobile, carrying out testing at local and 
accessible settings, but the number of patients involved still results in the need 
for substantial resources.   
 Screening for AAA would bring extra work to the vascular surgeons in terms 
of increasing the elective AAA repair workload.  This may be particularly 
intensive to begin with, but should reach a plateau level once the screening 
programme is established.  This increased workload has all kinds of service 
implications including the need for extra theatre space, equipment & staff, 
extra vascular wards, beds and staff, and extra clinics, vascular, anaesthetic and 
cardiology.  However, in time the screening programme should reduce the 
number of unpredictable emergency AAA repairs necessary, which require 
relatively more resources than elective surgery. 
 AAA screening results in the detection of a significant number of AAAs 
<5.5cm which require surveillance, a further resource consideration. 
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1.2.4. AAA screening studies 
The Birmingham Community Aneurysm Screening Project (Smith et al., 1993) invited 
3500 men aged 65-75 years for AAA ultrasonographic screening at their own general 
practitioner’s surgery.  2669 (76%) attended (52% inner city areas vs 90% suburbs), 
and 97.3% of scans successfully imaged the abdominal aorta.  219 patients (8.4%) had 
an aortic diameter of >2.9cm, and 79 (3.0%) with diameter >4.0cm were referred for 
vascular surgical assessment.   
Scott (Scott et al., 1995), randomised over 15,000 men and women aged 65-80 years to 
AAA ultrasound screening or non-intervention.  Of 7887 invited to screening 5394 
(68.4%) accepted, and AAA was detected in 218 (4%) participants and 7.6% of men.  
The relative risk of rupture was reduced by 55% in the screened group compared to 
controls. 
Lindholt (Lindholt et al., 2005) carried out a randomised controlled trial of AAA 
screening involving 5 hospitals within the county of Viborg, Denmark, between 1994 
and 1998.  They randomised more than 12,000 men aged 64-73 years to either 
ultrasonic AAA screening or non-intervention.  AAAs with diameters > 5cm were 
referred to vascular surgeons, whilst AAAs with diameters between 3-5cm, and 2.5-
3cm were rescanned at 1 and 5 years respectively.  Outcome measures included AAA 
specific mortality, overall mortality, number of elective and emergent operations for 
AAA, and number of ruptured AAAs.  Over 6,300 patients (50.1%) were randomised 
to screening, of which 76% attended.  44 scans (0.7%) were unsuccessful in measuring 
the aorta and identifying or excluding an AAA.  The incidence of AAA in the screened 
group was 191(4%), of which 24 (0.5%) had an AAA≥5cm.  There were 9 deaths due 
to AAA in the screened group compared to 27 in the unscreened group (p=0.003), and 
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total deaths were 939 in the screened group compared to 1019 in the unscreened group 
(p=0.053).  The number of ruptured AAAs was also reduced in the screened group (8 
versus 29 ruptures, p=0.001).  Mean follow up was 52 months.  During the first 18 
months aneurysm related deaths were the same in both groups.  It was calculated that 
32 life years were gained from AAA related deaths after offering screening to 6333 
men during the first 5 years, and this was estimated by extrapolation to 107, and 158 
life years at 10 and 15 years respectively.  The number of patients required to be 
screened to save 1 life was 352. 
A study carried out in Western Australia (Norman et al., 2004, Spencer et al., 2004) 
randomised 41,000 men aged 65-83 years of age to either ultrasonic AAA screening or 
no intervention.  Attendance was 70% in the screening group, the incidence of AAA 
>3cm was 7.2% and of AAA >=5.5cm was 0.5%.  Elective AAA repair was twice as 
common in the screened group than in the no-intervention group (107 vs 54, p=0.002).  
Between screening and end of follow up (5 years) 18 men in the screened group and 25 
in the control group died from AAA (mortality ratio 0.61, 95% CI, 0.33 to 1.11).  
Benefit (mortality ratio 0.19, 95% CI, 0.04 to 0.89) was confined to the younger age 
group cohort (65-75 years).  The authors concluded that national screening for the age 
group 65-83 years was not effective, and that a more select age group, with exclusion 
of inappropriate patients may make screening effective. 
The Multicentre Aneurysm Screening Study (MASS) involved more than 67,000 men 
aged 65-74 years of age and demonstrated that AAA screening with abdominal 
ultrasonography results in a relative reduction in AAA rupture of 49%, and in AAA 
related mortality of 42% (from 0.33%) through early detection and surgical 
intervention (Multicentre Aneurysm Screening Study Group, 2002a).  Cost 
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effectiveness analysis of the MASS study (Multicentre Aneurysm Screening Study 
Group, 2002b), showed the cost of a quality-adjusted life year (QALY) to be £36,000 
over the four years of the study although they estimated that the cost would reduce to 
£10,500 per QALY after 10 years of running the screening programme at national 
level (full costs of screening analysed including costs for elective and emergency 
intervention).  They stated that although the costs as calculated at 4 years were at the 
margins of acceptability to the NHS, the estimated costs at 10 years would be 
acceptable.  The latest analysis from the MASS group states the cost per QALY at 10 
years to be £7,600 (95% CI: £5,100 - £13,000) (Thompson et al., 2009), and that 
screening continues to have a relative risk reduction in AAA related deaths of 48% 
compared to the control group at 10 years.  The incremental cost per man recruited to 
the programme at this stage is £100.   
A more recent Danish study calculated the cost per QALY of AAA screening to be 
£43,500 (Ehlers et al., 2009), and concluded that AAA screening was not cost effective 
and would probably not be acceptable to health systems valuing a QALY at £30,000 
(the UK NHS).  Their calculations were based on a computerised analytical model 
which used data from other studies, and AAA outcome data from the Danish vascular 
registry.  Data from their study suggested that at 5 years after the introduction of 
screening, the screened group would still have higher aneurysm related mortality 
compared to the non-screened group.  It would be 8 years after the introduction of 
screening when aneurysm related mortality would be similar between the groups.  
Their conclusions however were still based on were also based on 5 years of screening, 
rather than the more recent report of the MASS study which looked at 10 years of 
screening data.  Increased screening time is associated with ongoing potential benefit 
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from increased survival in the intervention group, and also discounts on screening and 
service costs.  In fact the earlier cost effectiveness analysis of the MASS study 
(Multicentre Aneurysm Screening Study Group, 2002b) carried out at 4 years of 
screening showed a QALY as costing £36,000 – not too dissimilar to this study.  
1.2.5. Screening for AAA in the US 
Routine screening for AAA has been recommended by various organisations in the 
United States including the United States Preventative Services Task Force, American 
Heart Association / American College of Cardiology, the Society for Vascular Surgery 
and Society for Vascular Medicine in the United States (Pande and Beckman, 2008).  
The prevalence of AAA amongst smokers is up to 5 time that amongst non-smokers 
(Lederle et al., 2000), a much stronger association than that of coronary heart disease 
(Lederle et al., 2003).  Smoking and AAA also demonstrates a dose dependent 
relationship, which increases with number of years smoked, and number smoked per 
day, and decreases with number of years after quitting (Lederle et al., 1997).  The US 
Preventative Task Force modelled the potential benefits of screening based on 
smoking status and determined that screening a hypothetical group of men aged 65 
who were smokers would detect 89% of AAAs in this group (Fleming et al., 2005).  
Based on this data, the US Preventative Task Force recommend one time duplex 
screening for AAA in men aged 65-75 years of age who have ever smoked.  Despite 
the possible benefits in mortality reduction in similar aged men who have never 
smoked, due to the reduced prevalence of AAA, there is no recommendation for 
screening for AAA in this group.  In contrast there is a specific recommendation 
against screening for AAA in women from the Preventative Services Task Force 
(Fleming et al., 2005). 
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The Centres for Medicare and Medicaid Services in the United States have thus agreed 
to fund one time duplex screening for AAA in men aged 65-75 years of age who have 
ever smoked, or men or women more than 60 years of age with a family history of 
AAA (Pande and Beckman, 2008). 
1.2.6. The NHS AAA screening programme (NAAASP) 
The NHS AAA Screening programme (UK national screening committee, 2009) was 
announced on 4 January 2008 by the Secretary of State for Health, and has started at 
early implementation sites.  The programme will continue to roll out throughout the 
UK until 2012/3 at which time it is anticipated there will be up to 60 operational 
centres, covering all 270,000 men aged 65.  The aim of this screening programme is to 
reduce the mortality from ruptured AAA in the population of men aged 65 and over.  It 
will seek to identify asymptomatic AAA through ultrasonography of all 65 year old 
men, with older men able to self refer via their general practitioner.  All men with 
aortic diameters below 3cm will be discharged.  Ultrasound surveillance will be 
carried out on all participants with aortic diameters from 3-5.4cm, and participants 
with aortic diameters 5.5cm or above will be referred to a vascular surgeon. 
1.2.7. Methods of AAA detection 
Physical examination by doctor 
Physical examination by a doctor is the traditional method by which AAAs are 
detected, however sensitivity & specificity varies between 33-100% (Allardice et al., 
1988, Arnell et al., 1996) and 44-100% (Allardice et al., 1988, Cabellon et al., 1983) 
respectively. The largest study of physical examination to date, involves patients in a 
general practice setting, and consists of 4171 patients.  This quotes a sensitivity of 
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42%, but has no details of specificity, and has a rather low prevalence of AAA of 0.6% 
reflecting the fact that a rather young age range was involved - 45-69 years (Zuhrie et 
al., 1999).  A meta-analysis involving 2955 patients with an AAA prevalence of 6.5% 
despite the age range of 17-90 years, demonstrated a sensitivity of 39%, which 
improved to 76% in AAAs ≥5cm in diameter (Lederle and Simel, 1999).    
We studied the value of doctor and directed self-examination via a simple 4 stage 
process in a group of patients with known AAA, controlled with a group of patients 
attending the vascular laboratory for carotid duplex scanning.  This showed a 
sensitivity of 88% on blinded examination by a doctor, and 86% in un-blinded patients 
following an instructional self-examination sheet.  In AAA >5cm the sensitivity of 
doctor examination was 98%, and patient examination 93%, with specificities 64% and 
69% respectively (Venkatasubramaniam et al., 2004c).  
1.2.8. Study aim 
Our aim was to assess the effectiveness of directed self-examination in the detection of 
clinically significant (5 cm) AAAs in a blinded community population, and to assess 
the psychological consequences of this study. Our secondary aim was to assess the 
effectiveness of tandem 2nd person examination in the detection of clinically 
significant AAAs, and the overall effectiveness of self and tandem examination in the 
detection of all AAAs (3cm). 
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 [normal stress] = F [force] / A [area] 
1.3. Biomechanics & Abdominal Aortic Aneurysms 
1.3.1. Biomechanics 
Biomechanics is the study of the mechanics of living organisms with the application 
and derivation of engineering principles. 
In order to examine the biomechanics of AAA,  it is necessary to understand some of 
the engineering principles involved in material and structural science.  
1.3.1.1. Stress 
Stress is a measure of force per unit area.  It is normally separated into normal (also 
called axial) and shear components.  Normal stress is defined as the force 
perpendicular to the cross sectional area of the member divided by the cross sectional 
area (figure 4, below).  It is often symbolised by the Greek letter sigma (). 
 
 Definition of stress Figure 4.
Axial stress is the equivalent of pressure in a liquid or gas, and the units are force / unit 
area (Newtons/m
2
, also known as pascals (Pa)).  As with force, stress cannot be 
measured directly and is therefore inferred from strain measurements, and knowledge 
of the elastic properties of the material.   
Static fluids can support normal stresses, but will flow if subject to shear stress.  In 
solids, ductile materials will fail under shear stress, and brittle materials will fail under 
normal stress.   
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1.3.1.2. Strain 
When a load is applied to a material, it experiences a force (or stress when measured 
per unit area), and deforms.  This deformation initially occurs in a reversible fashion 
which is often nearly proportional, (figure 5, below) up to the yield strength, later in a 
non-reversible, non-proportional fashion up to the ultimate strength, and finally 
undergoes fracture.  This deformation - the change between initial and final state - is 
referred to as strain.  The actual shape of the stress/strain curve depends on the 
characteristics of the material involved. 
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yp yield point, u ultimate strain, f fracture, ys 
yield strength, uts, ultimate strength 
 
 Stress/strain curve Figure 5.
1.3.1.3. Material strength 
The definitions of strength are; 
 Yield strength: The stress a material can withstand without permanent 
deformation. 
 Ultimate strength: The maximum stress a material can withstand. 
 Breaking strength: The stress coordinate on the stress-strain curve at the point 
of rupture. 
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1.3.1.4. Deformation 
Elastic deformation 
The initial deformation of a reversible, manner is referred to as elastic deformation.  In 
the aorta this reversible deformation would be due to elastin fibres in the medial layer 
stretching from its resting random coil structure before returning to a different random 
coil structure of about the same initial length once relaxed. 
Plastic deformation 
The second phase of deformation that occurs is referred to as plastic deformation 
where there is non-reversible deformation of the material.  In the aorta this would be 
mainly due to collagen contained in the outer adventitial layer.  
1.3.2. Stress Distribution and the AAA 
Law of Laplace 
Early estimations of AAA wall stress used the law of Laplace, also referred to as the 
Young-Laplace equation, =P*r/t where , circumferential wall stress; P, intraluminal 
pressure; r, vessel radius; t, thickness of vessel wall (Stringfellow et al., 1987).  This 
stated that the stress experienced by the wall was proportional to the stress within, the 
radius (or diameter) of the vessel, and inversely proportional to the thickness of the 
wall.   
However the Law of Laplace was developed to describe the pressure difference over a 
meniscus between two fluids (Marquis de Laplace, 1806).  Thus it assumed a single 
radius of curvature – which would equate to a sphere or perhaps the longitudinal walls 
of a perfect cylinder. 
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The main two problems with using this equation to determine wall stress, is the 
required assumption of an idealised cylinder for the shape of the aneurysm, and the 
assumption of axisymmetric geometry, neither of which are true.  AAA geometry is 
complex with many major and minor wall curvatures.  In addition, this equation 
assumes the cylinder involved is thin-walled.  Although the walls of most aneurysms 
probably fall within this category, if intra-luminal thrombus plays a role in altering 
wall stress, then the equation would be even less accurate.  Finally only an estimate of 
average stress experienced by the arterial wall was produced.  A review article by 
Dobrin (Dobrin, 1989) also quoted studies using the law of Laplace. 
Finite element analysis 
Finite element analysis (FEA) is an established engineering method of predicting 
stresses involved in various structures by dividing complex structures into a large 
number of simpler elements, and allowing these to interact via equations derived from 
the study of the material properties of the structure.  (Mower et al., 1993) first claimed 
that FEA predicted stress distributions better than aneurysm diameter in hypothetical 
aneurysms.  They assumed linear elasticity for the tissue characteristics i.e. a linear 
relationship between stress and strain.  A few other papers continued to work on this 
principle, and although results were more reliable than using the law of Laplace, newer 
studies on aneurysm tissue ex-vivo showed that large strains (20-40%) were 
experienced by the tissue prior to failure (He and Roach, 1994, Raghavan et al., 1996), 
demonstrating that the tissue was in fact hyperelastic.  Thus a more complex 
constitutive relation (the stress/strain relationship in the material, or the deformation or 
stretch that a particular stress produces) was necessary.  Yamada et al, using a 
hyperelastic material model and other parameters initially designed for normal aortic 
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wall, first carried this out.  However the mechanical properties and thus constitutive 
behaviour was demonstrated to be markedly different for AAA tissue compared to 
normal aortic tissue (Raghavan et al., 1996, He and Roach, 1994).  (Raghavan and 
Vorp, 2000) then mechanically tested 69 samples of AAA tissue to determine its 
mechanical properties and constitutive behaviour.  This was building on previous work 
adding 5 longitudinal and 3 circumferential specimens to bring the numbers up to 50 
and 19 respectively. Because of their previous assumption that the material was 
isotropic, they thought it fit to combine the groups to make a single group of 69 
specimens.  Their main aim was to develop a constitutive model for AAA tissue and 
determine the effect of variation of aneurysm specific parameters on the aneurysmal 
wall stress following finite element analysis.  They developed a constitutive model 
which apparently had good agreement with all the experimental results (min R
2
 > 0.9).   
They determined that varying the parameters within the 95% confidence interval 
varied the computed stress up to 4%.  
No aneurysm is an ideal cylinder, and most AAAs are not axisymmetric due to a 
difference in the anterior and posterior support to the aneurysms, ie the vertebral 
column in posterior support.  (Vorp et al., 1998) looked at artificially constructed 
aneurysms, and varied posterior to anterior diameter (a measure of axisymmetry) and 
diameter.  The results showed that altering the posterior to anterior diameter to 0.3:1 
could increase the local wall stress by 85% whilst increasing the diameter from 4 to 
8cm would only increase the wall stress at the same area by 33% (figure 6, below).  
Interestingly peak wall stress increased 137% on increasing diameter from 4cm to 
8cm, but only 45% on increasing the asymmetry as above.  This was also shown in an 
earlier study by (Elger et al., 1996). 
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 The effect of varying AAA asymmetry versus AAA diameter (Dmax -Figure 6.
maximum diameter of AAA, β – ratio of posterior to anterior radii) (Vorp et al., 
1998) 
Raghavan et al (Raghavan et al., 2000) analysed Spiral CT scans of 7 patients (6 
AAAs and 1 control) and reconstructed 3-D models of the aortas to calculate peak wall 
stress using a finite element analysis method.  They found that the 6 aneurysms had a 
higher peak wall stress than the control aneurysm although no statistical significance 
was mentioned presumably due to the small numbers involved.  They did conclude that 
volume seemed to correlate best with peak wall stress in this study.  Interestingly 
maximum AAA diameter, AAA height, and systolic pressure all had about the same 
correlation coefficient (about 0.56), but aneurysm volume had a correlation coefficient 
of 0.7 with peak wall stress (control patient was removed for this analysis).   
Isotropy versus anisotropy 
Another element involved in the assumption that peak wall stress sites are the sites 
most likely to rupture when the critical wall strength is reached is the assumption that 
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all areas of the wall are the same or similar in strength and the wall is homogeneous.  
This may not be the case.  Initial FEA studies assumed the wall was isotropic in 
character meaning that the mechanical characteristics are the same in both 
circumferential and longitudinal directions.  However, evidence in general suggests 
that AAA tissue is anisotropic (mechanical characteristics are different in 
circumferential and longitudinal directions).  Canine abdominal aortic tissue has been 
proven to be anisotropic (Patel, 1972), but studies have consistently failed to show a 
statistically significant difference between circumferential and longitudinal tissue 
elasticity in humans.  These tend towards a difference but none has been demonstrated 
conclusively.  (Vande Geest et al., 2006a) demonstrated a significant reduction in 
circumferential strain in AAA compared to normal abdominal aortic tissue during 
biaxial testing, suggesting that aneurysm formation increases circumferential tissue 
stiffness, but still did not conclusively prove anisotropy within AAA tissue.  When 
Raghavan developed his isotropic (mechanical characteristics same in circumferential 
and longitudinal directions) constitutive AAA model in 2000, he speculated that AAA 
tissue may be anisotropic, but due to technical considerations, and the desire to 
simplify things, the model was left with isotropic characteristics (Raghavan and Vorp, 
2000).  He pointed out the similarity in mechanical behaviour between longitudinal 
and circumferential samples, but confirmed that he could not prove isotropic behaviour 
either.   
Other studies have demonstrated that the tissue of the normal aortic wall is 
heterogeneous (Sumner et al., 1970) and bi-phasic – undergoing large strains prior to 
failure (He and Roach, 1994, Raghavan et al., 1996) after presumably a more 
conventional, perhaps even linear, initial stress-strain constitutive relationship.  Studies 
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have modelled non-aneurysmal arterial tissue as hyperelastic (Vito and Hickey, 1980, 
Fung, 1967, Patel and Fry, 1969, Chuong and Fung, 1984, Vorp et al., 1995), some 
have assumed isotropy (characteristics not directionally dependent)(Vito and Hickey, 
1980, Fung, 1967), and others assumed anisotropy(characteristics directionally 
dependent)(Chuong and Fung, 1984, Vorp et al., 1995).  It has also been shown that 
vascular tissue is incompressible (Carew et al., 1968). 
1.3.3. The Formation and Progression of an Aneurysmal Aorta 
The formation and progression of aneurysmal growth is linked to plastic (non-
reversible change of shape in response to an applied force) deformation of the collagen 
in the aortic wall.  Collagen fibres generally take up excess load placed on the arterial 
wall after elastin fibres have exceeded their capacity (McMillan et al., 1997).  This 
may be due to extra-physiological forces being applied to the arterial wall (eg with 
geometry change resulting in localised high stress areas despite physiological blood 
pressures), resulting in stress being taken up by collagen after the load bearing 
capability of elastin has been exhausted.  It may also be due to the degradation of 
elastin (eg via increased elastase activity), resulting in lower load-bearing potential for 
elastin, and collagen being subject to stress at physiological wall stress levels.  A 
combination of the 2 factors is also possible.  The concentration of elastin has been 
seen to decrease, and the concentration of collagen increase in the formation of AAAs 
(Baxter et al., 1994). 
In an EVAR group of 48 successfully excluded aneurysms, a median reduction in 
aneurysm sac size of 8mm (p<0.0001) was recorded at 18 months post-procedure, 
using regular CT imaging.  Interesting in the 16 (n=64) that had persistent sac 
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perfusion (identified as type 2 endoleak – side-branch), there was no statistically 
significant difference in diameter of aneurysm sac after 18 months, where an increase 
might have been expected.  Since the numbers involved were small, there may have 
been a type II statistical error (Resch et al., 1998).   
Another study comparing CT and US follow-up of EVAR patients showed 
successfully excluded aneurysms underwent a median reduction in diameter of 4mm 
per year (Thompson et al., 1998). 
EVAR repair of AAAs also seems to change the length of the aneurysm, which 
presents a problem in particular to modular stent-grafts – leading to an increased risk 
of modular dislocation, and stent kinking or distortion (Harris et al., 1999). 
1.3.4. The Rupture of an Aneurysmal Aorta 
Risk of rupture is related to maximum AAA diameter.  This is true simply because 
maximum diameter is an important component of AAA geometry.  It is also true that 
diameter is not the most important determinant of rupture risk as we know that certain 
small aneurysms do rupture, and some large aneurysms have been found in autopsy 
studies that must have been so called “clinically significant” for years, but not ruptured 
(Darling et al., 1977).  Biomechanically, aneurysm rupture is due to gross mechanical 
failure of the aneurysm wall.  This occurs when the mechanical stress on the wall 
exceeds its failure strength.  Thus either increasing levels of stress on the aneurysm 
wall or a decreasing strength of the wall tissue or both could lead to eventual AAA 
rupture.  Ex vivo studies have shown that the failure strength of aneurysmal wall tissue 
is lower than normal aortic wall tissue (Raghavan et al., 1996, Vorp et al., 1996b).  
They demonstrated that failure strength decreases from 1.21MPa in healthy aorta, 
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down to 0.65MPa in AAA tissue.  This would seem to be in agreement with the 
compensatory process by which AAA forms and grows.  The loss of elastin and 
replacement by collagen, albeit excessive but disordered, wound result in this lower 
failure strength (Petersen et al., 2000).  Rupture would then occur either because of 
this lower failure strength and/or probably a localised peak wall stress area.   
(Raghavan et al., 2000) also calculated that the lower wall stress and higher strength 
within the wall of a normal aorta results in the peak wall stress being only about 10% 
of failure strength, whereas an AAA seems to run between 45-69% of its failure 
strength. 
1.3.5. The Future 
The mechanical properties of AAA tissue differ in each aneurysm and in each site 
within a particular AAA. Since ex-vivo destructive mechanical testing is not possible 
for an intact non-ruptured AAA, it is usually necessary to use average characteristics 
for AAA tissue.  However it has been postulated that as imaging improves, in vivo 
deformations under physiological stresses can be identified, measured and used to 
calculate aneurysm specific material properties.  This would enable more accurate 
modelling of specific aneurysms and more accurate prediction of rupture risk in the 
future.   
1.3.6. Finite Element Analysis 
Finite element analysis is a method of analysing complex structures by breaking them 
down into a number of simpler elements.  The elements involved can thus be more 
accurately modelled and analysed in turn, and separate rules governing the interaction 
of elements put into force thus leading to an equilibrium state.  Differential equations 
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describing the physical problem considered are taken to hold over this region or 
element, and although this is an approximation, this is more valid then when applied 
globally over the entire structure.  Once the behaviour of these elements is determined, 
the elements are patched together with specific rules to form the entire region or 
structure, and this enables an approximate solution for the behaviour of the entire 
body.  
The accuracy of the finite element analysis with the resultant equilibrium state, 
including stress distribution, peak and low wall stress sites, together with the values for 
the stresses experienced at these sites are mainly dependent on the quality of the 
mathematical model for tissue characteristics.  Clearly, the information on which the 
model is based is also important including constraints (character and position), applied 
pressures, wall thickness, and finally thrombus.  There is on-going debate regarding 
the biomechanical influence of thrombus on the arterial wall.  There is some evidence 
that it protects or buffers the wall against tangential stress.  However it may also 
reduce the wall strength by creating a hypoxic environment or acting as a matrix 
metalloproteinase reservoir which degrade collagen and elastin.   
The approximation for a single region is usually a polynomial equation, this allows for 
the changing of the variable over the element, and it is an interpolation over the 
element, with the assumption that the value is known at certain points within the 
element.  These points are often boundary or nodal points 
Steps in FEA 
 Establishment of stiffness relations for each element.  Material properties and 
equilibrium conditions for each element are used in this establishment 
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 Enforcement of compatibility – the connection of the elements 
 Enforcement of equilibrium conditions for the whole structure 
 Assembling – the construction of the system of equations for the entire 
structure 
 Enforcement of boundary conditions  
 Solution of the system of equations. 
Identifying an area rather than a single point at risk is more realistic, because in a 
symmetrically shaped aneurysm, the same or very similar peak stress will occur over 
an area, or even at a number of locations, and small changes in the local geometry, 
wall thickness or constraint conditions will shift it within that area. On the other hand, 
a highly asymmetric shape will have a more focussed region of high stress, a steeper 
local stress gradient, and therefore be relatively insensitive to local variations in the 
geometry or wall thickness. The surface of a purely cylindrical aneurysm will have a 
uniform peak stress with all points having the same probability of failure. A finite 
element analysis of such a cylindrical shape will always identify a single point with the 
maximum stress because of rounding errors in the post-processing. 
1.4. Matrix Metalloproteinases 
1.4.1. Background 
There are substantial physical and structural obstacles to many processes, both 
physiological, and pathological, which require the dissolution or at least co-operative 
permeability of substantial biological barriers, commonly collagenous membranes, or 
material.  These processes include physiologic mechanisms such as the involution of 
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the female uterus, eruption of teeth, fetal development and pathologic mechanisms 
such as the progression of cancer, rheumatoid arthritis, and arterial aneurysmal 
development and progression. 
Collagenases 
Collagenases are enzymes, which have the ability to cleave intact collagen molecules, 
and are seen in many tissues, in both in procaryotic, and eucaryotic organisms.  Since 
collagens represent the major structural proteins of all tissues, and are the chief 
obstacle to cell migration, collagenases play a pivotal role in many processes.  These 
are important in normal development, and also in certain disease states (Grillo and 
Gross, 1967, Harper, 1980).  In normal physiological conditions, collagenases are 
present in very low quantities in mammalian tissues and are therefore difficult to 
detect.  They are more prominent in connective tissue cell cultures and tissues that 
undergo rapid resorption (eg involuting uterus)(Cawston and Murphy, 1981).  Most 
mammalian collagenases appear to be metalloproteinases (Seltzer et al., 1977), but 
collagenases from micro-organisms, and invertebrates come from metalloproteinases, 
and other classes of proteinases including the serine proteinases, and thiol proteinases 
(Keil, 1979).  
Mammalian collagenases 
Mammalian collagenases are zinc dependent enzymes, often also requiring calcium for 
activation.  They are seen in culture media of connective tissue cells (e.g. fibroblasts & 
chondrocytes).  The collagenases are usually latent and require activation. In vitro 
methods of activation include the addition of mercurial compounds, chaotropic agents 
(which disrupt the 3-dimentional stability of macromolecules, e.g. Urea 6-8mol/l, 
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lithium perchlorate 4.5mol/l), short treatments with trypsin or trypsin-related enzymes, 
or prolonged incubation at 37C.  The nature of the latent collagenase is uncertain; it is 
unclear whether it is a pro-enzyme which needs proteolytic cleavage, or whether it is 
complexed with inhibitors that are removed by proteolysis or adding chemical agents 
(Murphy and Sellers, 1980). 
The specificity of mammalian collagenases is very limited.  They cleave the collagen 
triple helix at a point of weakness, three-quarters of the way along from the N-terminal 
residue.  The susceptible bond is the Gly-Leu or Gly-Ile bond (Harper, 1980, Cawston 
and Murphy, 1981). 
Earlier reports that these collagenases do not work on non-collagen proteins are 
incorrect, as studies have shown proteins like casein undergo limited cleavage, 
however the products can be difficult to detect as they are not soluble in trichloracetic 
acid (Murphy and Sellers, 1980). Type I collagen is most rapidly cleaved followed by 
type III then type II collagens. 
1.4.2. History 
The first matrix metalloproteinase (MMP) to be discovered was interstitial collagenase 
(MMP1), which was discovered in 1962 during analysis of the collagen remodelling 
necessary for tadpole tail metamorphosis (Gross and Lapiere, 1962).  It was later found 
in human skin as ‘Human Skin Collagenase’ (Eisen et al., 1968).  Subsequently further 
MMPs were discovered, many of which were not limited to collagen as their preferred 
substrate.  These MMPs shared common functional domains, a dependency for zinc, 
and between them had the ability to degrade all components of the extracellular matrix.  
These MMPs were numbered according to their order of discovery. 
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1.4.3. Definitions 
Metalloproteinases & Metzincins 
There are 4 major classes of proteolytic enzymes, the metalloproteinases, serine 
proteinases, cysteine proteinases, and the aspartic proteinases.  Each class of proteinase 
has a common mechanism of action dependant upon the amino acid at the active site.  
Amongst these enzymes, the metalloproteinases are most abundant with over 200 
genes listed in the human genome (Sterchi, 2008). 
A large number of enzymes seem to require metal ions, with the assumption that the 
metal ions aid activation of the enzyme or that the action of the enzyme is inhibited by 
metal chelating agents.  For true metalloproteinases however, the metal ion should be 
at the centre of the active site, and involved in the catalytic event(Hofmann, 1985). 
The metzincins are a super family of zinc endopeptidases which account for almost 
half the metalloproteinases (Sterchi, 2008).  These have a highly conserved motif, 
which contain 3 histidines that bind to zinc at the catalytic site, and a conserved 
methionine that sits beneath the active site.  The metzincins are subdivided into 4 
multigene families; seralysins, astacins, ADAMs/adamalysins, and MMPs (Cao and 
Zucker, 2008). 
Matrix metalloproteinases 
The matrix metalloproteinases are a family of zinc dependent endopeptidases that have 
the ability - between them - to degrade all components of the extracellular matrix.  
More recently it has been recognised that MMPs cleave many other types of peptides 
and proteins, and have important abilities that may not be related to their proteolytic 
activity (Overall and Lopez-Otin, 2002).  They are initially synthesized in a latent form 
MD Thesis  MST Heng 86 
known as a zymogen, or ‘pro’ form, and require activation through the removal of a 
pro-peptide domain and the cysteine switch (Van Wart and Birkedal-Hansen, 1990).  
Certain sequence homologies are shared within the group.  Their activity is regulated 
by gene expression (controlled by pro- and anti- inflammatory cytokines and growth 
factors) and also inhibitors, including a matrix metalloproteinase specific family called 
“tissue inhibitor of matrix metalloproteinases” (TIMPs).   
The MMPs are numbered according to their order of discovery (table 1, below), and 
also grouped according to their substrate specificity;  
 Collagenases; degrade only collagen type I to III  
 Gelatinases (or type IV collagenases); specificallydegrade basement membrane 
components, and partially degraded collagen  
 Stromelysins; which have a broad substrate specificity  
 Matrilysin  
 Membrane type MMPs  
 “Others” (eg MMP12 macrophage metalloelastase).   
However despite this classification most MMPs are not specific for one substrate, and 
will display activity for a number of substrates.  Their distinct but overlapping 
substrate specificities lead to a lack of clear phenotypes in MMP knockout mice with 
lack of specific MMPs.  For example, mice deficient in MMP14 (MT1-MMP), whose 
substrates include collagen I, II, III, gelatin, MMP2 and MMP13, demonstrate 
dwarfism, arthritis, osteopenia, and craniofacial dysmorphism suggesting the 
importance of soft connective tissue modelling, and collagen turnover by resident cells 
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in the development and maintenance of the hard tissues of the skeleton (Holmbeck et 
al., 1999).  MMP9 (gelatinase B) deficient mice demonstrate abnormal skeletal growth 
plate vascularisation and ossification, with progressive lengthening of the growth plate 
to about 8 times normal.  Transplantation of wild-type bone marrow cells rescues 
vascularisation and ossification suggesting that these processes are mediated by 
Gelatinase-B expressing cells of bone marrow origin, designated chondroclasts (Vu et 
al., 1998).   
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Table 1. The major MMP subtypes and their substrates 
MMP Enzyme Principal substrate 
Collagenases   
MMP1 Collagenase-1 (Interstitial 
collagenase) 
Collagens I, II, III, VII, VIII, X, gelatin, aggrecan, MMP2 
and 9 
MMP8 Collagenase-2 (Neutrophil 
collagenase) 
Collagens I, II, III, V, VII, VIII, X, gelatin, aggrecan 
MMP13 Collagenase-3 Collagens I, II, III, IV, gelatin, aggrecan, PA12 
MMP18 Collagenase-4 (Xenopus 
collagenase) 
Collagen I 
Gelatinases   
MMP2 Gelatinase A (72 kDa gelatinase) Gelatin, collagens I, IV, V, VII, X, XI, XIV, elastin, 
Fibronectin, aggrecan 
MMP9 Gelatinase B (92 kDa gelatinase) Gelatin, collagens IV, V, VII, X, elastin 
Stromelysins   
MMP3 Stromelysin-1 Collagens III, IV, IX, X, gelatin, aggrecan, MMP1, 7, 8, 
9, 13 
MMP10 Stromelysin-2 Collagens III, IV, V, gelatin, casein, MMP1, 8 
MMP11 Stromelysin-3 Gelatin, Collagen IV, fibronectin, casein, 
proteoglycans 
Matrilysins   
MMP7 Matrilysin-1 (PUMP-1) Collagen IV, X, fibronectin, gelatin 
MMP26 Matrilysin-2 Collagen IV, fibronectin, gelatin, proMMP9, fibrinogen 
Membrane type MMPs  
MMP14 MT1-MMP Collagens I, II, III, gelatins, MMP2 and 13 
MMP15 MT2-MMP MMP2, gelatin 
MMP16 MT3-MMP MMP2 
MMP17 MT4-MMP Gelatin, proMMP2 
MMP24 MT5-MMP Proteoglycans, proMMP2, collagen I, gelatin, 
fibronectin, laminin 
MMP25 MT6-MMP Collagen IV, proMMP8, proMMP9 
Others   
MMP12 Macrophage metalloproteinase Collagen IV, gelatin, elastin, fibronectin 
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MMPs have a complex range of targets / effects which extend beyond classical 
remodelling.  They are known to precisely regulate the action of bioactive molecules 
by proteolytic processing.  MMPs also regulate cell-surface receptor cleavage and 
release, cytokine activation and inactivation and release of apoptotic ligands (Egeblad 
and Werb, 2002).  These cellular processes regulated by MMPs therefore may have 
tumour growth promoting potential (proliferation, adhesion, dispersion, migration, 
differentiation, angiogenesis, apoptosis, and host defence evasion), and some will 
suppress normal tissue function and host defence mechanisms.  Thus the effect of 
MMP suppression is not straightforward.  Some studies have suggested that MMPs 
may play a pivotal role in early disease despite the classical idea that their role is in 
disease progression and malignant metastases (Egeblad and Werb, 2002, Coussens et 
al., 2002).   
1.4.4. Structure 
Several highly conserved domains are common to various MMPs (figure 7, below)   
 The signal peptide domain directs the MMP towards the secretory or plasma 
membrane insertion pathway. 
 The prodomain, found in the zymogen, has the highly conserved sequence 
PRCGVPNPD.  The cysteine residue within this sequence coordinates with the 
zinc ion within the active site, occupying the active zinc site, and therefore 
conferring latency to the enzyme by making the catalytic enzyme inaccessible 
to substrates.  This is cleaved during activation of the MMP, the so-called 
cysteine switch.    
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 The catalytic domain contains the zinc-binding area, called the metal ion 
binding domain (MBD).  Another highly conserved sequence HExGHxxGxxH 
is found in this domain in all MMPs.  It contains 3 histidine residues which 
interact with the zinc ion.   
 The C-terminal domain has structural similarities to the serum protein 
hemopexin, and is therefore often termed the ‘hemopexin domain’.  It has a 4-
bladed B-propeller structure. B-propeller structures provide a large flat surface, 
thought to be involved in protein-protein interactions.  The hemopexin domain 
determines the specificity of the enzyme through mediating interactions with 
substrates, and this is also the site for interactions with TIMPs.  Certain MMPs 
do not have this domain including the short MMP7, and another MMP in the 
Matrilysin subtype, MMP26 (or matrilysin 2), together with MMP23a and 
MMP23b. 
 The hinge region links the catalytic and hemopexin domains. 
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 The structure of MMPs Figure 7.
(University of British Colombia website: 
http://www.clip.ubc.ca/archive/mmp_timp_folder/mmp_schematic_master.gif) 
Key: Y tyrosine, D aspartic acid, G glycine – amino acids that are present in the 
catalytic domain of all collagenases. 
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Certain differences exist, for example the smallest MMP (MMP7), lacks the 
hemopexin domain, however it still has substrate specificity.  The membrane type 
MMPs (MT-MMP) contain an additional 20 amino acid trans-membrane domain, and 
a small cytoplasmic domain (MMP14, MMP15, MMP16, MMP24), or a 
glycosylphosphatidyl inositol linkage (MMP17, MMP25), which attaches these 
proteins to the cell surface.  MMP2 and MMP9 (gelatinases), contain fibronectin-like 
domain repeats, which aid in substrate binding(Strongin et al., 1993). 
1.4.5. Control of MMP activity 
The activity of MMPs is tightly controlled in vivo at several levels.   
 Transcription is tightly regulated in both directions by cytokines and growth 
factors including interleukins (IL-1, IL-4, IL-6), transforming growth factors  
(EGF, HGF, TGF), or tumour necrosis factor alpha (TNF).  Of these, IL-1, 
PDGF, TNF-α are known to stimulate or induce MMP synthesis, and TGF-β, 
heparin and corticosteroids have an inhibitory effect.  Some of these can be 
activated or inactivated proteolytically by MMPs (feedback effect).  The  
relationship between cytokines and MMP and TIMP expression is complex 
(Wang et al., 1996). 
 Latency is conferred by the prodomain group occupying the active site zinc in 
the newly synthesized zymogen. 
 Activation of the MMP depends on disruption of the interaction between the 
prodomain and the active site.  This may occur through conformational 
changes, or proteolytic removal of the prodomain.  In vivo the actual 
mechanism of activation is poorly understood.  Certain MMPs (MMP11, MT-
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MMP, MMP28) contain furin-like recognition domains within the propeptides, 
and can be activated in the trans-Golgi network by members of the subtilisin 
family of serine proteases.  MMP14 plays a role in the cell surface activation of 
MMP2 from pro-MMP2.  Other protease groups, such as the serine protease 
plasmin can activate extracellular secreted MMPs.  This suggests some co-
operation between groups of enzymes in remodelling of the extra-cellular 
matrix.  Some active MMPs can activate other pro-MMPs, eg MMP3 
(stromelysin) can activate MMP9 and MMP1, and in fact proteolytic activity is 
potentiated 5-8 times by cleavage of collagenase by stromelysin at the carboxy 
terminal.  It has been suggested that there are similarities between this system 
and the coagulation cascade as for example activation of stromelysin by 
plasmin results in further activation of other MMPs with potentiation of effect 
as detailed above (Dollery et al., 1995). 
 Post activation control of MMPs may be achieved by endogenous inhibitors, 
autodegradation, and selective endocytosis.  MMP2, MMP9, and MMP13 have 
been found to undergo endocytosis via a low density lipoprotein receptor 
related protein mechanism(Yang et al., 2001).  MMP9 is also able to bind to 
the cell surface following cell secretion, and here it is somewhat protected from 
local inhibitors. 
 Tissue Inhibitors of MMPs (TIMPs) are a 4-member-family of homologous 
MMP inhibitors (TIMPs 1-4) (figure 8, below).  The N-terminus of all 4 TIMPs 
bind to the catalytic domain of most activated MMPs therefore inhibiting 
function.  The C-terminus of TIMP1 and TIMP2 bind to the hemopexin domain 
of pro-MMP2 and pro-MMP9 respectively; this also regulates MMP function 
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(Cao and Zucker, 2008).  TIMPs are found in much higher concentrations than 
MMPs in tissue and extracellular fluid thus limiting MMP activity to focal peri-
cellular areas.  Other, more complex interactions of TIMPs have also been 
discovered eg low concentrations of TIMP2 enhance MMP14 activation of 
MMP2 by forming a triplex on the cell surface.  Growth promoting activities of 
TIMPs, independent of their MMP inhibiting actions, have also been observed, 
and TIMP-3 has apoptosis-inducing properties.  Control of TIMPs is similar to 
MMPs, with cytokines and growth factors promoting TIMP transcription eg 
TGF, TNF, IL-1, IL-6.   
 
 Schematic representation of TIMP1 structure (www.abcam.com ) Figure 8.
 Other inhibitors of MMPs include the endogenous factor plasma protein 2-
macroglobulin.  This is a large plasma protein, part of the 2 band in protein 
electrophoresis, and is produced by the liver.  Its effects are limited by the large 
size of the molecule.  It is able to inactivate a wide variety of proteinases 
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including serine, cysteine, aspartic and metalloproteinases.  It functions by 
attracting proteinases to a 35 amino acid ‘bait’ region, and when the 
proteinases binds and cleaves the region, it becomes bound to 2-
macroglobulin, forming a complex which can be recognised by macrophages, 
and removed.  A study of MMPs in diseased aorta tissue found that gelatinase 
activity increased 3-5 fold after the destruction of 2-macroglobulin with 
potassium thiocyanate (KSCN) (Vine and Powell, 1991).   
 exogenous factors such as heparin.  
 a surface inhibitor, the Reversion-Inducing Cysteine rich protein with Kazal 
motifs (RECK inhibitor), is a membrane-anchored glycoprotein, which is vital 
for normal vasculogenesis, and has been found to inhibit membrane type 1 
MMP (MMP14), MMP2 and MMP9.  Down regulation of RECK has been 
implicated in tumour angiogenesis and progression (Span et al., 2003).  The 
‘Kazal Motif’ refers to three pairs of conserved cysteine residues (Morris and 
Carruthers, 2003).  The figure below demonstrates schematically TIMP1.  The 
N-terminus of all 4 TIMPs bind to the catalytic domain of most activated 
MMPs therefore inhibits function.  The C-terminus of TIMP1 and TIMP2 binds 
to the hemopexin domain of proMMP2 and proMMP9 respectively; this also 
regulates MMP function (Cao and Zucker, 2008). 
1.4.6. Natural history 
MMPs are generally produced locally, with stimulation by local factors, but seepage 
into the blood stream accounts for changes in serum or plasma MMP concentration 
(Zucker et al., 1995).  
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Studies have shown that levels of MMP9 increased 30-fold after healthy volunteers 
were injected low dose bacterial lipopolysaccharide to simulate endotoxin in septic 
shock.  These levels were achieved within 2 hours, but fell within 4-6 hours suggesting 
rapid inactivation through some yet unidentified mechanism.  The rapid release of 
MMP9 was presumably due to storage in neutrophils.  MMP2 levels in contrast did not 
alter dramatically (Albert et al., 2003). In further studies on septic shock, plasma 
MMP9 levels were noted to be significantly higher in non-survivors compared to 
survivors or control patients (Nakamura et al., 1998). 
1.4.7. Natural occurrences 
The MMPs are involved in normal physiological remodelling, such as occurs during 
tissue development and repair in wound healing, ovulation, bone and growth plate 
remodelling, post-partum involution of the uterus, and embryonic development 
(Zucker et al., 1992a).  These processes involve cell motility, the release of growth 
factors bound in tissues, and remodelling of the extracellular matrix (ECM). 
1.4.8. Pathological associations 
Over-expression and activation of MMPs, or an imbalance of active MMPs and 
inhibition by TIMPs has been associated with disease states involving the breakdown 
and remodelling of the extracellular matrix eg, rheumatoid arthritis, periodontal 
disease, tumour invasion & metastasis, and vascular diseases such as atherosclerosis, 
angiogenesis and aneurysms.  It may also play a part in Alzheimer’s disease.  The 
more recent recognition of roles other than that of matrix degrading enzymes for the 
MMPs, and inhibitors of MMPs for the TIMPs, is leading to the exploration of fields 
not previously visited for these enzymes. 
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Some uncertainly remains regarding the role of MMPs in disease – as to whether it is 
part of the disease process, and initiates tissue damage, or indeed whether it is part of 
the repair mechanism.   
In a similar way, the increased production of TIMPs may be a response to MMPs in an 
attempt to inhibit protease function, but may also be independently produced with 
other effects in mind (Zucker et al., 1999).  
As regards to the timing of MMPs in a particular situation, stromelysin-3 (MMP11), 
and matrilysin (MMP7) are released early in tumour development (colonic adenomas 
and breast carcinoma in situ), prior to the development of metastatic potential and this 
suggests that these MMPs are not involved in metastasis (Zucker et al., 1999). 
There has been interest for a long time on MMPs in cardiovascular disease, mainly in 4 
areas, the role of MMPs in development of atherosclerotic plaque, aneurysms, release 
of smooth muscle cells after angioplasty, and the role of MMPs in cardiac failure.  
1.4.8.1. Atherosclerosis 
Atherosclerosis relates to the build-up of intimal atheroma and one of the earliest 
events to occur in process is the adhesion of circulating monocytes to the vascular 
endothelium.  Cellular migration has been studied in rat vascular SMC (smooth muscle 
cell), and MMP2 (gelatinase A) has been determined to be necessary for cells to cross 
the basement membrane layer (composed of type IV collagen) (Pauly et al., 1994).   
Commonly an atherosclerotic plaque consists of a thickened intimal layer and an 
asymmetrical lesion that encroaches into the lumen.  These lesions can be fibrous or 
consist of a lipid core with a fibrous cap.  They contain mainly macrophages and SMC 
(smooth muscle cells), but there are also “foam cells” frequently seen - macrophages 
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containing lipid within cytoplasm, and giving these cells a foamy appearance.  Levels 
of MMP, particularly MMP9 (gelatinase B), MMP3 (stromelysin-1), and MMP1 
(interstitial collagenase) were over-expressed in areas of foam cell accumulation in 
coronary atherosclerotic lesions (Galis et al., 1994).  The lipid cores are often unable to 
bear the circumferential tension from systole, and redistribution of the stress to the 
fibrous cap occurs.  Regions of high stress may develop (Richardson et al., 1989), and 
certain factors contribute to an increase in stress across these caps including the loss of 
content and structure of the connective tissue matrix, and increase in the size of the 
lipid core (Davies et al., 1993c).  It has been postulated therefore that the most 
common event initiating coronary thrombosis is intimal tearing, which occurs in 
regions of cap weakness.  This is correlated with accumulation of macrophages and 
seems to be found in the shoulders of the plaque.  Although there is no direct evidence 
of association of MMP activity with increased risk of vessel occlusion, MMP9 
(gelatinase B) has been shown to be elevated in arterectomy samples from patients 
with unstable angina compared to patients with stable angina (Brown et al., 1995).       
MMP in atherosclerotic plaques has been shown to be localised to smooth muscle 
cells, and macrophages by in situ zymography.  In situ hybridization has indicated that 
the MMPs are also produced by these cells (Henney et al., 1991, Galis et al., 1994).  
MMP3 (Stromelysin) mRNA transcripts have been localised to macrophages and SMC 
in fibrous and lipid filled atherosclerotic plaques through examination of frozen 
sections.  Since the accumulation of large numbers of macrophages and foam cells in 
the arterial wall is not normal, it is reasonable to assume that the production of these 
MMPs is also pathological.  In contrast, radioimmunoassay has demonstrated that 
TIMP1 is normally present within the matrix of aortic wall (Brophy et al., 1990).  This 
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further raises the possibility that the fine balance between MMPs and TIMPs is 
disrupted in certain pathological situations.  Vine and Powell demonstrated that MMP9 
(gelatinase B) was raised in homogenates made from the luminal aspect of 
atherosclerotic but not normal aortas (Vine and Powell, 1991).   It is postulated 
therefore that certain cytokines (eg TNF-α) induce the production of MMP3 
(stromelysin) and other MMPs in response to a localised area of mechanical stress, and 
this triggers the cascade-like response resulting in plaque rupture and vascular 
occlusion (Dollery et al., 1995).  High levels of TIMP1 and MMP9 have been located 
at the vasa vasorum (which may be involved in the maintenance and genesis of the 
plaque) of human AAA specimens examined with Immunoprecipitation (Herron et al., 
1991).    
In porcine coronary arteries there was a higher intrinsic gelatinolytic activity and rapid 
cell outgrowth in the adventitia, whereas the media had slower cell outgrowth, with a 
preferential expression of TIMPs.  The impairment of TIMP synthesis may thus 
contribute to the pathogenesis of coronary lesion formation (Shi et al., 1999).  
Angina 
In a study looking at unstable and stable angina patients, both groups had positive 
staining for MMP9  (83% of each group), but interestingly 10/10 patients in the 
unstable angina group but only 3/10 patients in the stable angina group had 
intracellular localisation of MMP9 suggesting more active synthesis in the unstable 
angina group, and the potential contribution of MMP9 to acute coronary ischaemia, 
perhaps through degradation of matrix and rupture of atherosclerotic plaque(Brown et 
al., 1995).  
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Myocardial infarction 
At the DNA level a single nucleotide polymorphism (SNP) for MMP9 has been shown 
to be associated with the level of severity of coronary atherosclerosis, but no 
association with myocardial infarction.  This study looked at 584 male patients with 
myocardial infarction and compared genotypes with 645 age-matched healthy male 
controls.  No significant difference was found in genotype, however on sub-group 
analysis, in 374 patients with available angiographic data, 26% with the SNP had 
>50% stenosis in 3 coronary vessels compared to 15% of patients without the sequence 
variation (Zhang et al., 1999). 
Another study used sandwich ELISA to demonstrate an increase in MMP1 in infarcted 
heart tissue from coronary heart disease patients compared to heart tissue from donor 
patients (75 +/- 11 ng/mg vs 9 +/- 2ng/mg, P<0.01), and a decrease in TIMP1 (12 +/- 5 
ng/ml vs 37 +/- 8ng/ml, P<0.001).  Northern blot analysis in the study showed that 
mRNA levels for both MMP1 and TIMP1 were elevated 3-4 fold in the infarcted 
tissue, suggesting up-regulation of MMP and TIMP gene transcription following 
infarction, however since the level of TIMP1 is actually decreased, post-translational 
regulation of TIMP1 was assumed.  This study therefore suggests that post-
translational modification was important in this situation.  Other bands seen during 
zymographic analysis were at 66kDa and 92kDa and were thought to be MMP2 and 
MMP9 respectively, although it described the probability of part of the 66kDa band 
belonging to plasmin, and hence perhaps tPA converting plasminogen to plasmin, in 
turn activating MMPs and inactivating TIMP1 post-translationally (Tyagi et al., 1996).  
During myocardial infarction, MMP9 deficient mice seem to be partially protected 
against ventricular enlargement, collagen accumulation, and cardiac rupture, which can 
MD Thesis  MST Heng 101 
all complicate myocardial infarction.  Mice deficient in urokinase-type plasminogen 
activator were completely protected against cardiac rupture, but showed impaired scar 
formation and infarct revascularisation, even after treatment with vascular endothelial 
growth factor.  These mice died of cardiac failure due to depressed contractility, 
arrhythmias and ischaemia.  However temporary TIMP1 administration to wild-type 
mice completely prevented cardiac rupture and did not abort infarct healing (Heymans 
et al., 1999).  Mice lacking one MMP9 allele showed a reduction in ischaemia 
reperfusion induced expression of pro-MMP9(78%), and active MMP9(69%) 
compared to wild-type mice after the LAD coronary artery was occluded for 30 
minutes followed by 24 hours of reperfusion.  TIMP1 was elevated 4.7 fold in these 
mice.  Immunohistochemical methods revealed that neutrophils were the primary 
source of MMP9, and less neutrophils were seen in the ischaemic region of the heart 
following ischaemia reperfusion injury but only in mice with both alleles of MMP9 
absent compared to wild-type mice.  Myeloperoxidase activity (a marker enzyme of 
neutrophils) also demonstrated a reduction (44%) in neutrophils infiltrated into the 
ischaemic myocardium in MMP9 absent mice compared to wild-type mice (Romanic 
et al., 2002).     
1.4.8.2. Post-angioplasty restenosis 
Ischaemic heart disease is a major cause of mortality and morbidity in the UK, and 
percutaneous transluminal coronary angioplasty is widely used in its treatment.  A 
balloon catheter is used to compress an atheromatous narrowing into the vessel wall.  
The initial success rate is >80%, but unfortunately up to half these patients have 
recurrence of their symptoms within 6 months due to restenosis at the same site 
(Landau et al., 1994, Editor the Lancet, 1987).  This is due to migration and rapid 
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proliferation of SMC at the ‘site of injury’ causing the pattern of fibrocellular intimal 
hyperplasia (Waller et al., 1990).  Also adding to the problem is that a mature 
angioplastied lesion is associated with increased extracellular matrix, and that the 
overall dimensions of the vessel change (Glagov, 1994).  Studies on a rat model have 
suggested that certain growth factors contribute to the proliferation of extracellular 
matrix; fibroblast growth factor controlling SMC replication, and PDGF (platelet 
derived growth factor) controlling cell migration.  Intimal hyperplasia is present to 
some extent in all cases after angioplasty, and restenosis is thought to be an 
exaggeration of this effect.  Restenosis can be remarkably resistant to treatment, but 
manipulation of the healing process of the vessel wall may prevent accumulation of 
occlusive neointima.   
Mechanical damage has been shown to stimulate gene expression of collagenase, and 
stromelysin in vascular SMC (James et al., 1993), this supplies a possible “on-off 
switch” for post-injury stenosis.  Studies of rat carotid artery has demonstrated a 
sequence, with MMP9 expressed the day after angioplasty, and expression of 
gelatinase A 4-5 days later (Bendeck et al., 1994).  The authors speculated that MMP9 
may induce the migration of SMC from the media to the intima.  There is some 
evidence of up-regulation of plasminogen activator after balloon injury in both rat and 
rabbit models, which may activate the MMP cascade (Clowes et al., 1990, More et al., 
1995, Tyagi et al., 1996).   Porcine studies also show initial induction of MMP9 (day 
3), followed by gelatinase A (day 7) on zymography, with elevation of levels until day 
21 (Southgate et al., 1996).   Administration of a systemic matrix metalloproteinase 
inhibitor resulted in a 97% reduction of early migration of SMC into the intima.  
Although this may have potential for treatment of post-injury stenosis lesions, arresting 
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migration itself may not in fact lead to a reduction in stenosis since compensatory 
proliferation may indeed itself cause restenosis, and 80% of restenosis lesions are 
made up of connective tissue rather than SMC. 
1.4.8.3. Abdominal Aortic Aneurysms  
In 1991, Vine and Powell found elevated gelatinase activity in atherosclerotic and 
aneurysmal aortas highest in at luminal portion of the aortic media.  The gelatinase 
was principally 92kDa in atherosclerotic aorta but covered a spectrum from 55 to 
92kDa in aneurysmal aorta in zymographic studies.  2-macroglobulin removal by 
potassium cyanate resulted in a 3-5 fold increase in gelatinase activity.  Collagenase 
and stromelysin was also tested for and found via immunoblotting in aneurysmal aorta, 
rarely in atherosclerotic aorta and never in control aorta.  Activities of these were low, 
but increased after destruction of TIMP by the order of 2-3.  The highest activities 
were found on the adventitial aspect of the aortic media in contrast to gelatinase (Vine 
and Powell, 1991).  
Thompson et al used zymography and immunohistochemical methods and found 
elevated levels of MMP9 in the aortic wall tissue samples of athero-occlusive disease, 
but the most elevated levels in aortic aneurysmal wall tissue samples.  These localised 
to macrophages within the damaged wall of aneurysmal aortas suggesting chronic 
release of this MMP contributing to the degradation of the extracellular matrix 
(Thompson et al., 1995). 
Further studies showed high levels of MMP2 in smaller aneurysms (4.0-5.5cm) 
through zymography & immunoblotting, but reducing levels in larger aneurysms, with 
an increasing activity of MMP9.  Tissue homogenates prepared from both groups 
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showed a similar total activity against gelatin or type IV collagen.  The concentration 
of MMP2, determined by immunoassay was highest for small aneurysms; median 
concentrations 385, 244, 166ng/mg protein for small aneurysms, large aneurysms and 
atherosclerotic aorta respectively.  Immunolocalisation studies demonstrated 
concentrations of MMP2 along fibrous tissue of the acellular medial layer, and the 
atherosclerotic plaque.  The recruitment of inflammatory cells into the adventitia, with 
subsequent higher levels of metalloproteinases (including MMP9) may contribute to 
the rapid growth and rupture of larger aneurysms.  MMP9 has therefore been 
suggested to be an important factor in the transition to large aneurysm (Freestone et al., 
1995). 
Sakalihasan et al, studied gelatinase (MMP2 and 9) activity by examining samples of 
aortic wall, thrombus and serum in 10 patients with AAA, and 6 aged-matched 
controls.  Thrombus was found to contain up to twenty times more gelatinase activity 
than serum (luminal thrombus twenty-fold activity, parietal thrombus ten fold activity), 
with the predominant found as MMP9.  Although total gelatinase activity was in the 
same range in AAA and control tissue, a significantly higher proportion of MMP9 was 
found in the aneurysmal wall samples.  Also a significant proportion of MMP9 was in 
its active form, which was not seen in control samples.  A higher proportion of active 
MMP2 was also seen in aneurysmal wall samples (Sakalihasan et al., 1996). 
MMP9 mRNA has also been shown in higher levels in AAA than normal aortic tissue 
(0.855 +/- 0.180 vs 0.046 +/- 0.23, P<0.02), with aorto-occlusive disease in between at 
a non-significant difference from either.  The mRNA localised to adventitial 
macrophages in areas of neovascularisation (McMillan et al., 1995). 
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Davis et al investigated the levels of MMP2 and 9 mRNA, and protein, and found 
significantly higher levels of MMP2 mRNA and protein levels in AAA tissue 
compared to aortic tissue from patients with aorto-occlusive disease (AOD) or non-
diseased control tissues.  Protein and mRNA levels for MMP9 however were raised in 
both AAA and AOD samples compared to control tissue, but there was no significant 
difference between AAA and AOD samples (Davis et al., 1998).  Analysis of MMP 
mRNA levels was by quantitative competitive reverse transcription-polymerase chain 
reaction (QCRT-PCR) and by gelatin zymography.   
Pyo et al as part of Rob Thompson’s St Louis group used MMP9 and MMP12 
deficient mice, together with wild-type mice, and experimentally induced aneurysms 
using a porcine pancreatic elastase aortic infusion at laparotomy, with a control group 
being infused heat-inactivated porcine elastase.  In the wild-type mice, there was an 
increase in the aortic diameter of both control and elastase groups immediately after 
the infusion (at least 5 minutes after restoration of lower limb perfusion), but the 
difference between groups was statistically significant (mean percentage change in 
aortic diameter: 54 +/- 3% vs 74 +/- 5% P<0.05).  There was no further significant 
change in aortic diameter until measurement at 14 days when 91% (21 out of 23) of 
elastase infused mice had developed aneurysms (arbitrary study definition set at aortic 
diameter increase of 100%).  None of the wild-type control group developed 
aneurysms (mean percentage change in aortic diameter: elastase group 134 +/- 8% vs 
control group 41 +/- 6%, P<0.05).  A subgroup was treated with doxycycline (known 
to be a non-selective MMP inhibitor)(n=8) for 14 days, and this showed a significant 
reduction in change in aortic diameter compared with non-doxycycline treated wild-
type mice(n=15) at the end of the fourteen days(89 +/- 17% vs 134 +/- 9%, P<0.05), 
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and 50% versus 93% reached study aneurysm threshold.  MMP9 and double deficient 
MMP9/12 mice both had experienced less aortic dilatation compared to the wild type 
mice when these were exposed to elastase infusion (87 +/- 10% vs 79 +/- 9% vs 134 
+/- 8%, significant difference between either deficient group and wild-type mice, 
P<0.05).  The number of mice developing aneurysms was 40%, 20%, and 94% 
respectively.  MMP12 deficient mice however were not significantly different to wild-
type mice with an increase of aortic diameter of 134 +/- 7%, and an aneurysm 
development rate of 100%.  Gelatin zymography demonstrated only level of MMP2 
prior to infusion of elastase, but levels of MMP2 and 9 immediately after infusion, and 
when animals were sacrificed on days 2, 7 and 14.  Reverse-transcriptase PCR with 
Southern blot demonstrated elevated levels of MMP9 and 12 on days 2, 7 and 14.  
When these same tests were done on MMP deficient mice, the results were as expected 
with no MMP9, 12 or both as per genotype.  Interestingly there was no ‘compensatory’ 
increase in any other elastolytic MMP (MMP2, 9 or 12) in the absence of MMP9 or 12 
or both.  In the final arm of the study, wild-type mice, and MMP9 deficient mice were 
subject to lethal irradiation and underwent bone marrow transplantation 6 hours later 
with either bone marrow from wild-type mice or MMP9 deficient mice, giving 4 
groups.  10 weeks later, elastase infusion was carried out as above, and the wild-type 
mice that had bone marrow transplantation from the MMP9 deficient group had 
significantly smaller aortic diameter increases than those transplanted with bone 
marrow from wild-type mice.  In a similar fashion MMP9 deficient mice that had bone 
marrow transplantation from the MMP9 deficient group had significantly smaller artic 
diameters than mice with bone marrow transplants from wild-type mice (table 2, 
below).  This suggests that the important factor in aneurysm promotion is expression 
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of MMP9 in infiltrating inflammatory cells rather than developmental abnormalities in 
aortic wall structure or the absence of MMP9 expression by resident aortic wall cell 
types (Pyo et al., 2000).  
Table 2. Effects of bone marrow transplantation on elastase-induced 
aneurysmal dilatation 
 Mouse aortic diameter (mm) 
Donor Host n Pre-elastase Post-elastase 14 days 
Wild-type Wild-type 7 0.50 +/-0.01 0.83 +/-0.02 0.90 +/-0.04 
MMP9(-/-) Wild-type 10 0.52 +/-0.01 0.87 +/-0.02 0.79 +/-0.02
c
 
MMP9(-/-) MMP9(-/-) 9 0.52 +/-0.01 0.83 +/-0.02 0.78 +/-0.02 
Wild-type MMP9(-/-) 12 0.50 +/-0.01 0.87 +/-0.02 1.00 +/-0.03
c
 
Pyo et al., 2000. c p<0.05, student’s t test 
Traditionally, elastases (including MMP2 & 9) were thought to have a role in the 
formation and growth of AAAs.  More recently MMPs with collagenase activity 
(including MMP8, 13) are thought to contribute to AAA rupture.  Complicating the 
issue is the fact that most MMPs have more than 1 function.  For example, MMP9 is 
principally an elastase, but is also known to have collagenase activity on partially 
degraded forms of collagen.   
A study carried out in 2002, demonstrated that ruptured AAAs have a higher level of 
tissue MMP9 than non-ruptured AAAs.  The same paper, also showed that larger 
AAAs had a higher level of MMP2 compared to smaller AAAs (Petersen E et al., 
2002).  Another study found a localised tissue increase in MMP8 at the site of rupture 
compared to the arteriotomy site within the same aneurysm (Wilson et al., 2004).  
Interestingly this study looked at the other MMPs which were considered to be 
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collagenases (MMP1 & 13), and found no difference in those between rupture and 
arteriotomy sites.   
In summary then, studies dating back to 1994 demonstrated elevated tissue levels of 
MMP2 and 9 in human AAA, and these were thought to be implicated in the formation 
of AAAs.  The MMPs involved were elastases, and the mechanism of aneurysm 
formation and growth was thought to be the loss of elastase in the medial wall of the 
aorta.  The importance of these MMPs was confirmed by the studies in gene 
manipulated mice, where genetic deficiencies in the genes coding for MMP2 and 9 
resulted in the rapid formation of aneurysms.  More recent studies have shown 
elevated tissue levels of MMP8 at sites of aneurysm rupture compared to paired 
samples taken from an arteriotomy site in the same aneurysm.  However it is not 
certain whether the elevated levels of MMPs predate and contribute to rupture, or 
whether indeed they are a result of the actual process of AAA rupture. 
Blood 
Plasma MMP9 has been found to be elevated in AAA patients(n=22) compared to 
aorto-occlusive disease(AOD)(n=9) or healthy controls(n=8) (86 +/-12ng/ml vs 26 +/- 
4ng/ml(P<0.001) vs 13 +/-2ng/ml(P<0.001).  The healthy controls were organ donors, 
and thus there was a significant age difference between the groups (mean age 
73yrs(AAA), 61yrs(AOD), 35yrs(healthy).  It is plausible that these age differences 
may account for some of the variation in MMP levels.  Tissue explants from patients 
were also cultured (smaller groups less difference in mean age between groups), and 
supernatants taken from these cultures at 48hrs were analysed for MMP9.  These 
showed significantly higher levels of MMP9 from diseased aorta (combination of both 
AAA and aorto-occlusive groups) compared to normal aorta, suggesting that the aorta 
MD Thesis  MST Heng 109 
was the source of the MMP9. In an attempt to counter controversy regarding the age 
effect in the three patient populations, the authors went on to demonstrate higher levels 
of plasma MMP9 in patients with multiple aneurysms in comparison to patients with 
an isolated infrarenal aortic aneurysm (McMillan and Pearce, 1999).  They suggested 
that the extent rather than the size of an aneurysm might have a direct relationship with 
the level of plasma MMP9.   
Lindholt et al suggested that plasma MMP9 and plasma antitrypsin may predict the 
natural history of patients with aneurysms after demonstrating that increased plasma 
MMP9 levels were significantly related to the size and expansion of small AAAs, and 
plasma antitrypsin was significantly associated with AAA expansion.  This group also 
found a difference between serum and plasma levels of MMP9, which they attributed 
to release of MMP9 from platelets (Lindholt et al., 2000b).    
Open and endovascular surgery for AAA has been shown to reduce plasma MMP3 and 
9 levels to less than half their original level.  There was also an interesting and 
significant difference in these levels in patients with and without endoleak following 
EVAR (MMP9: 44.3+/-20.7 vs 14.6+/-7.0ng/ml, 2P<0.005; MMP3: 25+/-11.5 vs 
10.3+/-5.4ng/ml, 2P<0.005) (Sangiorgi et al., 2001).  These findings highlighted the 
potential for MMP levels to be used as an indicator for the success or otherwise of 
individual EVAR procedures. 
Wilson et al (Wilson et al., 2008) studied MMP and TIMP1 levels in patients with 
elective (n=52) and ruptured AAA (n=16) and found significantly higher levels of 
MMP1 (median 8.9, [IQR 5.57-15.69] vs 20.18 [16.09-28.68], P<0.001) and MMP9 
(17.54 [10.3-34.24] vs 59.11 [20.82-123.70], P=0.006), in the ruptured AAA group.  
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1.4.9. Specific Metalloproteinases 
1.4.9.1. Matrix Metalloproteinase 2 (Gelatinase A) 
Matrix metalloproteinase 2 is a 72 kDa gelatinase/type IV collagenase.  It is also 
known as Gelatinase A or 72kDa Gelatinase.  It cleaves a variety of substrates 
including gelatines, collagen types IV, V VII, X XI, fibronectin, proteoglycan and 
elastin. 
MMP2 is derived from fibroblasts (Mannello et al., 2003).  
It is secreted in precursor form (72kDa, pro-MMP2) and can be activated in vitro by 
organomercurial compounds such as p-aminophenylmercuric acetate (APMA).  It can 
also self activate (Bergmann et al., 1995).  The active form has a molecular weight of 
62kDa or 59kDa(Davies et al., 1993b, Davies et al., 1993a).  Pro-MMP2 can be 
inhibited by binding of the C-terminus of TIMP1 to its hemopexin domain (Cao and 
Zucker, 2008).  Pro-MMP2 and pro-MMP2 complexed with TIMP2 are specifically 
activated in vivo by active MT-MMP on the surface of tumour cells.  Cao confirmed 
that MT1-MMP (MMP14) could activate MMP2 and that its propeptide domain was 
necessary for this (Cao et al., 1998).  This occurs in benign and malignant conditions. 
MMP2 is secreted as a latent pro-enzyme complexed with TIMP2.  This complex has 
been found to be capable of activation as a complex, and without MMP2 being 
separated from it.  It is speculated that the reason that MMP2 is secreted as a complex 
is that this complex is more stable.  MMP2 would auto-activate and undergo rapid 
degradation. MMP2 contains a stabilisation site that is separate from the inhibition site.  
This stabilisation site can be occupied by various MMP inhibitors including MMP2 
and 1,10-phenanthroline, but not TIMP1.  The occupation of the stabilisation site by 
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MMP2 does not inhibit gelatinolysis – thus it is possible to have an MMP2 / TIMP2 
complex that is active (Howard et al., 1991b).  Certain studies have shown the 
possibility of this MMP/TIMP complex being activated by cellular mechanisms rather 
than the more frequently seen organomercurial mediated activation (Brown et al., 
1993).   
Further studies by Howard et al show greater inhibitory effect of TIMP2 compared to 
TIMP1.  In studying auto-activated MMP2 - which produces 2 active peptides and 
various inactive fragments – TIMP2 had greatest effect on the 42.5kDa active 
fragment – up to 10 times more effect than TIMP1.  It was also more than 2 times 
more effective than TIMP1 on MMP2 / TIMP2 complex activated by APMA.  It was 
also noted to be more than 7 times more effective than TIMP1 on MMP9 activated by 
APMA.  Radio-labelled TIMP1 and TIMP2 incubated in equal quantities with MMP9, 
autoactivated MMP2, and 42.5kDa fragment (from auto-activated MMP2) showed 
TIMP2 / TIMP1 ratios of 4.4, 10, and 33 respectively.  TIMP1 was however noted to 
be more than 2 times more effective compared to TIMP2 in inhibition of MMP1 
(interstitial collagenase) (Howard et al., 1991a).   
Plasma MMP2 is not found to be increased in many cancers (including advanced 
gastrointestinal cancer, breast cancer, gynaecological cancer, lung cancer, and 
lymphoma-leukaemia), and on the basis of in vitro studies, this is thought to be due to 
the sizeable contribution made by endothelial, and other normal cells hiding the 
MMP2 increase from solid tumour cells (Zucker et al., 1992b).  Fujimoto used home 
made kits, and found a significant decrease in MMP2 levels in osteoarthritis, 
rheumatoid arthritis, gastric and pancreatic cancer compared to normal patients.  They 
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also found significantly increased levels in hepatocellular cancer, hyperthyroidism and 
biliary cirrhosis (Fujimoto et al., 1993).   
Garbisa et al looked only at stage IV lung cancer, and did find a markedly significant 
difference between serum levels of MMP2 in these patients versus normal patients 
(P<0.0001).  They also found a less significant difference in MMP2 levels in patients 
with versus patients without distant metastases(P<0.01) (Garbisa et al., 1992).   
Note: Gelatin is an irreversibly hydrolysed form of collagen (Wikipedia, 2008) 
Studies have suggested that MMP2 and 9 are similar in various ways including having 
identical substrate specificities (type IV and V collagen and gelatin), and sharing 4 
highly homologous domains with the exception of an extra collagen-like domain in 
MMP9 (Okada et al., 1990).  They do however have different gene expressions, and 
have different activation mechanisms.    
1.4.9.2. Matrix Metalloproteinase 8 (Neutrophil 
collagenase) 
MMP8 is known as neutrophil collagenase due to the fact that it was thought to be 
confined to polymorphonuclear leukocytes (neutrophils, PMN), stored in granules and 
secreted upon activation.  MMP8 has been demonstrated in osteoarthritic 
chondrocytes, synovial fibroblasts, and endothelial cells.   
MMP8 is known as neutrophil collagenase due to the high content found in normal 
neutrophils. 
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It is secreted in a pro-form 75kDa in the case of MMP8 secreted from neutrophil, and 
50-55kDa when secreted from other cells.  The difference in size is due to 
glycosylation of neutrophil MMP8.   
Pro-MMP8 can be activated by organomercurial compounds such as p-
aminophenylmercuric acetate (APMA), oxidative agents such as oxygen radicals, 
hydrogen peroxide, or hypochlorite, and proteinases such as trypsin, -chymotrypsin, 
cathepsin G, tissue kallilrein, and MMP13.  MMP8 activity can be inhibited by TIMP1 
and TIMP2 in a 1:1 molar ratio. 
The active form of MMP8 is 68kDa.  
1.4.9.3. Matrix Metalloproteinase 9 (Gelatinase B) 
Matrix metalloproteinase 9 is a 92 kDa gelatinase/type IV collagenase in its initially 
secreted ‘pro’-form.  It is also called or 92kDa Gelatinase.  It cleaves a variety of 
substrates including gelatines, collagen types IV, V VII, X, and elastin. 
It can be activated from its precursor form by organomercurial compounds in vitro 
(e.g. APMA) and in vivo by proteinases such as trypsin, -chymotrypsin, cathepsin G, 
and others including MMP3 and hypochlorous acid.  Pro-MMP9 can be inhibited by 
binding of its hemopexin domain by the C-terminus of TIMP2 (Cao and Zucker, 
2008).  The active form of MMP8 is 83kDa.  Activation is inhibited by TIMPs in a 1:1 
molar ratio.   
MMP9 is produced in a variety of cells, in particular fibroblasts, and has been 
demonstrated to be elevated in serum samples of patients with hepatocellular 
carcinoma.  It has also been shown to play in role in other disease processes including 
Alzheimer’s disease. 
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MMP9 is derived from neutrophils (Mannello et al., 2003, Romanic et al., 2002).  
Work carried out on human prostatic tissue has shown that MMP26 (Matrilysin-2) has 
the ability to activate MMP9 (Zhao et al., 2003).  This has also been shown in 
oesophageal cancer cells (Yamamoto et al., 2004). 
1.4.10. Specific Tissue Inhibitor of Matrix 
Metalloproteinase 
The regulation of such powerful enzymes as MMPs is crucial and after control of gene 
expression, and post-translational control in the extra-cellular space, active MMPs are 
inhibited by substances including 2-macroglobulin and TIMPs (tissue inhibitors of 
MMP), a family of MMP-specific inhibitors.  These complex with active MMPs in 
order to inhibit them.  In addition some TIMPs can inhibit the activation of pro-MMPs.  
In general this inhibition seems to occur in a 1:1 molar ratio. 
TIMPs 1 to 4 all form physiologically irreversible complexes with activated MMPs at 
the amino terminal of the MMP, in order to inhibit these enzymes.  In addition to this, 
TIMP1 and 2 also form complexes with MMP9 and 2 respectively at the carboxyl 
terminal which stabilizes the MMP, but does not actually convey latency.   
TIMPs also act as growth factors for euthyroid precursors (Dollery et al., 1995). 
Expression studies suggest that there are different roles for the TIMPs.  TIMP1 seems 
to be inducible and is stimulated by cytokines and hormones, whereas TIMP2 is 
constitutive, following the expression of MMP2, with which is interacts specifically.   
There is only 43% sequence homology between TIMP1 and 2, but they are essentially 
interchangeable in their ability to inhibit MMPs.  TIMP1 and 2 are however 
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distinguished by their interactions with the pro-gelatinases.  TIMP-3 shares 37% 
sequence homology with TIMP1 and 42% with TIMP2.  It seems to be localized 
specifically to the extracellular matrix unlike the other TIMPs (Leco et al., 1994).  
TIMP1 to 3 have 6 disulfide bridges in order to maintain their 3-D structure.     
1.4.10.1. Tissue Inhibitor of Matrix Metalloproteinase 1 
TIMP1 is a 184 amino acid glycoprotein of 28.5kDa.  TIMP1 inhibits all the MMPs 
and is the most widely distributed TIMP.  The inhibition is via high affinity, reversible 
non-covalent binding to form a 1:1 complex.  It is however thought that in vivo, the 
binding is irreversible (Dollery et al., 1995).  When reversible, TIMP1 is not cleaved 
by this binding and has been shown to maintain full functionality after recovery from 
complexes with MMP3 (Stromelysin-1) (Murphy et al., 1989).   
TIMP1 has been shown to have erythroid potentiating activity. 
TIMP1 contains 12 cysteine residues, which form 6 loop structures through disulphide 
bonds.  This is demonstrated schematically in the diagram above (see previous section 
on TIMPs). 
It is known that platelets contain some TIMP1, and that serum samples have higher 
levels of TIMP1 than plasma samples from the same patient due to the release of 
TIMP1 from platelets during the clotting process.  The majority of reports however 
still seem to describe the use of serum for TIMP analysis (Zucker et al., 2004).  
TIMP1 is produced by most types of connective tissue cell, as well as macrophages 
and acts against all members of the collagenase, gelatinase and stromelysin classes of 
MMP (Dollery et al., 1995).   
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TIMP1 is produced by transformed fibroblasts, together with TIMP2 (Howard et al., 
1991a). 
TIMP1 has been shown to be produced by hepatic stellate cells, activated when the 
liver is under stress (Iredale et al., 1992).   
It is highly expressed in resorbing tissue, as its role is to regulate enzyme activity, in 
activation from latent form and inhibition of catalytic activity (Leco et al., 1994). 
1.4.10.2. Tissue Inhibitor of Matrix Metalloproteinase 2 
TIMP2 is a 21kDa, 194 amino acid unglycosylated protein with some similarity to 
TIMP1 and TIMP-3 (43% and 44% amino acid sequence homology respectively).  It 
inhibits the activity of all active MMPs, and regulates the activation of pro-MMP2 by 
binding to the C-terminal region of pro-MMP2.  This reduces the risk of spontaneous 
activation (which can occur in MMP2 and 9) and also the MMP2/TIMP2 complex 
whether activated or not, is more susceptible to inhibition by other TIMPs (Denhardt et 
al., 1993).  MMP2/TIMP2 complex can be activated, but is 20 times less active than 
uncomplexed activated MMP2 (Fridman et al., 1993).  Fridman et al also demonstrated 
an 86% decrease in activity of active MMP2 when TIMP2 was added in a 1:1 molar 
ratio. 
TIMP2 has also been shown to have erythroid potentiating activity, and cell growth-
promoting activity.  However TIMP2 complexed to pro-MMP2 has no cell growth-
promoting activity at all.  
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1.4.11. Hypothesis and aim of study 
Matrix metalloproteinases (MMPs) have been shown to be elevated in AAA tissue 
compared to normal aortic tissue (Vine and Powell, 1991, McMillan et al., 1995).  
Furthermore certain MMPs are also increased within the same aneurysm at the site of 
aneurysm rupture compared to anterior aneurysm wall (Wilson et al., 2006).  It is 
thought that the increase in MMPs brings about a state of proteolysis which initially 
causes the development of aneurysms through the breakdown of elastin, but eventually 
causes catastrophic rupture mediated by the collagenases (Dobrin and Mrkvicka, 
1994). 
Finite element analysis (FEA) is an engineering tool which identifies stress levels 
within a structure (Fagan, 1992).  It has been shown that stress levels as identified by 
FEA is higher in ruptured AAAs as compared to AAAs of a similar size but non-
ruptured and undergoing elective repair (Venkatasubramaniam et al., 2004b).  Peak 
wall stress sites have been anecdotally linked to rupture sites by observation in theatre, 
and on CT scans.  Theoretically the site in a structure with the highest stress would be 
the most likely to rupture in a situation where the stresses involved are of the same 
magnitude as the failure strength of the structure.  It makes sense therefore that the 
peak stress site undergoes the most remodelling, and that this remodelling is mediated 
by MMPs. 
Since in engineering theory the peak wall site is most likely to rupture, and 
biochemically, the site highest in collagenase is most like to rupture, it is probable that 
this site is in fact the same. 
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The hypothesis of this study is that at peak stress sites, the level of MMPs would be 
elevated compared to other sites within the aneurysm.  This difference would be 
greatest when comparing peak stress sites with minimum or low stress sites.  
Due to the desire to minimise risk to the patient, the site chosen to compare to the peak 
stress site is the arteriotomy site, where the incision is made in order to carry out the 
elective AAA repair. 
Aim of study 
The aims of the study were; 
 To compare the levels of tissue MMP2, MMP8, MMP9 (both active and total 
concentrations) and their natural inhibitors TIMP1 and TIMP2 at peak wall 
stress sites and arteriotomy sites in elective patients undergoing abdominal 
aortic aneurysm repair. 
 To compare the levels of tissue and circulating MMP2, MMP8, MMP9, TIMP1 
and TIMP2. 
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2. AAA Screening 
2.1. Materials & Methods 
2.1.1. Design 
We designed a community prospective cohort study, and obtained full institutional 
(Hull and East Yorkshire NHS Trust Research and Development approval number: 
ELSY2599) and local regional ethics committee approval (Corec Ethics Committee 
approval number: LREC/12/01/253).   
2.1.2. Sample size 
The statistical objective of the study is to estimate the proportion of true positives 
detected by the various examinations out of the total number of patients with AAAs 
(sensitivity).  In our pilot study, 93 % of patients with an AAA ≥ 5cm were able to feel 
a pulsation. To have clinical significance we expect 80% sensitivity, within 10% of the 
correct value, for which 35 patients with AAA ≥ 5cm will be needed (using the 
negative binomial distribution).  As the prevalence is about 0.7% (The Multicentre 
Aneurysm Screening Study Group, 2002), 5100 patients will have to be screened. The 
response rate in most of the AAA screening programmes is around 60%, hence 
targeting 9,000 patients for the study. The above calculations were done with the kind 
help of Dr. E.D. Gardiner, independent consultant medical statistician. 
MD Thesis  MST Heng 120 
2.1.3. Study participants 
Inclusion criteria 
All male patients aged 65 and above (n=10,591), enrolled in 15 general practices 
located in 10 separate small semi-rural towns and villages, and 1 large city in north of 
England were invited to participate.  
Exclusion criteria 
All patients reported by the general practice to have a known AAA were excluded.  
Patients subsequently reporting a known AAA via the screening form were also 
excluded.  In addition, the general practice was asked to indicate anyone that they 
thought was too unwell to participate in the study.  In an attempt to avoid inviting 
recently deceased patients, up to date patients lists were obtained from the GP practice 
prior to each batch of invitations being dispatched.  
2.1.4. Invitation and self-examination 
Patients were invited via a 2 sided letter from the practice, with the second side 
detailing the study (see appendix).  Enclosed with this letter was another 2 sided sheet 
with self-examination instructions (previously validated (Venkatasubramaniam et al., 
2004c)), a medical history enquiry section, and a study consent section (figures 9 & 
10, below).  The self-examination instruction sheet was 1 side of A4, and contained 
both self-examination and 2nd person examination instructions.  Self-examination 
instructions were a simple 4-step process, detailed alongside 2 hand-drawn line 
illustrations.  Second person examination was an optional additional part if somebody 
was available.  The answers required in both sections consisted a simple tick box.  
Contact telephone numbers were included for queries. 
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Also included was a stamped addressed envelope.  These invitational packs were sent 
in batches of 100-200.   
The entire cohort from one practice was also sent a questionnaire to assess the 
psychological aspect of being selected for this study (hospital anxiety & depression 
scale – HAD scale – see appendix).   
Those that did not respond after 4 weeks were sent 1 reminder letter.  No further 
reminders were sent after this.  All responses and non-responses of participating 
patients were recorded in a database (Microsoft Access XP).   
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 AAA Screening: Self-examination instruction sheet Figure 9.
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 Medical History enquiry sheet Figure 10.
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2.1.5. Abdominal ultrasound 
Appointments were sent out to all participating patients within 3 months of receipt of 
returned participant pack for an abdominal ultrasound scan, purely to ascertain 
abdominal aorta size.  Scanning took place at the GP practice in one cohort and at a 
local cottage hospital (within the town) in the other (simultaneous scanning in 2 rooms 
by 2 vascular technologists and a vascular research fellow).  All scans were performed 
on one of;  
 SonoSite TITAN, C60/5-2MHz convex probe, mainly B-mode 
 Philips ATL HDI 5000, 3.5MHz convex probe, abdominal aorta settings, 
mainly B-mode 
 Fukuda Denshi (FF sonic UF-4000), FUT-C111A (convex 3.5 MHz 60R) 
probe, B-mode. 
All patients with abdominal aortas < 3cm were reassured and discharged. A vascular 
surgical research fellow counselled patients with abdominal aortas from 3 to 5cm, a 
standard printed information sheet on AAA was given, they were enrolled on a AAA 
surveillance programme, and the patient’s GP was informed by letter.  Patients with 
AAAs ≥5cm were referred to a consultant within the vascular unit on an elective or 
emergent basis depending on the presence or absence of symptoms. 
2.1.6. Psychological assessment 
The psychological consequences of the study were assessed with the HAD scale at the 
time of self-examination, immediately after abdominal ultrasound scanning and 1 
month after scanning. 
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Hospital anxiety and depression scale is a rapid 1-side of A4, 14 item psychological 
assessment questionnaire that takes about 3-5 minutes to complete.  It is made up of 
questions from 2 separate subscales which provide independent anxiety and depression 
scores.  Each of the 14 questions is assigned a mark from 0-3, allowing a result 
between 0-21 for each of the subscales.  Results from 0-7 were considered normal, 8-
10 mild, 11-14 moderate, 15-21 severe for each scale. 
The HAD scale was designed to be simple and reliable, in response to the fact that 
many other scales were lengthy and required administration by trained staff (Zigmond 
and Snaith, 1983, Snaith, 2003).  In order for it to be short, the scale was designed only 
to look at anxiety and depression, with depression focusing on anhedonia.  It has been 
frequently validated for use by the elderly and also for use in other age groups, and has 
been reported to be suitable for screening (White et al., 1999).  It does not have to be 
used in the context of an in-patient hospital stay, having been validated in the 
community and primary care setting (Bjelland et al., 2002). 
HAD scales were read off the printed sheet straight into a spreadsheet (Microsoft 
Excel XP) with the appropriate calculator for the 2 independent subscale results 
(anxiety and depression).  These 2 separate marks were recorded into our database. 
These results were recorded for the 3 time-points – at self-examination, post scan, and 
1 month post scan.  Analysis was carried out using a statistics package (SPSS v11.5) 
using paired t-test for comparison of 2 time periods at a time within a subscale.  The 
proportion of patients with abnormal scores (>7) in each of the 2 subscales was also 
analysed, and compared at different time points. 
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2.1.7. Analysis of self-examination 
Sensitivity, the proportion of patients correctly diagnosed by the test as having an 
AAA out of all the patients that actually had an AAA, was calculated by dividing true 
positives by true positives plus false negatives.  Specificity, the proportion of patients 
correctly diagnosed by the test as not having an AAA, was calculated by dividing the 
true negatives by the true negatives plus false positives.   
The positive predictive value (PPV), the proportion of patients with positive test 
results whom actually had an AAA, was calculated by dividing the true positives by 
the true positives plus the false positives.  The negative predictive value (NPV), the 
proportion of patients with negative results who did not have an AAA, was calculated 
by dividing the true negatives by the true negatives plus the false negatives.   
The positive likelihood ratio (PLR) indicates the value of the test for increasing 
certainty about a positive diagnosis and provides a direct estimate of how much a test 
result will change the odds of having a disease.  It is calculated by dividing sensitivity 
by (1-specificity).  The negative likelihood ratio (NLR) [(1-sensitivity) / specificity] 
expresses the decrease in the odds of having a disease when the finding is negative. 
2.2. Results 
2.2.1. Patients and demographics 
We invited 10,591 men ≥65 years of age.  9,474 (89%) replied resulting in a non-
response rate of 11% (1,117) (table 3, below).   
Of the 9,474 men who replied, 2,006 (19%) declined to participate, whilst a further 
580 (5%) did not participate for one reason or another (detailed below).  Thus 6,888 
MD Thesis  MST Heng 127 
(65%) men, median age 72 (IQR 68-77) years, agreed to participate, and took part in 
the study. 
Of the 580 (5%) men who did not decline, but did not participate in the study, the 
reasons were; 1.7% having a known or previously repaired AAA, 0.7% being recently 
deceased (despite mechanisms in place to reduce this number), 1.3% wrong address, 
0.4% recent scan, 0.5% unwell but willing to join later, 0.5% failed to attend the 
ultrasound appointment twice, 0.1% subsequently changed mind (did not now want to 
participate in study), 0.1% out of country, 0.1% moving or moved out of area.   
5,881 replies (62% of all replies) were received within 2 weeks of the initial pack 
being sent, and a further 1,468 replies (15%) were received prior to the end of week 4.  
3,262 reminders (31% of invited group) were sent out after 4 weeks, and 2,127 replies 
(22% of all replies) were received after this (table 4, below). 
Demographic analysis showed an incidence of 65% of ex-smokers, 47% hypertension, 
39% hypercholesterolaemia, 32% ischaemic heart disease, 15% diabetes, 11% current 
smokers, and 8% previous cerebrovascular event.  2.4% also reported a family history 
of AAA (table 5, below). 
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Table 3. AAA Screening: response 
  no. % 
Total invited 10591   
Total replied 9474 89% 
No reply 1117 11% 
Agreed 6888 65% 
Declined 2006 19% 
See comments 580 5% 
Reminder 3262 31% 
 
Table 4. AAA Screening: time to response 
 Total yes no comments blank 
% of all 
replies 
% of total 
yes 
replied 2wks 5881 4612 933 336 0 62% 67% 
replied 4wks 1468 1143 236 88 1 15% 17% 
replied longer 2127 1133 837 156 1 22% 16% 
Total 9476 6888 2006 580 2   
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Table 5. Family history of AAA 
  no. % of total 
Father 27 16.9% 
Brother 59 36.9% 
Son 25 15.6% 
Uncle 5 3.1% 
Nephew 6 3.8% 
Mother 18 11.3% 
Sister 8 5.0% 
Daughter 1 0.6% 
Aunt 3 1.9% 
Niece 0 0.0% 
Cousin 8 5.0% 
Total 160   
 
2.2.2. Self, second person and tandem examinations 
Self-examination 
6035 patients carried out abdominal self-examination for AAA.  This was 88% of 
patients who agreed to take part in the study, and 57% of the total number invited.  
1262(21%) reported ‘a pulse in their tummy,’ whilst 4773(79%) could not. 
Second person examination 
4528 patients had abdominal examination carried out by a second person.  This was 
66% of patients who agreed to take part in the study, and 43% of the total number 
invited.  1125(25%) reported ‘a pulse in the patients tummy, whilst 3403(75%) could 
not. 
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Tandem examination 
6231 patients had either abdominal self-examination or second person abdominal 
examination or both.  This was 90% of patients who agreed to take part in the study, 
and 59% of the total number invited.  1652(27%) reported detecting ‘a pulse in the 
tummy’ in at least one of the 2 tests, whilst 4579(73%) could not detect ‘a pulse in the 
tummy’ in both tests. 
2.2.3. Results by practice 
15 GP practices from a variety of situations were recruited.  Roos, Hedon, Patrington 
and Preston are small villages on the outskirts of a large city (Hull), Beverley, Market 
Weighton and Driffield are small market towns, Withernsea and Hornsea are small 
seaside towns and Bridlington is a slightly bigger seaside town and holiday resort. 
Reply rates varied from 85% to 94%.  2 week replies varied from 40% to 65%.  
Consent varied from 56% to 77%.  Self-examination varied from 45% to 68% (table 6, 
below). 
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Table 6. AAA screening response rate by general practice 
GP Practice Location Men 
Replied 
% 
Replied 
in 2wks 
% 
Consent 
% 
Self-
exam % 
Manor Rd Surgery Beverley 937 90 56 64 57 
Cranwell Rd Surgery Driffield 862 91 56 64 58 
Eastgate Surgery Hornsea 1185 90 57 66 58 
Patrington Surgery Patrington 259 86 54 68 61 
Withernsea Surgery Withernsea 748 88 40 64 56 
Roos Surgery Roos 90 86 50 70 66 
Morrill Street Surgery Hull 796 87 53 60 50 
Hedon Group Practice Hedon 823 90 57 70 62 
Church View Surgery Preston 798 93 58 77 68 
Market Weighton Market Weighton 559 94 58 68 58 
Bridlington Surgery Bridlington 1032 89 52 62 55 
Marfleet Group Practice Hull 915 85 58 56 45 
Practice 1 Bridlington Bridlington 489 93 65 66 59 
Faith House Surgery Hull 443 87 55 67 60 
Practice 2 Bridlington Bridlington 655 90 63 65 57 
  Total/Mean 10591 89 56 65 57 
General practices were recruited in the above order, starting with Manor Road Surgery in Beverley. 
2.2.4. Abdominal aortic aneurysms 
216(3.1 % of consented patients) AAAs (diameter 3cm) were detected by abdominal 
ultrasonography, of which 45(0.7%) were 5 cm in diameter.  
Self-examination 
Clinically significant AAAs (5cm) had a self-examination sensitivity of 49%, 
specificity of 79%, PPV of 1.6% and NPV of 99.6%.  The PLR was 2.35, and NLR 
was 0.65 (table 7, below).   
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Sensitivity for self-examination in the detection of all AAAs was 37%, with a 
specificity of 80%.  PPV was 5.8% and NPV was 97%.   
Second person examination 
Second person examination for AAA 5cm had a sensitivity of 69%, specificity of 
75%, PPV 1.8%, NPV 99.7%, PLR 2.81, and NLR 0.41. 
Tandem examination 
When analysis was carried out on tandem 2nd person examination (at least one 
positive result from either self-examination or 2nd person examination) for AAA 
5cm, sensitivity was 68%, specificity 79%, PPV 2.2% and NPV 99.7%.  PLR was 
3.31, and NLR 0.4.   
Variation with time 
Sensitivity for self-examination in AAA ≥5cm was 83% after analysis of the first 
cohort of 1000 patients, this reduced to 67% after the first 2 cohorts and finally on 
completion of the study it was 49%.  Specificity was 86%, 83% then 79% respectively 
at the same points in the study (table 8, below). 
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Table 7. Sensitivity and specificity of self, second person and tandem 
examinations 
  Self Exam 2nd Person Exam Tandem Exam 
  ≥3cm ≥5cm ≥3cm ≥5cm  ≥5cm 
Sensitivity 37 49 48 69   68 
Specificity 80 79 76 75   79 
Positive predictive value 5.8 1.6 6 1.8   2.2 
Negative predictive value 97.4 99.6 97.9 99.7   99.7 
Positive likelihood ratio 1.84 2.35 1.98 2.81   3.31 
Neg likelihood ratio 0.79 0.65 0.69 0.41   0.4 
 
Table 8. Sensitivity and specificity of self-examination with study progression 
Invited pts Sensitivity Specificity 
1000 83 86 
1984 67 83 
10591 49 79 
 
2.2.5. Psychological scores 
Psychological impact as measured by scores from the HAD subscales of anxiety and 
depression decreased significantly between self-examination (mean scores anxiety 
4.17, depression 3.42) and immediately post-scan (mean scores anxiety 3.80, 
depression 3.04) (anxiety p<0.001, depression p<0.001), and between self-examination 
and 1 month post scan (mean scores anxiety 3.89, depression 3.22) (anxiety p<0.001, 
depression p=0.022) (figure 11, below). No significant change was seen between 
immediate post scan and 1-month post scan anxiety scores (p=0.678), although there 
was an increase in depression score (p=0.02) between immediate post scan and 1 
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month post scan scores. The proportion of patients with abnormal scores on the anxiety 
subscale was 16.8% at self-examination, reducing to 12.8% after ultrasonography and 
16.1% after 1 month. 
 
 AAA screening: hospital anxiety and depression score Figure 11.
2.3. Discussion 
This study was set up during the time when it was thought that AAA screening would 
be on the border for acceptability for the NHS in the UK, and thus the purpose of the 
study was to reduce costs in a way which was clinically reasonable.  The idea of a 
screening test to filter patients prior to a diagnostic test is quite normal for screening 
programmes, however due to the diagnostic test for AAAs (ultrasonography) being 
relatively cheap, all the studies on screening have been done with ultrasonography.  
The principle however is valid, if the diagnostic test is too expensive, a screening test 
or filtering test should be done prior to the diagnostic test to bring the costs of a 
screening programme down to an acceptable level. 
Hospital Anxiety and Depression (HAD)  
scale in AAA Screening 
2.5 
3 
3.5 
4 
4.5 
pre-scan post-scan 1 month post 
HAD depression HAD anxiety 
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2.3.1. Participation 
The response rate was 89%, with 65% agreeing to participate, but only 59% completed 
some form of abdominal examination.  19% of the cohort declined to participate.  
Through informal discussions with the participants, suggested reasons for not 
participating were; ‘not wanting to know,’ ‘not wanting surgery,’ ‘too much trouble,’ 
time constraints, perceived difficulty of self-examination, and having to attend for an 
ultrasound scan.  It was also felt by some participants that the research nature of this 
programme could have adversely affect them, since this would suggest there was an 
experimental and voluntary side to the programme, and that this was not part of 
standard recommended medical care.  
6% of the entire cohort failed to complete any kind of abdominal examination despite 
having already consented to participate.  Direct questioning by the team during 
scanning sessions revealed that many had actually carried out self-examination but 
were afraid of getting the question ‘wrong’ and therefore just left the section blank.  
Others just failed to turn the page over (2 sided sheet), and the introduction of a simple 
“PTO” (please turn over) seemed to improve this.  In addition, we did not restrict the 
upper age group as this was a study to look at the feasibility of self-examination rather 
than primarily to pick up AAAs, thus some may not have been able to complete the 
examination.  
It was also interesting how the consent rates varied with area; villages - Preston 77%, 
Roos 70%, Hedon 70%, Patrington 68%; market / seaside towns – Market Weighton 
68%, Hornsea 66%, Beverley 64%, Driffield 64%, Withernsea 64%; and bigger towns 
/ cities (Bridlington / Hull) – 67%, 66%, 65%, 62%, 60%, 56%.  This effect has been 
noted before (Smith et al., 1993), and seems applicable in this study.  
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2.3.2. Designed to detect AAAs >5cm 
Data from our pilot study showed poor detection of small aneurysms, and that 
detection generally improved with AAA diameter.  Therefore we aimed to detect the 
largest diameter AAA that would not affect normal AAA management.  At 5cm we 
felt there would be enough time to invite the patient to a normal, routine out patient 
clinic appointment, and carry out all standard pre-AAA repair investigations. Choosing 
a large AAA diameter would also mean that fewer patients would be subject to the 
anxiety involved in a long term surveillance programme.  This would also lower the 
costs associated with the surveillance.  The ability to repeat the questionnaire would 
obviate the obvious risk of missing smaller AAAs. 
2.3.3. Test effectiveness 
Sensitivity or detection rate, is the ability of a test to find those with the condition in 
question.  Our pilot study (164 patients -125 AAAs, 39 controls) showed that it was 
possible to obtain a sensitivity of 93% for self-examination in clinically significant 
AAAs (≥5cm) with an un-blinded group of AAA patients. However in this real-life 
community setting a sensitivity of 49% and specificity of 79% was obtained.  This was 
rather disappointing, but the pilot study served to demonstrate the best possible 
sensitivity obtainable, a target sensitivity level.   
Interestingly the sensitivity of self-examination for clinically significant AAAs (≥5cm) 
seemed to drop as the study progressed.  When the first cohort of patients was 
completed (n=1,000), the sensitivity was 83.3%, and specificity was 85.5%.  On 
completion of the second cohort (n=1,984) the sensitivity became 67%, and specificity 
83%.  At completion of the study the sensitivity was 49% and specificity 79%.  It is 
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possible that these results stem from the fact that the later cohorts of patients came 
from more deprived inner city areas.  However why should deprivation lead to a 
poorer sensitivity and specificity for self-examination?  Uptake of tests could be 
expected to be poorer due to lack of interest or time or both, but here we are effectively 
only comparing groups that have ‘administered’ the test.  We could not think of any 
reason that deprivation could explain this finding.  This would not explain the initial 
fall either between cohort 1 and cohort 2.  The instructions and diagrams for self and 
second person examination have not been altered, although the general leaflet design 
has changed to allow more efficient capture of information.  Again we do not believe 
that this could account for the decrease in sensitivity and specificity.  
Tandem testing involves carrying out 2 or more tests, with a positive test from either 
identifying disease – or in this case the possibility of disease.  Analysis of the entire 
sample by this method (not only where a 2nd person actually carried out examination) 
increased sensitivity to 68%.  The best sensitivity however comes from second person 
examination of clinically significant AAAs at 69%.  This perhaps makes sense as it 
make be difficult to detect a pulsation if this is the same as your heart.   Second person 
examination by doctors is also the method that AAAs have been detected for decades, 
albeit with varying degrees of success. 
These sensitivities compare poorly to mammography for breast cancer screening 82-
85%, and reasonably to conventional cervical cytology for cervical cancer screening 
29-56%, prostate specific antigen (4ug/l cutoff) for prostate cancer screening 44%, and 
faecal occult blood testing for colorectal cancer in an average risk population 10.8%.  
The problem in AAA screening is that ultrasonography is so good.  It can visualise the 
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aorta in over 99% of patients (Lindholt et al., 1999), with sensitivities estimated at 87-
99%   
Specificity is the ability of a test to correctly identify those without the condition.  
Non-specific tests ie low specificities, result in more worry for patients and 
unnecessary investigations for these false positives.  Our specificity for self-
examination of 79%, or tandem 2nd person examination specificity also of 79% 
compares unfavourably with mammography (90%), and PSA (4um/l) (94%), however 
both the latter situations would result in a biopsy whereas, our test requires a non-
invasive, low risk, rapid examination (ultrasound) if a false positive is detected.  Again 
ultrasonography is the gold standard with sensitivities of 99% (Lindholt et al., 1999). 
These assessments of test effectiveness are thus not directly comparable (but are 
certainly of interest) as situations, interventions, and outcome differ depending on the 
condition involved. 
To clinicians, positive and negative predictive values (PPV & NPV) are perhaps more 
important.  This gives the chance that the patient has the condition after a positive 
result, and conversely the chance that the patient doesn’t have the disease given a 
negative test result.  This unfortunately is immensely affected by disease prevalence, 
and therefore primarily because the incidence of AAA in the population is low, the 
PPV is low and the NPV is high. 
The likelihood ratio gives the increase in odds that the patient has the condition when 
the test is positive (positive likelihood ratio - PLR) or the decrease in odds that the 
patient does have the condition when the test is negative (negative likelihood ratio – 
NLR).  This is not affected by the prevalence of the condition involved and therefore a 
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better clinical indicator of the usefulness of a test or otherwise. The positive likelihood 
ratio for self-examination in clinically significant AAAs is 2.35, suggesting that these 
patients are more than 2 times as likely as the average man aged 65 and above to have 
an AAA.  The best result in PLR comes from tandem examination (3.31).  This reflects 
the fact that PLR is proportional to sensitivity and inversely proportional to specificity, 
and although it is marginally superior to second person examination (≥5cm) in 
sensitivity, it is much better in specificity. 
2.3.4. Psychological Assessment 
HAD scores, at all time points were within normal population ranges (0-7), ie 
invitation for self-examination and ultrasound scanning did not produce pathological 
anxiety or depression.  However, comparison of scores at self-examination to both 
immediately post-scan, and 1 month for both anxiety and depression were significantly 
reduced, indicating either a subtle elevation initially and subsequent reduction, or a 
general reduction in anxiety and depression due to “one less thing to worry about.”  No 
formal baseline was established prior to self-examination, so no comparison could be 
made to pre-screen levels.  Examination of the percentage of patients with abnormal 
anxiety or depression levels also showed a similar trend, with levels decreasing 
significantly between self-examination and post-ultrasonography, but levels then rise 
significantly between post-ultrasonography and 1 month time points.  
Other screening programmes and methods have also demonstrated the possible ill 
effects of screening, and in particular false positives.  This needs to be a real 
consideration for any screening study, as the effects can be devastating to the 
individuals concerned. 
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2.4. Conclusion 
Our results show that screening for AAA by self-examination is ineffective for 
clinically significant (≥ 5cm) AAAs, particularly in comparison to ultrasonography.  
Although psychological anxiety and depression were within normal range throughout 
the study, there was a statistically significant reduction on completion.  Second person 
examination and self-examination in tandem with 2nd person examination can 
marginally improve sensitivity, and specificity, however these do not improve results 
enough to justify this method of screening for AAAs.   
The cost-effectiveness, sensitivity, and acceptability of ultrasonography leaves little 
room for other AAA screening modalities.  The funding for a national ultrasound 
screening programme for AAAs is finally here, so the final cost barrier to 
ultrasonographic screening has now been removed.   
In future perhaps, this method can be used in other groups – women, smokers under 65 
year of age, young and middle aged relations with a family history of AAA - that 
remains to be explored.  
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3. MMPs 
3.1. Materials & Methods 
3.1.1. Planning and ethics 
Full local research ethics committee (LREC) approval was gained through application 
on the web-based COREC application system and attendance at the Hull LREC 
(COREC study number: 04/Q1104/42). 
Institutional research and development department approval (Hull and East Yorkshire 
Hospitals NHS Trust (HEYT) and University of Hull (UoH)) was also gained (Hull 
and East Yorkshire NHS Trust Research and Development no: LG/EL/R0067 with a 
memorandum of understanding with the UoH).   
All university staff involved had honorary contracts with HEYT. 
3.1.2. Sample size calculation 
Sample size calculation 
The sample size calculation was carried out during the study design period, prior to 
submission to the regional ethics committee.  Certain variable have therefore changed 
during the course of the study, but the original samples size calculations and 
assumptions are detailed. 
A normal distribution was assumed and the “Paired T-Test” was used on calculations 
involving a null hypothesis.  Correlation between each 2 paired samples was taken to 
be worse-case scenario and assumed at 0.  Data was taken from a previously presented 
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study with details published in the conference proceedings (Wilson et al., 2004) The 
study examined MMP levels in ruptured AAA from arteriotomy and rupture sites.   
The null hypothesis (H0) for this study was – there is no difference in tissue MMP 
level between high and low stress sites in elective aneurysms. 
Population means (of MMP level) taken to be;  
 high stress: 30ng/mg (previous study ruptured site 44 ng/mg) (taken to be lower 
than rupture site as not yet ruptured, but higher than “normal” as we 
hypothesize that local MMP elevation contributes to aneurysm expansion and 
local change in geometry leading to high stress areas and eventual rupture). 
 low stress: 15ng/mg (previous study arteriotomy site 17ng/mg) (taken to be 
slightly lower then arteriotomy site as this is the lowest wall tensile stress site 
and we hypothesize that this has “normal” levels of MMP). 
Range of results (MMP level) taken to be; 
 High stress areas 50ng/mg (previous study ruptures site 59ng/mg (20-79)) 
(assume slightly lower degree of variation due to lower mean value assumed 
and the observation that variance seems to be very much reduced in the 
arteriotomy site samples with their much lower mean level of MMP). 
 Low stress areas: 7ng/mg (previous study arteriotomy site 8ng/mg (14-22) 
(assume variance continues to decrease with smaller size of mean). 
Mean difference in tissue MMP between high and low stress sites = 15ng/mg. 
Standard deviation of mean difference calculated as 12.6ng/mg with correlation 
between samples = 0. 
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Sample size calculation carried out with statistical software package “PASS 2002” 
from NCSS (Number Crunching Statistical Systems, Kaysville, Utah, US), using 
paired T-test.  N=10 for 95% power at p=0.05 (N=8 for 81% power at p=0.05). 
3.1.3. Patient recruitment & history 
Patients listed for elective open AAA repair surgery with any of the 5 consultant 
surgeons in the academic vascular unit, Hull and East Yorkshire Hospitals NHS Trust 
were approached and full informed consent was obtained for inclusion in this trial.  
Information including relevant co-morbid and drug history was obtained, as was 
systolic blood pressure obtained at pre-assessment clinic, on admission for elective 
AAA repair or at most recent surgical clinic (in order of preference). 
Exclusions 
Patients undergoing emergency AAA repair and elective EVAR were not included. 
3.1.4. CT scan and calculation of peak wall stress 
Abdominal spiral CT scans were carried out as part of normal care (Mx8000 quad slice 
and Mx8000 dual slice, Philips) with scan initiation at peak of contrast uptake (100ml 
Ultravist 300, Schering AG Germany, product licence 0053/0174, administered with 
bolus pro software).  Nominal slice thickness was 3.2mm with 50% overlap and a 
helical pitch of 0.875.  The scanners were set to 120kV and 250mA with a standard 
algorithm. Abdomen and pelvis was imaged to visualise the infra-diaphragmatic aorta 
down to common iliac artery.   
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3.1.4.1. AAA image extraction / FEA analysis 
Our AAA image extraction technique has been published (Heng et al., 2008), and is as 
follows. 
CT images from renal arteries to aortic bifurcation were selected and imported to 
image processing software (Scion Image v4.0, Scion corporation, Maryland, USA), 
and each individual slice was analysed manually to obtain the location of the external 
aortic wall by a number (30-50) of mouse clicks, recording x,y coordinates (figure 12, 
below).  The z coordinate was subsequently added by inputting the slice thickness.  
This data formed a cloud of points (figure 13, below) which was imported into 3D 
image rendering software (Rhinoceros v2, Seattle, USA), creating a 3D image of the 
external surface of the aneurysm. This surface data was exported in a RAW-triangle 
format into a finite element analysis programme (Ansys 7.0, ASN Systems Ltd, 
Cannonsburg, USA).  Other information was also input including material properties 
(Raghavan et al., 2000), constraints and loading conditions (which includes systolic 
blood pressure).  A von-Mises stress diagram was produced (figure 14, below) which 
showed the aneurysm in a state of equilibrium with stress values represented by 
different colours.  It also specifically indicated with maximum stress site (MX) and 
value for each aneurysm, and also the minimum stress site (MN).  This data was 
conveyed to the vascular surgeons in the form of a simplified diagram indicating the 
peak stress site (see tissue biopsy section below), and this information was also given 
as clock face position, and position with relation to aortic bifurcation and renal arteries 
(ie 3 o’clock, 3/5 of way up from aortic bifurcation to renal arteries). 
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 CT image with manually outlined edge of AAA  Figure 12.
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 Cloud of points generated from manually extracted CT AAA edge data Figure 13.
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 Von Mises stress diagram demonstrating stress patterns within the Figure 14.
AAA, and the peak stress site (MX - peak wall stress site; MN – minimum 
stress site) 
3.1.5. Blood samples 
Both venous plasma and serum samples were obtained with consent as part of the 
protocol from patients involved in the study, on the day of admission, (1 day prior to 
AAA repair).  The serum blood samples were collected into a gold top SST BD 
vacutainer bottles containing spray-coated silica and a polymer gel for serum 
separation.  The plasma samples were collected into dark green top BD vacutainer 
bottles containing spray coated lithium heparin, with no gel separator.  These samples 
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were centrifuged within 30 minutes of venepuncture, the liquid fraction pipetted into 
sarstedt tubes, labelled and slow frozen to -80C. 
3.1.6. Tissue Biopsy 
A clinical vascular research fellow would be in theatre at the time of the aneurysm 
repair, to liaise with the surgeon, receive the tissue biopsy and prepare it for snap 
freezing in liquid nitrogen.   
A surgeon’s stress map was produced for each patient with the area of peak stress 
marked (figure 15, below), together with positional information as detailed in the AAA 
image extraction section above.  The low stress areas could also be marked on the 
stress map, but this wasn’t used since the second biopsy sample was an arteriotomy 
sample.  2 biopsies were obtained from each patient, one from the peak wall stress site 
and one from the arteriotomy site.  The biopsies were requested to be 15 x 5mm 
minimum in dimension, but sometimes due to technical difficulties, smaller samples 
were obtained.  The sample preparation was carried out with gloves and separate 
instruments for each biopsy site, and consisted; washing the sample in sterile sodium 
chloride, dividing the sample into 3 (minimum size 5 x 5mm) for MMP testing, 
weighing these resultant samples and wrapping the samples in aluminium foil with 
appropriate labelling prior to insertion into the liquid nitrogen for snap freezing, to 
ensure preservation of the enzymes involved.  Where smaller samples were obtained, 
less dividing of samples was carried out as each specific sample had a minimum size.  
The maximum time between harvesting of sample and snap freezing was 10 minutes.  
The liquid nitrogen canister was transferred to the Biological Sciences Laboratory, 
University of Hull, once a week for transfer of samples and storage in -80C freezers.   
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 Surgeon’s stress map Figure 15.
3.1.7. Tissue storage 
Tissue was stored at -80C freezers, in a secure university biomedical laboratory, with 
remote high temperature alarms. 
3.1.8. Tissue extraction and purification of MMPs / TIMPs 
Tissue extraction was carried out following a validated technique, previously used in 
several published papers (Vine and Powell, 1991, Wilson et al., 2006). 
3.1.8.1. Tissue homogenisation 
Tissue homogenisation is a procedure enabling substances within cells and the 
extracellular matrix to be analysed, and consists of mechanical and chemical disruption 
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of the substance to destroy cell membranes and release proteases from chemical bonds.  
Tissue homogenisation was carried out with approximately 1ml/100mg wet tissue 
weight cold homogenising buffer (distilled water, Brij 35, Urea, Tris-hydrochloric 
acid, EDTA, pH 7.6 – details below). The average sample size was 300mg requiring 
3ml of buffer.  Due to running ELISA tests in duplicate, and analysing active and total 
fractions of MMPs, a set of ELISA plates (1 ELISA plate each to test for MMP2, 
MMP8, MMP9, TIMP1, TIMP2) required 20 samples, and thus 60ml (3ml x 20) of 
buffer was required, but 100ml was prepared to allow for wastage.  The mechanical 
homogenisation process was carried out manually with 2 scalpels, and the sample on 
ice.  Physical disruption of the cell membrane and extracellular matrix is often carried 
out with a specialised tissue blender, but after consultation, this was considered 
unnecessary.  More importance was associated with chemical homogenisation, and the 
details of previous studies regarding homogenising buffer was followed exactly.  
Homogenising buffer 
The homogenising buffer was prepared 1 to 2 days in advance of use, but pH was 
adjusted on the day of use and protease inhibitor was also added at that time.  The 
buffer was stored in the fridge and used cold.  As detailed above, distilled water is used 
as the main ingredient of the homogenising buffer. The ingredients of the 
homogenising buffer are detailed in the appendix.  
3.1.8.2. Centrifugation 
Centrifugation was at 15,000rpm for 59minutes at 2C then the supernatant was 
aspirated leaving debris behind.   
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3.1.8.3. Dialysis 
Samples were then dialysed overnight in dialysis tubing (pre-boiled visking tubing 12-
14kDa molecular cut-off) with 75ml/1ml sample dialysis buffer (pH 8.5, distilled 
water, Brij35, calcium chloride, Tris-hydrochloric acid, details below), with both ends 
of each sample sealed with plastic clips.  The samples were then labelled and slow 
frozen down to -80C. 
Visking tubing is a form of processed cellulose which has pores, and is considered a 
partially permeable membrane.  It is available in a variety of pore sizes from 1350Da 
to 12-14kDa which is one of the bigger sizes of pore.  This size is chosen as it is 
smaller than the smallest of substances with which this study is interested (TIMP2, 
21kDa).  Since the membrane is supplied dry, it is necessary to carefully re-hydrate it, 
and some cleaning is usually recommended.  Boiling the visking tubing achieves both 
these ends, but it is necessary to ensure that the prepared tubing is kept fully immersed 
in distilled water until it is used, and that this is not for a prolonged period of time. 
3.1.8.3.1. Dialysis Buffer 
The dialysis buffer was prepared 1 to 2 days prior to dialysis, and the pH was adjusted 
on the day of use.  Approximately 3 litres of dialysis buffer was used each time.  The 
ingredients of the buffer are detailed in the appendix.   
3.1.9. ELISA testing & protein concentration determination 
ELISA testing carried out with Biotrak MMP activity assay kits, Biotrak TIMP assay 
kits, and protein concentrations were determined using the Bradford Assay, with 
Biorad protein concentration assay. 
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MMP, TIMP and protein levels were routinely analysed in duplicate or more as per 
standard lab practice for quality control purposes.  Certain trials were carried out with 
individual samples where this was simply to gauge dilution levels prior to full plate 
testing.  Certain plasma samples were also tested individually alongside duplicated 
samples (which would validate the plate and my technique) in an attempt to analyse 
more samples.   
Duplicated levels that disagreed more than 35% - suggesting a problem with the pair of 
samples, were removed at an early stage before analysis.  Values out of standard range 
were removed at an early stage, prior to analysis.  Where several results were obtained 
for a given sample, the most recent result was used for final analysis (final results 
table).  Where values were found that demonstrated a problem with the MMP detection 
of the sample ie total level of MMP2 found to be lower than active level of MMP2 in a 
given sample, the pair of results was removed from the final analysis table, and an 
older set of results used.  If possible, the entire set of results (ie patient no. 4 active 
MMP2 high stress site, patient no. 4 total MMP2 high stress site, patient no. 4 active 
MMP2 arteriotomy site, and patient no. 4 total MMP2 arteriotomy site) was used from 
an earlier plate. 
Final results for analysis were taken to be the latest result, as these plates would have 
the benefit of the earlier plates to sort out teething problems, and methodology.  Where 
the standard and extended ranges for a plate was used, if no additional results were 
gained in the extended range compared to the standard range, then the extended range 
was disregarded. 
Details of individual kits and procedures used as detailed in the appendix.  
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3.1.10. Data recording and statistical analysis 
Lab data including plate identification tables, and dilutions were recorded in the lab on 
pre-prepared plate template sheets, and notes were taken of actual timings etc.  These 
were then stuck into a lab book.   
Electronic lab data including optical density plate readings results were recorded on 
Microsoft Excel format and stored as separately labelled files.  The output tables were 
labelled, and this labelling was kept with the data in order to minimise the risk of the 
results tables being mixed up.  These source files have been kept unaltered except for 
data transfer computer to computer and for data backup purposes.   
These results tables were copied into analysis files where data was manipulated as 
demonstrated in the examples above to obtain results in ng/mg protein for tissue 
samples, and ng/ml for plasma samples.   
Basic descriptive data was obtained from Microsoft Excel, and detailed descriptive 
together with statistical analysis were obtained using SPSS for windows version 11.5 
to version 16. 
3.1.11. Statistical analysis 
Descriptives 
The age of patients involved in the study was presented as range (median).  Various 
co-morbid factors were presented as % (absolute number).  AAA diameter and peak 
wall stress are also presented as range (median). 
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Correlations 
Correlations for normally distributed data were reported with Pearson’s correlation 
coefficient (r), and the appropriate significance level.  Correlations for non-normally 
distributed data were reported with rank correlation coefficients - Spearman’s ρ (rs), 
and Kendall’s τ (τ), with the appropriate significance. 
Tests for normality 
MMP tissue and plasma concentration data was tested for normal distribution, using 
visual histogram, Q-Q plots and the Kolmogorov-Smirnov test (non-significance 
indicating normal distribution, i.e. p>0.05).  In general these data were non-normally 
distributed therefore non-parametric tests were used for analysis of these data. 
MMP / TIMP concentrations 
These were reported as median (interquartile range), and the null hypothesis was that 
there was no difference between concentrations of an individual MMP or TIMP at the 
peak stress site versus the arteriotomy site.  This hypothesis was tested using the data 
and the Wilcoxon signed ranks test for testing non-parametric paired data.  
Significance was taken at p≤0.05, and indicated rejection of the null hypothesis. 
MMP ratios 
MMP ratios (eg the ratio of active to total MMP2 at peak stress site, and the ratio of 
active to total MMP2 at arteriotomy site) were tested and reported as normally 
distributed.  The difference in ratios were reported as means, 95% confidence interval, 
and tested with the paired t-test. 
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TIMP ratios 
The ratio of individual TIMPs at arteriotomy site to peak stress site was simply 
reported.  The ratios of certain MMPs against certain TIMPs at peak stress versus 
arteriotomy sites were also compared by non-paramatric paired tests (Wilcoxon signed 
ranks test). 
Reliability of runs 
This was compared using the samples from the same patients and analysing these 
samples using the same tests, but after a time interval.  Correlations, and the 
significance of these were assessed, together with analysis to determine the mean 
absolute difference, mean percentage differences, and mean differences from the mean 
found between the test results. 
3.2. Results 
3.2.1. Patients and demographics 
36 patients were recruited into the study with informed consent, of which 26 CT scans 
successfully retrieved, finite element analysis performed and peak wall stress levels 
calculated.  22 of these patients then went on to have tissue biopsied.  There were 
various reasons that patients recruited did not have tissue biopsied including, digital 
CT scan images not obtained (not sufficient time to obtain scan, CT archive not 
accessible, scan carried out at separate facility -private), finite element analysis not 
performed (not sufficient time, lab computer not available), research fellow not 
available at time of AAA repair to direct and obtain tissue sample (on-call at separate 
hospital), request for tissue denied at time of AAA repair due to patient instability 
(n=1).  There were no patient refusals.  Of these 36 patients, the age range was 63 to 
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85(median 73), 83%(30) were male, 39%(14) were current smokers, 89%(32) smoked 
at some point in their life, the median number of pack years was 32.  56%(20) had 
hypertension, 25%(9) had a previous cerebrovascular accident or transient ischaemic 
attack, 25%(9) had a history of ischaemic heart disease, 22%(8) had a previous 
myocardial infarction and 8%(3) had a history of diabetes mellitus.  In the drug 
history, 61%(22) were on aspirin, and 39%(14) were on statins (table 9, below). 
Table 9. Demographics of recruited patients 
Demographics n=36 
Age range (median) 63-85 (73) 
Sex (male) 83% (30) 
Co-morbid History 
Current smokers 39%(14) 
History of smoking (at any point) 89%(32) 
Pack years range (median) 5-104(32) 
Hypertension 56%(20) 
Range of systolic blood pressure (median) 105-194(155) 
Previous CVA / TIA 25%(9) 
Ischaemic heart disease 25%(9) 
Myocardial infarction 22%(8) 
Diabetes mellitus 8%(3) 
Drug History 
Aspirin 61%(22) 
Statin 39%(14) 
 
3.2.2. AAA Diameter 
AAA diameter ranged from 5cm to 8.5cm, with a median size of 5.8cm. 
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3.2.3. Peak wall stress 
Peak wall stress varied from 0.46 to 1.33MPa (median 0.74MPa).  There was no 
correlation between Peak Wall Stress and AAA diameter (rs = 0.49, p=0.18, 
Spearman’s ranked correlation coefficient) (figure 16, below). 
 
 
 Scatter graph of AAA diameter and peak wall stress Figure 16.
3.2.4. Tissue MMP & TIMP 
7 testing runs were carried out during the course of this project.  A run consisted of the 
process from the removal of a snap frozen selection of tissue samples from -80°C 
storage, through tissue homogenisation, dialysis, and ELISA analysis of MMP and/or 
TIMP concentration, with protein determination of each selection of tissue samples.  
Tissue homogenates were frozen after dialysis, and thawed prior to ELISA analysis 
and protein concentration determination. 
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Run 1 was mainly to establish the range of concentrations on our samples (obtained 
initially from literature), and to fine tune dilutions and techniques.  Run 2 was a 
straightforward run.  Run 3 was a duplicate of run 2 in order to ascertain the 
reproducibility or reliability of the results obtained from run to run.  Run 4 was a 
limited run involving only some tests as not all tests were available.  Run 5 was carried 
out to complete the tests not carried out in run 4. Run 6 was again a complete run 
involving AAA tissue, and finally run 7 was for plasma MMP / TIMP concentration 
determination.   
3.2.4.1. MMP2 
The number of samples analysed for MMP2 was 22.  An inadequate sample was 
obtained for subject 11 resulting in no total MMP2 concentration at the arteriotomy 
site being obtained.  Analysis of active and total forms of MMP2 measured at peak 
stress and arteriotomy sites showed a non-normal distribution, except for active MMP2 
at the arteriotomy site which may have a normal distribution (p=0.2, Kolmogorov-
Smirnov test).  Non-parametric tests were therefore used to compare these results.  
Raw results are found in a tabulated form in appendix 4. 
Active MMP2 
The median concentration of active MMP2 was 2.80ng/mg (interquartile range 1.49-
4.89) at the peak stress site, and 2.45ng/mg (1.38-4.87) at the arteriotomy site (figure 
17, below).  There was no statistically significant difference between these sites 
(p=0.81, Wilcoxon signed ranks test).   
No correlation was found between active MMP2 at peak wall stress and arteriotomy 
sites [τ = 0.117 p=0.446 (Kendall’s τ rank correlation coefficient), rs = 0.171 p=0.446 
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(Spearman’s ρ rank correlation coefficient)].  A scatter graph with regression line for 
the above data is shown below (figure 18, below). 
Total MMP2 
The median concentration of total MMP2 was 24.41ng/mg (12.87-36.45) at the peak 
stress site, and 21.87ng/mg (13.00-32.82) at the arteriotomy site (figure 17, below).  
Again there was no statistically significant difference between these sites (p=0.66, 
Wilcoxon signed ranks test).  
Correlation was found between total MMP2 samples found in peak wall stress and 
arteriotomy sites (τ = 0.314 p=0.046, rs = 0.440 p=0.046).  A scatter graph with 
regression line for the above data is shown below (figure 19, below). 
MMP2 Ratios 
The ratio of active to total MMP2 at peak wall stress sites, and arteriotomy sites (figure 
20, below) were normally distributed (p=0.2, p=0.09 respectively, Kolmogorov-
Smirnov test).  There was no significant difference between the ratios of active MMP2 
to total MMP2 at peak wall stress versus arteriotomy sites (Mean difference -0.024, 
95% CI -0.062-0.015, p=0.212, paired t-test).  The negative mean difference seen here 
suggests that the ratio of active to total MMP2 is actually higher at the arteriotomy site 
compared to the peak wall stress site, although the 95% confidence interval includes 0 
and therefore shows no significant difference between the ratios. 
There was also no difference found on comparing the ratio of MMP2 to total MMPs 
(MMP2+MMP8+MMP9) at the peak stress site to the arteriotomy site. 
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Tissue MMP2 Concentration - 
active and total at peak wall stress and arteriotomy sites
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 Tissue MMP2 concentration – active and total at peak wall stress and Figure 17.
arteriotomy sites 
High Active: Active MMP2 at peak wall stress site, High Total: Total MMP2 at peak wall stress site; 
Art Active: Active MMP2 at arteriotomy site; Art Total: Total MMP2 at arteriotomy site. Box and 
whisker plots show median, 25th, 75th centiles with whiskers extending to 10th and 90th centiles and 
outliers beyond this indicated. 
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Active MMP2 Concentration: 
arteriotomy site versus peak wall stress site
Tissue active MMP2 concentration
at arteriotomy site (ng/mg)
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 Active MMP2 Concentration: arteriotomy versus peak wall stress sites Figure 18.
Scatter plot with regression line. 
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Total MMP2 Concentration: 
arteriotomy site versus peak wall stress site
Tissue total MMP2 concentration
at arteriotomy site (ng/mg)
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 Total MMP2 Concentration: arteriotomy versus peak wall stress sites Figure 19.
Scatter plot with regression line. 
MD Thesis  MST Heng 163 
Tissue MMP2 Ratio - 
active to total at peak wall stress and arteriotomy sites
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 Tissue MMP2 Ratio – active to total at peak wall stress and Figure 20.
arteriotomy sites 
Box and whisker plots show median, 25th, 75th centiles with whiskers extending to 10th and 90th centiles 
and outliers beyond this indicated. 
3.2.4.2. MMP8 
The number of samples analysed for MMP8 was 22.  Subject 11 had no satisfactory 
result obtained for total MMP8 concentration either at the peak wall stress site or the 
arteriotomy site.  Analysis of active and total forms of MMP8 measured at peak stress 
and arteriotomy sites showed possible normal distributions (active MMP8 peak stress 
site p=0.2, total MMP8 peak stress site p=0.12, active MMP8 arteriotomy site p=0.16, 
Kolmogorov-Smirnov test), except for total MMP8 at the arteriotomy site which has a 
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non-parametric distribution.  As not all data had normal distributions, non-parametric 
tests were used to compare these results.  Raw results are found in a tabulated form in 
appendix 4. 
Active MMP8 
The median concentration of active MMP8 was 5.20ng/mg (interquartile range 2.54-
9.82) at the peak stress site, and 6.99ng/mg (3.65-15.72) at the arteriotomy site (figure 
21, below).  There was no statistically significant difference between these sites 
(p=0.15, Wilcoxon signed ranks test).   
A positive significant correlation was found between active MMP8 samples found in 
peak wall stress and arteriotomy sites (τ = 0.385 p=0.012, rs = 0.523 p=0.012).  A 
scatter graph with regression line for the above data is shown below (figure 22, below). 
Total MMP8 
The median concentration of total MMP8 was 18.80ng/mg (9.82-31.85) at the peak 
stress site, and 16.44ng/mg (10.81-31.98) at the arteriotomy site (figure 21, below).  
There was no statistically significant difference between these sites (p=0.52, Wilcoxon 
signed ranks test).   
A positive significant correlation was found between total MMP8 samples found in 
peak wall stress and arteriotomy sites (τ = 0.381 p=0.016, rs = 0.508 p=0.019).  A 
scatter graph with regression line for the above data is shown below (figure 23, below). 
Ratios 
The ratio of active to total MMP8 at peak wall stress sites, and arteriotomy sites (figure 
24, below) were normally distributed (p=0.13, p=0.2 respectively, Kolmogorov-
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Smirnov test).  There was a trend towards significance in the difference between the 
ratios of active MMP8 to total MMP8 at peak wall stress versus arteriotomy sites 
(Mean -0.14, 95% CI -0.29-0.01, p=0.064, paired t-test), with higher ratios being seen 
in 14 of the 21 samples at the arteriotomy sites compared to the peak wall stress site. 
There was also no difference found on comparing the ratio of MMP8 to total MMPs 
(MMP2+MMP8+MMP9) at the peak stress site to the arteriotomy site. 
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Tissue MMP8 Concentration - 
active and total at peak wall stress and arteriotomy sites
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 Tissue MMP8 Concentration – active and total at peak wall stress and Figure 21.
arteriotomy sites 
High Active: Active MMP8 at peak wall stress site, High Total: Total MMP8 at peak wall stress site; 
Art Act: Active MMP8 at arteriotomy site; Art Total: Total MMP8 at arteriotomy site.  Box and whisker 
plots show median, 25th, 75th centiles with whiskers extending to 10th and 90th centiles and outliers 
beyond this indicated. 
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Active MMP8 Concentration: 
arteriotomy site versus peak wall stress site 
Tissue active MMP8 concentration
at arteriotomy site (ng/mg)
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 Active MMP8 Concentration: arteriotomy versus peak wall stress sites Figure 22.
Scatter plot with regression line 
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Total MMP8 Concentration: 
arteriotomy site versus peak wall stress site
Tissue total MMP8 concentration
at arteriotomy site (ng/mg)
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 Total MMP8 Concentration: arteriotomy versus peak wall stress sites Figure 23.
Scatter plot with regression line 
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Tissue MMP8 Ratio - 
active to total at peak wall stress and arteriotomy sites
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Peak Wall Stress Arteriotomy
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 Tissue MMP8 Ratio – active to total at peak wall stress and Figure 24.
arteriotomy sites 
Box and whisker plots show median, 25th, 75th centiles with whiskers extending to 10th and 90th centiles 
and outliers beyond this indicated. 
3.2.4.3. MMP9 
The number of samples analysed for MMP9 was 22.  Subject 11 had no satisfactory 
result obtained for total MMP9 concentration either at the peak wall stress site or the 
arteriotomy site.  Analysis of active and total forms of MMP9 measured at peak stress 
and arteriotomy sites showed a non-normal distribution, except for total MMP9 at the 
peak stress site (p=0.2, Kolmogorov-Smirnov test), and total MMP9 at the arteriotomy 
site which may have a normal distribution (p=0.14).  Since not all data was normally 
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distributed, non-parametric tests were used to compare these results.  Raw results are 
found in a tabulated form in appendix 4. 
Active MMP9 
The median concentration of active MMP9 was 0.58ng/mg (interquartile range 0.38-
0.85) at the peak stress site, and 0.54ng/mg (0.32-0.97) at the arteriotomy site (figure 
25, below).  There was no statistically significant difference between these sites 
(p=0.78, Wilcoxon signed ranks test).   
No correlation was found between active MMP9 at peak wall stress and arteriotomy 
sites (τ = 0.083 p=0.592, rs = 0.154 p=0.493).  A scatter graph with regression line for 
the above data is shown below (figure 26, below). 
Total MMP9 
The median concentration of total MMP9 was 9.70ng/mg (3.95-24.47) at the peak 
stress site, and 11.34ng/mg (8.55-20.49) at the arteriotomy site (figure 25, below).  
There was no statistically significant difference between these sites (p=0.85, Wilcoxon 
signed ranks test).   
A positive significant correlation was found between total MMP9 samples found in 
peak wall stress and arteriotomy sites (τ = 0.457 p=0.004, rs = 0.629 p=0.002).  A 
scatter graph with regression line for the above data is shown below (figure 27, below) 
Ratios 
The ratio of active to total MMP9 at peak wall stress sites, and arteriotomy sites (figure 
28, below) were normally distributed (p=0.12, p=0.20 respectively, Kolmogorov-
Smirnov test).  There was no significant difference between the ratios of active MMP9 
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to total MMP9 at peak wall stress versus arteriotomy sites (Mean 0.0054, 95% CI -
0.0070-0.018, p=0.38, paired t-test). 
There was also no difference found on comparing the ratio of MMP9 to total MMPs 
(MMP2+MMP8+MMP9) at the peak stress site to the arteriotomy site.  
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 Tissue MMP9 Concentration – active and total at peak wall stress and Figure 25.
arteriotomy sites 
High Active: Active MMP9 at peak wall stress site, High Total: Total MMP9 at peak wall stress site; 
Art Active: Active MMP9 at arteriotomy site; Art Total: Total MMP9 at arteriotomy site.  Box and 
whisker plots show median, 25th, 75th centiles with whiskers extending to 10th and 90th centiles and 
outliers beyond this indicated. 
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Active MMP9 Concentration: 
arteriotomy site versus peak wall stress site
Tissue active MMP9 concentration
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 Active MMP9 Concentration: arteriotomy versus peak wall stress sites Figure 26.
Scatter plot with regression line 
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Total MMP9 Concentration: 
arteriotomy site versus peak wall stress site
Tissue total MMP9 concentration
at arteriotomy site (ng/mg)
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 Total MMP9 Concentration: arteriotomy versus peak wall stress sites Figure 27.
Scatter plot with regression line 
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Tissue MMP9 Ratio - 
active to total at peak wall stress and arteriotomy sites
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 Tissue MMP9 Ratio – active to total at peak wall stress and Figure 28.
arteriotomy sites 
Box and whisker plots show median, 25th, 75th centiles with whiskers extending to 10th and 90th centiles 
and outliers beyond this indicated. 
3.2.4.4. TIMP1 
The number of samples analysed for TIMP1 was 22.  Analysis of TIMP1 measured at 
peak stress sites showed a non-normal distribution, but TIMP1 at the arteriotomy site 
may have a normal distribution (p=0.2, Kolmogorov-Smirnov test).  Non-parametric 
tests were therefore used, since not all the data had normal distributions.  Raw results 
are found in a tabulated form in appendix 4. 
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TIMP1 concentration 
The median concentration of TIMP1 was 364.84ng/mg (Interquartile range 210.49-
523.26) at the peak stress site, and 229.84ng/mg (86.80-370.95) at the arteriotomy site 
(figure 29, below).  No statistically significant difference was seen between the sites 
(p=0.2, Wilcoxon-signed ranks test).   
There was no significant correlation between TIMP1 at the arteriotomy site and the 
peak wall stress site (see tables in appendix 4), 
TIMP1 Ratio 
The mean ratio of TIMP1 at arteriotomy to peak wall stress sites was 0.93 (range 0.07-
3.10). 
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Tissue TIMP1 Concentration - 
peak wall stress and arteriotomy sites
Site
Peak wall stress Arteriotomy
T
is
s
u
e
 T
IM
P
1
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
g
)
0
200
400
600
800
1000
1200
1400
 
 Tissue TIMP1 Concentration – peak wall stress and arteriotomy sites Figure 29.
Box and whisker plots show median, 25th, 75th centiles with whiskers extending to 10th and 90th centiles 
and outliers beyond this indicated. 
3.2.4.5. TIMP2 
The number of samples analysed for TIMP2 was 22.  Analysis of TIMP2 measured at 
peak stress (p=0.14, Kolmogorov-Smirnov test) and arteriotomy sites (p=0.14) showed 
a possibly normal distribution, however since the rest of the data was tested using non-
parametric tests, these were also used here.  Raw results are found in a tabulated form 
in appendix 4. 
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TIMP2 concentration 
The median concentration of TIMP2 was 17.10ng/mg (Interquartile range 8.55-29.08) 
at the peak stress site, and 14.64ng/mg (8.56-29.93) at the arteriotomy site (figure 30, 
below).  No statistically significant difference was seen between the 2 sites (p=0.76, 
Wilcoxon-signed ranks test).   
There was no significant correlation between TIMP2 at the arteriotomy site and the 
peak wall stress site (see tables in appendix 4) 
TIMP2 Ratio 
The mean ratio of TIMP2 at arteriotomy to peak wall stress sites was 2.24 (range 0.15-
14.32). 
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Tissue TIMP2 Concentration - 
peak wall stress and arteriotomy sites
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 Tissue TIMP2 Concentration – peak wall stress and arteriotomy sites Figure 30.
Box and whisker plots show median, 25th, 75th centiles with whiskers extending to 10th and 90th centiles 
and outliers beyond this indicated. 
3.2.4.6. Protein concentration 
The number of samples analysed for protein concentration was 22.  Analysis of protein 
concentrations measured at peak stress (p=0.2, Kolmogorov-Smirnov test) and 
arteriotomy sites (p=0.2) showed a possibly normal distribution, however since the rest 
of the data was tested using non-parametric tests, these were also used here.  Raw 
results are found in a tabulated form in appendix 4. 
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Protein concentration 
The median concentration of Protein was 2.27mg/ml (Interquartile range 1.55-3.28) at 
the peak stress site, and 2.23mg/ml (1.16-3.77) at the arteriotomy site (figure 31, 
below).  No statistically significant difference was seen between the 2 sites (p=0.96, 
Wilcoxon-signed ranks test). 
Ratio of protein concentration at arteriotomy to peak stress sites 
The mean ratio of protein concentration at arteriotomy to peak wall stress sites was 
1.22 (range 0.07-5.12). 
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 Tissue Protein Concentration – peak wall stress and arteriotomy sites Figure 31.
Box and whisker plots show median, 25th, 75th centiles with whiskers extending to 10th and 90th centiles 
and outliers beyond this indicated. 
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3.2.4.7. Special MMP/TIMP ratios 
MMP2/TIMP ratios 
No significant difference was found in MMP2/TIMP1 or MMP2/TIMP2 ratios 
between peak stress and arteriotomy sites. 
MMP8/TIMP ratios 
Analysis of MMP8/TIMP ratios revealed all had non-normal distributions, therefore 
analysis was carried out with the Wilcoxon signed ranks test. 
Active MMP8 / TIMP1 ratio at peak wall stress sites had a median value of 0.0161 
(IQR 0.0064-0.0386).  Active MMP8 / TIMP1 ratio at arteriotomy site had a median 
value of 0.0341 (IQR 0.0159-0.1004)(figure 32, below).  A statistically significant 
difference was found between active MMP8 / TIMP1 at peak stress sites versus 
arteriotomy sites (p=0.039, Wilcoxon signed ranks test)(see table 10 below).  Thus the 
ratio of active MMP8 / TIMP1 was significantly lower at peak wall stress sites 
compared to arteriotomy sites. 
Due to the number of statistical tests carried out in this study, the Bonferroni method 
(Bland, 2000) should be applied to the above finding.  If we assume that we have 5 
independent populations (corresponding to each of the MMPs and TIMPs – even 
though they are not fully independent), then we should only accept significance at the 
α/κ (=0.05/5) 0.01 level.  Thus we cannot assume that the above result is statistically 
significant. 
No other significant differences were found. 
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MMP9/TIMP ratios 
No significant difference was found in MMP9/TIMP1 or MMP9/TIMP2 ratios 
between peak stress and arteriotomy sites. 
Ratio of Active MMP / TIMP1 - 
at peak wall stress and arteriotomy sites
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 Ratio of Active MMP8 / TIMP1 – at peak wall stress and arteriotomy Figure 32.
sites 
Box and whisker plots show median, 25th, 75th centiles with whiskers extending to 10th and 90th centiles 
and outliers beyond this indicated. 
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Table 10. Comparison of MMP8/TIMP ratios at peak stress versus arteriotomy 
sites 
Test Statistics
c
 
 MMP8 art active / 
TIMP1 art - MMP8 
high active / TIMP1 
high 
MMP8 art total / 
TIMP1 art - MMP8 
high total / TIMP1 
high 
MMP8 art active / 
TIMP2 art - MMP8 
high active / TIMP2 
high 
MMP8 art total / 
TIMP2 art - MMP8 
high total / TIMP2 
high 
Z -2.094
a
 -1.373
a
 -.666
a
 -1.338
b
 
Asymp. Sig. (2-tailed) .036 .170 .506 .181 
a. Based on negative ranks.    
b. Based on positive ranks.    
c. Wilcoxon Signed Ranks Test    
 
3.2.4.8. Reliability of runs 
The degree of reproducibility of results from run to run was tested between run 2 and 
run 3 (table 11, below).  This repeated the entire process from frozen tissue sample, 
through MMP/TIMP extraction from tissue, freeze/thaw cycle, ELISA testing for 
MMP and TIMP concentrations and Bradford analysis for protein concentration in 
order to compare the final MMP/TIMP concentrations for these particular subjects.  
The samples although from the same subjects, had been separated immediately after 
harvesting.  The runs were carried out 4 months apart. 
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Table 11. Reliability of results (comparison of run2 and run3) 
Reliability of results (comparison of run2 & run3) 
  MMP2 MMP8 MMP9 TIMP1 TIMP2 Protein 
Spearman's correlation coefficient 0.80 0.61 0.80 0.64 0.66 0.49 
Significance 0.00 0.00 0.00 0.00 0.00 0.04 
Mean absolute difference (sd) 
23.27 
(58) 
17.6 
(88) 
13.78 
(26) 
600.55 
(1804) 
38.74 
(89) 1.93(2.6) 
Median absolute difference 5.40 5.88 5.00 196.71 13.33 0.77 
Median sample value 5.16 9.58 2.90 224.05 31.80 2.20 
Mean % absolute difference 86 80 99 105 72 64 
Mean % difference from mean 43 40 49 53 36 32 
% positive (run2-run3) 22 28 47 8 34 72 
 
Correlation 
Although there was good significance of correlation between the runs for the various 
plates (mostly significant at the 0.01 level), the actual degree of correlation was 
surprisingly low, with Spearman’s correlation coefficient varying from 0.49 (protein 
concentration) to 0.80 (MMP2 and MMP9). 
Differences 
There was quite a marked difference between the results in run 2 and run 3, with 
percentage differences varying from 64% (protein concentration) to 105% (TIMP1).  
However often reporting of spread often looks at difference from the mean (see mean 
% difference from mean) from which variances and standard deviations are calculated, 
and is effectively half the value of the absolute difference.   
The ‘percentage positive’ results show that generally higher results were obtained in 
the later test (run 3), except for protein concentration. 
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3.2.5. Plasma 
Blood plasma levels of MMP and TIMP are reported in weight per unit volume 
(ng/ml) of plasma therefore results are also reported in these units here.  For 
comparison to tissue MMP however, it is necessary to analyse concentrations in 
comparative units to which tissue MMP was reported (weight per unit of protein 
weight - ng/mg).  For this purpose therefore the concentration of plasma protein was 
also measured, and this provided plasma MMP concentration in ng/mg protein – 
similar units to the reporting of tissue MMP although the protein divisor in the case of 
tissue MMP is obviously tissue protein. 
3.2.5.1. Plasma MMP2 
The number of samples analysed for MMP2 was 20.  Analysis of active and total 
forms of plasma MMP2 demonstrated a possibly normal distribution for both (p=0.08, 
p=0.2, Kolmogorov-Smirnov test).   
Plasma active MMP2 
The median concentration of active MMP2 was 23.71ng/ml (interquartile range (IQR) 
20.99-35.64).   
Plasma total MMP2 
The median concentration of total MMP2 was 655.64ng/ml (IQR 549-813).   
Plasma active to total MMP2 ratio 
The ratio of active to total plasma MMP2 was normally distributed (p=0.2, 
Kolmogorov-Smirnov test).  The mean ratio was 0.04 (IQR 0.29-0.06). 
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Tissue and plasma MMP2 
Concentrations compared were tissue MMP2 in ng/mg tissue protein and plasma 
MMP2 in ng/mg plasma protein.   
A significant correlation was found between plasma active MMP2 and tissue active 
MMP2 from peak wall stress site [τ = -0.345 (Kendall’s τ rank correlation 
coefficient)(p=0.039), rs = -0.498 (p=0.03)(Spearman’s ρ rank correlation coefficient)].  
A scatter graph with regression line for the above data is shown below (figure 33, 
below). 
There were no other significant correlations between tissue and plasma MMP2 either 
active or total forms (see tables in appendix 4).   
Active MMP2 Concentration: 
plasma versus peak wall stress site
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 Active MMP2 Concentration: plasma versus peak wall stress site Figure 33.
Scatter plot with regression line. 
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3.2.5.2. Plasma MMP8 
Unfortunately 50% of plasma levels for active MMP8 were too low for analysis at the 
plate concentration.  This was despite earlier trial analysis on tissue MMP8 plates to 
determine rough concentrations needed for the plasma MMP8 plate.  Active MMP8 
was analysed at 8 times the concentration of total MMP8, but still to no avail.  11 
results were however obtained.  Plasma total MMP8 was unaffected, although less 
plasma active to total ratios were obtained. 
The number of samples analysed for plasma active MMP8 was 10, and for plasma total 
MMP8, 20.  Analysis of active and total forms of plasma MMP8 demonstrated a 
possibly normal distribution for both (p=0.2, p=0.2, Kolmogorov-Smirnov test).   
Plasma active MMP8 
The median concentration of active MMP8 was 0.51ng/ml (interquartile range (IQR) 
0.36-0.70).   
Plasma total MMP8 
The median concentration of total MMP8 was 3.10ng/ml (IQR 1.73-5.59).   
Plasma active to total MMP8 ratio 
The ratio of active to total plasma MMP8 was normally distributed (p=0.07, 
Kolmogorov-Smirnov test).  The mean ratio was 0.21 (IQR 0.070-0.372). 
Tissue and plasma MMP8 
Concentrations compared were tissue MMP8 in ng/mg tissue protein and plasma 
MMP8 in ng/mg plasma protein. 
MD Thesis  MST Heng 187 
A significant correlation was found between plasma total MMP8 and tissue total 
MMP8 from arteriotomy site (τ = 0.340 p=0.042, rs = 0.475 p=0.040).  A scatter graph 
with regression line for the above data is shown below (figure 34, below). 
There were no other significant correlations between tissue and plasma MMP8 either 
active or total forms (see tables in appendix 4).   
Total MMP8 Concentration:
plasma versus arteriotomy site
Plasma total MMP8 concentration (ng/mg)
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 Total MMP8 Concentration: plasma versus arteriotomy site Figure 34.
Scatter plot with regression line 
3.2.5.3. Plasma MMP9 
The number of samples analysed for MMP9 was 20.  Analysis of active and total 
forms of plasma MMP9 demonstrated a possibly normal distribution for total MMP9 
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(p=0.2, Kolmogorov-Smirnov test), but non-normal distribution for active MMP9 
(p=0.023).   
Plasma active MMP9 
The median concentration of active MMP9 was 4.26ng/ml (interquartile range (IQR) 
4.00-6.66).   
Plasma total MMP9 
The median concentration of total MMP9 was 55.51ng/ml (IQR 38.98-84.04).   
Plasma active to total MMP9 ratio 
The ratio of active to total plasma MMP9 was normally distributed (p=0.057, 
Kolmogorov-Smirnov test).  The mean ratio was 0.064 (IQR 0.048-0.185). 
Tissue and plasma MMP9 
Concentrations compared were tissue MMP9 in ng/mg tissue protein and plasma 
MMP9 in ng/mg plasma protein. 
There were no significant correlations between tissue and plasma MMP9 either active 
or total forms (see tables in appendix 4).   
3.2.5.4. Plasma TIMP1 
The number of samples analysed for TIMP1 was 20.  Analysis of plasma TIMP1 
demonstrated a possibly normal distribution (p=0.2, Kolmogorov-Smirnov test).   
Plasma TIMP1 
The median concentration of TIMP1 was 201.5ng/ml (interquartile range (IQR) 158.9-
217.1).   
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Tissue and plasma TIMP1 
Concentrations compared were tissue TIMP1 in ng/mg tissue protein and plasma 
TIMP1 in ng/mg plasma protein. 
There were no significant correlations between tissue and plasma TIMP1 (see tables in 
appendix 4).   
3.2.5.5. Plasma TIMP2 
The number of samples analysed for TIMP2 was 20.  Analysis of plasma TIMP2 
demonstrated a possibly normal distribution (p=0.2, Kolmogorov-Smirnov test).   
Plasma TIMP2 
The median concentration of TIMP2 was 141.8ng/ml (interquartile range (IQR) 118.7-
147.4).   
Tissue and plasma TIMP2 
Concentrations compared were tissue TIMP2 in ng/mg tissue protein and plasma 
TIMP2 in ng/mg plasma protein. 
There were no significant correlations between tissue and plasma TIMP2 (see tables in 
appendix 4).   
3.2.5.6. Degradation of plasma MMP samples 
A large percentage (50%) of the active MMP8 plasma samples produced unrecordably 
low results when ELISA tested for concentration.  This was due to having diluted 
down the samples too much despite several earlier trial runs with 2 or 3 wells of an 
ELISA plate alongside tissue samples for MMP8.  These earlier tests are done to 
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determine an appropriate dilution for the ELISA plate, and these dilutions seemed to 
change.  In fact the plasma sample of active MMP8 needed to be less and less dilute to 
keep in within the detection range of the ELISA kits as time went on.  The first 
dilution was 5mcl sample to 95mcl buffer (first plasma run – ELISA run 3 (10 Jan 
2006) – 2/2 samples in range), through 10mcl sample to 90mcl buffer (second plasma 
run – ELISA run 5 (2 March 2006) – 0/2 samples in range), and 40mcl sample to 
60mcl buffer (Third plasma run – ELISA run 7 (13 March 2006) - 9/24 samples in 
range).  So in fact despite a sample which was 8 times less concentrated in run 7, the 
early spot-on dilution became too dilute.  The samples had almost lost 90% of their 
activity within that 3 month timeframe.  A similar effect also seemed to have taken 
place on the plasma total MMP8 samples.  The samples were all kept together, so in 
fact this must have affected the MMP8 in all the samples.  Other MMPs or TIMPs did 
not have such noticeable problems with their plasma dilutions occurring.   
3.3. Discussion 
3.3.1. Results 
3.3.1.1. Peak wall stress levels 
The AAA peak wall stress levels found in this study varied from 0.46 to 1.33MPa.  
This is in line with AAA peak stress levels of 29 – 45 N/cm2 (0.29-0.45MPa) found by 
Raghavan and Vorp in their seminal paper in 2000 (Raghavan et al., 2000).  
Interestingly, in that paper they suggested that the typical failure strength of AAAs was 
about 65N/ cm
2
)(0.65MPa), referring to work done earlier (Vorp et al., 1996b).  This 
would indicate that these patients are being repaired at the right time, and that potential 
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rupture is not far off.  Indeed 15 out of 26 patients had peak wall stress values over 
0.65MPa.  Three patients had values over 1MPa, with AAA diameter 5.7, 6.1, and 
6.7cm, and systolic blood pressure over 150mmHg.  Of note, all 3 were women.  
Venkatasubramaniam of this unit obtained mean values for peak wall stress of 
0.62MPa in non-ruptured AAAs and 1.02MPa in ruptured AAAs 
(Venkatasubramaniam et al., 2004a), and Doyle found a mean value of peak wall stress 
in non-ruptured AAAs of 0.45MPa (range 0.32-0.90MPa)(Doyle et al., 2009). 
A correlation coefficient of 0.56 was obtained by Raghavan between peak wall stress 
and AAA diameter in his above paper, but unfortunately there was no mention of 
whether this was statistically significant.  This study found a non-significant (p=0.18) 
correlation coefficient of 0.49.   
3.3.1.2. MMP concentrations at peak wall vs arteriotomy 
sites 
Levels of tissue MMP and TIMP 
Levels of MMP and TIMP are broadly similar to those obtained by Wilson et al 
(Wilson et al., 2006)(table 12, below), however there are significant individual 
differences.  Comparing arteriotomy site samples in this study to anterior abdominal 
wall site samples from their study, there seems to be a large difference in the level of 
active MMP9, and a smaller difference in total MMP2.  The median level of active 
MMP9 in this study is 11 - 16 times less than quoted by Wilson et al, and does not fall 
between their 25
th
 and 75
th
 centiles.  Total MMP2 has a median in this study less than 
half quoted by Wilson et al, again with this median not falling between their 25
th
 and 
75
th
 centiles. 
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The ‘peak wall stress site’ used in this study is less directly comparable to the ‘site of 
rupture’ used by Wilson as although we are hypothesizing that the peak wall stress site 
has a high chance of becoming the ‘site of rupture’, the process leading up to rupture at 
this site may only be beginning, and the actual event of rupture may also contribute to 
the enzymes in this area.  Comparison of these sites reveals several enzyme groups in 
which the median concentration found in this study does not fall within the 25
th
 to 75
th
 
centiles as quoted by Wilson, namely; active and total MMP9, total MMP8, and 
TIMP1.   
Table 12. Concentration of MMP / TIMP: comparison with Wilson et al 
 Peak stress site Site of rupture Arteriotomy AAA wall (n) AAA wall (r) 
MMP2 (a) 2.80 (1.49-4.89) - 2.45 (1.38-4.87) - - 
MMP2 (t) 24.41 (12.87-36.45) 65.9 (12.8-83.4) 21.87 (13.00-32.82) 54.1 (34.1-94.2) 63.8 (41.1-108) 
MMP8 (a) 5.20 (2.54-9.82) 10.3 (3.98-16.0) 6.99 (3.65-15.72) 4.47 (1.41-10.3) 2.41 (1.19-5.31) 
MMP8 (t) 18.80 (9.82-31.85) 43.6 (20.1-79.3) 16.44 (10.81-32.98) 17.3 (12.1-24.6) 16.4 (6.17-30.9) 
MMP9 (a) 0.58 (0.38-0.85) 12.2 (7.77-16.2) 0.54 (0.32-0.97) 9.04 (5.25-13.8) 6.29 (4.68-14.6) 
MMP9 (t) 9.70 (3.95-24.47) 87.1 (56.3-113) 11.34 (8.55-20.49) 33.2 (12.1-87.7) 28.5 (8.02-97.0) 
TIMP1 364.84 (210.49) 180 (82.3-280) 229.84 (86.80-370.95) 151 (77.6-260) 148 (70.8-333) 
TIMP2 17.10 (8.55-29.08) 8.04 (5.24-20.0) 14.64 (8.56-29.93) 8.07 (4.13-16.8) 7.20 (4.10-12.9) 
Prot conc 2.27 (1.55-3.28) - 2.23 (1.16-3.77) - - 
Concentration in ng/mg protein, (n) anterior wall of non-ruptured AAA, (r) anterior wall of ruptured 
AAA, (a) active MMP, (t) total MMP, protein concentration, median (interquartile range), ‘site of 
rupture’, ‘AAA wall (n)’ and ‘AAA wall (r)’ columns originate from Wilson et al (Wilson et al., 2006). 
Loss of MMP activity 
A major concern when measuring and analysing MMP and TIMP concentrations is the 
degradation attributable to storage and freeze-thaw cycles.  It is therefore worth 
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considering this factor in the above comparison of the results of this study with the 
Wilson study. 
A substantial problem with degradation would produce a wide-scale lowering of the 
MMP or TIMP concentrations in one of the studies compared to the other.  This is not 
seen.  Rather there is a more subtle difference with the gelatinases (MMP2 and 9) 
reduced, and the collagenase (MMP8) preserved compared to the Wilson study.  
TIMPs on the other hand seem to be reduced in the Wilson study. 
The TIMPs have been suggested to be more susceptible to freeze-thaw cycles (Alby et 
al., 2002), but plasma MMP9 has been shown to degrade even during -80°C storage 
(Rouy et al., 2005), with TIMP1 and MMP2 stable over time in these storage 
conditions.  Auto-degradation of MMP9 is possible as MMP9 can self-activate, but 
this is also possible with MMP2 (Bergmann et al., 1995), which does not seem to 
degrade with time.  The effect of incomplete inhibition by TIMP1 on MMP9 allows 
auto-activation to occur whilst TIMP2 more successfully inhibits MMP2 from auto-
activation (Fridman et al., 1993) by forming complexes with MMP2.  In addition these 
MMP2/TIMP2 complexes themselves are more susceptible to inhibition (Denhardt et 
al., 1993).  Contrary to this mechanism would be the fact that no active MMP9 was 
detected in the samples without activation by APMA.  Regardless of these points 
however, Rouy points out that if samples did undergo degradation as described above 
– whatever the cause – in most situations all the samples would be subject to similar 
degradation and therefore comparative findings would still be valid.  The situation 
would be different if recruitment is markedly skewed for example, elective AAA 
patients recruited in the first 3 months of a study, but acute AAA patients recruited 
throughout a 1 year period, with all samples analysed at the end of this time. 
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Tissue samples (as opposed to the plasma samples discussed above) should be 
automatically protected from the above degradation due to various inhibitors which are 
normally administered during the various initial MMP extraction processes.  Some of 
these processes include dialysis, which may remove inhibitors.  However since a 
number of these inhibitors cause irreversible inhibition, the function of these proteases 
is not recovered.  The problem comes from inhibitors that are lost during dialysis 
which only reversibly inhibit.  In addition, if the problem really stems from auto-
activation or MMP activating each other, then –as inhibitors to MMPs are not used 
since they affect functional assays (assays that test the function of MMPs such as 
zymograms, or ELISA-style activity assays)- this could be a real problem.    Reliance 
is normally on the -80°C storage to prevent MMP activity prior to MMP activity 
testing.  The way forward could possibly be reversible inhibitors of MMPs that can be 
removed or deactivated prior to MMP activity testing. 
Although the problem of protein loss due to protease activity and MMP loss due to 
possible self-activation may be a problem in our study, the important results come 
from paired samples from the same patient, harvested, stored and processed under the 
same conditions.  The loss would therefore presumably be the same in each sample 
and enable valid comparisons to be made between these samples. 
The above process could account for the difference in MMP9 from the study of Wilson 
et al, but the difference in MMP2 or TIMP1 is still not satisfactorily accounted for. 
Thoracic aorta aneurysmal data 
Data has also been obtained by Schmoker et al looking at thoracic aortic aneurysms, 
and quantifying MMP and TIMP concentrations via methods including ELISA activity 
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kits (Schmoker et al., 2007).  Interestingly they found that active and total MMP2 was 
greater in their control group compared to atherosclerotic or non-atherosclerotic 
thoracic aortic aneurysms, and this was also the case with active MMP9, TIMP1 and 
TIMP2 (table 13, below).  However total MMP9 was found to be higher in 
atherosclerotic thoracic aortic aneurysms than control or non-atherosclerotic thoracic 
aortic aneurysms.  These results were surprising until the identity of their control group 
was revealed as patients undergoing elective coronary artery bypass grafting, when 
possible explanations come to mind, such as areas of relative ischaemia within the 
vessel wall leading to areas of remodelling and proteolysis.  Useful data in the way of 
MMP and TIMP concentrations in atherosclerotic thoracic aortic aneurysms – 
ascending and descending portions - can be used to compare to the results obtained in 
this study.  The low gelatinase concentrations as compared to the results of Wilson et 
al, now do not seem so low in the light of Schmoker’s results.  Granted the tissue is not 
exactly the same, but there is no reason to suppose that there should be a marked 
difference between the descending aorta data and the arteriotomy data from this study.  
In the absence of other aortic MMP / TIMP concentration data in aneurysmal patients, 
this seems a reasonable comparison.  Much of the previous data uses more traditional 
methods including mRNA data or zymographic data. 
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Table 13. Concentration of MMP / TIMP: comparison with Schmoker et al 
 Arteriotomy Ascending Descending 
MMP2 (a) 2.45 (1.38-4.87) 0.56 (0.58) 0.72 (0.49) 
MMP2 (t) 21.87 (13.00-32.82) 71 (59) 26 (20) 
MMP8 (a) 6.99 (3.65-15.72) - - 
MMP8 (t) 16.44 (10.81-32.98) - - 
MMP9 (a) 0.54 (0.32-0.97) 0.22 (0.42) 0.29 (0.45) 
MMP9 (t) 11.34 (8.55-20.49) 8.5 (8.4) 14.8 (20.5) 
TIMP1 229.84 (86.80-370.95) 274 (224) 173 (240) 
TIMP2 14.64 (8.56-29.93) 14.5 (10.0) 11.9 (15.7) 
Prot conc 2.23 (1.16-3.77)   
Concentration in ng/mg protein, ascending aorta, anterior aspect descending aorta taken at most dilated 
part, (a) active, (t) total, protein concentration, median (IRQ) or mean (sd), ‘ascending’ and 
‘descending’ columns from Schmoker et al (Schmoker et al., 2007). 
Peak wall stress vs arteriotomy site: MMPs 
Statistical analysis was carried out on the study results and suggested no significant 
difference in active or total MMPs or TIMPs at peak wall stress site compared to 
arteriotomy site. 
Wilson et al (Wilson et al., 2006) found significant differences in MMP8 and 9 levels 
(both total and active) in anterior aneurysm wall versus site of rupture in patients with 
ruptured AAA, using 12 patients in non-parametric matched pairs analysis (Wilcoxon 
paired test).  These levels were all higher at the site of rupture compared to anterior 
aneurysm wall.  No significant difference was found in MMP2, TIMP1 or TIMP2.  
MMP2 was slightly higher at anterior aneurysm wall site, and TIMP1 and 2 was non-
significantly elevated at rupture site.  Although the tissue involved (ruptured AAA 
tissue) is not the same as in this study, Wilson also demonstrated no significant 
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difference in MMP or TIMP levels from anterior aneurysm wall in 55 patients 
undergoing elective AAA repair compared to 21 patients undergoing emergency AAA 
repair.  Granted this is not the same as proving there is no difference between the 
enzymes levels at these 2 sites, but it does go some way in validating a reasonable 
comparison between anterior aneurysm wall MMPs and TIMPs in ruptured aneurysms 
and arteriotomy samples in this study.   
The site of aneurysm rupture is certainly different to the peak wall stress site, however 
the underlying hypothesis in this study is that the peak wall stress site eventually 
becomes the site of rupture due to progressively increasing stresses at this site due to 
extensive and excessive remodelling at this site.  The remodelling process would be 
directed by MMPs, initially elastases, and later collagenases as the histological make 
up of the aortic changes.  On the basis of this hypothesis, it is therefore reasonable to 
assume an elevated level of MMPs – either elastase or collagenase depending perhaps 
on degree of aneurysm progression – higher than in non-peak wall stress tissue.  This 
level may be at sub-rupture site levels, or perhaps even at supra-rupture site levels.   
The results of this study however do not seem to support this hypothesis, as no 
significant difference was found between MMP levels at peak wall stress sites 
compared to arteriotomy sites.  Furthermore median levels of active MMP8 
(collagenase) are higher at arteriotomy sites compared to peak wall stress sites.  This 
could however - as hypothesised above - be due to stage of aneurysm, with potential 
collagenase rises to be seen later (perhaps immediately prior to rupture) since this was 
the most significant difference seen in MMPs by Wilson et al in ruptured AAA tissue.  
The median level of elastases however, could support the hypothesis since both active 
forms (MMP2 and 9) are higher at peak wall stress sites compared to arteriotomy sites 
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(although these are non-significant differences in this study).  There are only minute 
differences between the median levels between these sites, and the ranges are also 
quite similar.  These suggest that if there is a difference a much larger study sample 
would be necessary to identify it.  If there is a true difference, why is the observed 
difference so small?  Possibilities include; 1) because this is the true difference, 2) 
because only a very tiny localised area has a very large difference (and we are 
therefore diluting down the MMP by harvesting a relatively large area, or 3) a large 
area has a moderately high level of MMP, but poor localisation leads us to only obtain 
part of this area together with lots of ‘normal’ aneurysm wall. 
Peak wall stress vs arteriotomy site: TIMPs 
Levels of TIMP1 and 2 are also non-significantly elevated in peak wall stress sites 
compared to arteriotomy sites.  Elevated levels of TIMP1 and 2 have been observed 
alongside elevated MMP levels(Oberg et al., 2000, Susskind et al., 2003), presumably 
trying (but unable) to compensate for MMP levels(Zucker et al., 1999).  
Type II statistical error 
It is possible that this study incorrectly fails to reject the null hypothesis (that there is 
no difference between MMP and TIMP levels between peak wall stress and 
arteriotomy sites), as since the median levels seen are similar between sites, and there 
is a substantial degree of variance, a larger number of subjects would be necessary to 
test conclusively for a difference between the sites 
This study assumed some similarity between MMP and TIMP levels seen at calculated 
peak wall stress sites and the rupture site in the Wilson study (Wilson et al., 2006).  It 
was entirely reasonable therefore that we expected to be able to draw a valid 
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conclusion about whether there is a difference in MMP and TIMP levels between peak 
wall stress and arteriotomy sites. 
What this study suggests is that peak wall stress site tissue is further from ruptures site 
tissue than was thought by our team.  This difference is biochemical, but in terms of 
time and location, there is still no reason to believe that these may not be quite close.  
This biochemical difference may narrow in days as the tissue spirals towards rupture.  
The location may indeed be correct as anecdotal and observational data points towards 
this, and theoretically the peak wall stress site would be subject to a vicious cycle of 
remodelling, with gradually increasing stresses until rupture.  
It is difficult to be certain that our negative findings in this study was not due to a type 
II statistical error, but we believe the study was designed appropriately with the 
information that was available at the time of study inception. 
Tissue MMP ratios 
Higher levels of activated MMP9 and MMP2 have been identified in AAA compared 
to normal tissue using traditional zymographic analysis (Sakalihasan, 1996).  It was 
hoped therefore to demonstrate significantly different ratios of activated to total 
MMP9 and MMP2 in peak stress areas compared to arteriotomy areas.  This was not 
seen.   
Also demonstrated have been higher proportions of MMP9 compared to total MMPs in 
AAA, and higher proportions of MMP2 in normal tissue.  In this study there was no 
significant difference found on comparing the ratios of the various MMPs to total 
MMPs (MMP2 + MMP8 + MMP9) at the peak stress site compared to the arteriotomy 
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site.  A reason could be that not all the MMPs were accounted for in this study, and no 
test was done that measured total MMP activity, activated or not.   
3.3.1.3. Plasma MMP / TIMPs 
Plasma MMP concentration 
Plasma MMP2 concentrations from this study was roughly in line with results from 
other contemporary studies, although again MMP and TIMP concentrations seem 
substantially lower in this study than in Wilson et al, and also McMillan (table14, 
below). 
Table 14. Table comparing plasma MMP / TIMP concentrations  
  Heng et al Wilson et al McMillan et al 
MMP2 23.71 (20.99-35.64) 42.14 (28.71-68.69) - 
 655.64 (549-813) - - 
MMP8 0.51 (0.36-0.70) - - 
 3.10 (1.73-5.59) - - 
MMP9 4.26 (4.00-6.66) 17.54 (10.30-34.24) - 
 55.51 (38.98-84.04) - 85.66 [11.64] 
TIMP1 201.5 (158.9-217.1) 460.80 (199.80-611.00) - 
TIMP2 141.8 (118.7-147.4) - - 
ng/ml, Median (interquartile range), mean [standard error], Wilson (Wilson et al., 2008) 
McMillan(McMillan and Pearce, 1999) 
Degradation of plasma active /total MMP8 
It is interesting that when to date MMP9 has been noted to be the most sensitive to 
degradation in storage and freeze-thaw cycles (Rouy et al., 2005), this study found 
significant problems with plasma MMP8.  Rouy et al studied only MMP9 so this 
perhaps just has not been reported in the past.  It would be worthwhile exploring the 
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degradation of MMP8, to ascertain just how sensitive it is to storage conditions and 
freeze-thaw cycles.  It is also interesting that although it is not possible to compare 
plasma MMP8 levels obtained here to levels obtained in another study, MMP2 and 9, 
and TIMP1 levels are reduced in this study compared to others.  In contrast, tissue 
MMP8 concentrations in this study are relatively spared compared to the other MMPs 
as demonstrated above.   
Ratio of tissue to plasma MMPs 
A negative correlation was found to be statistically significant between active MMP2 
from peak wall stress sites and active plasma MMP2 [rank correlation coefficient -
0.345 (p=0.039)(Kendall’s τ), rank correlation coefficient -0.498 (p=0.03)(Spearman’s 
ρ].  Since only active plasma MMP2 was normally distributed (active MMP2 from 
peak wall stress site was not normally distributed) it would not have been appropriate 
to use the Pearson correlation coefficient (Altman, 1991).  
3.3.2. Study design 
3.3.2.1. Active and total MMP 
At an early stage in the study it was decided to analyse both active and total forms of 
MMP via ELISA tests, although our initial proposal was only to analyse active forms 
of MMP.  This resulted in using double the number of kits as initially specified in the 
proposal for a given number of patients. 
3.3.2.2. Power calculation 
The comparison of MMP and TIMP levels in peak wall stress and low wall stress sites 
was powered at 80% and significance 0.05 level.  Sample calculation was based on the 
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best available data, and suggested n=8.  For the reasons explained earlier, it was 
decided to take arteriotomy samples rather than low stress site samples. 
Initial analysis was carried out and presented to the steering group at n=10, but 
statistical significance was not achieved.  It was felt that this was due to a type II error 
due to the fact that the difference expected was now smaller due to the change to the 
secondary biopsy site - from low stress site to arteriotomy site - and as the power 
calculation was based on best available data, and not exact data, that it was valid to 
continue collecting data for repeat statistical analysis with double the sample.   
3.3.3. Patient recruitment 
Patient recruitment was generally straightforward although several patients were 
missed due to the research fellow not being available (1 in 4, 24hr on-call, off research 
site), however this did not pose a problem as regards recruiting enough patients for the 
study.  There were no refusals from patients regarding recruitment in to the study. 
Many patients did not complete the study again due to the research fellow not being 
available to guide localisation of AAA tissue biopsy, and also to process these prior to 
snap freezing at the time of elective AAA repair.  On one occasion another research 
fellow was enlisted to direct AAA biopsy and process the tissue, and this was 
successful, however this was not continued as it is a time consuming process for the 
other research fellow, and the consistency about 1 research fellow processing all the 
tissue would be lost.  
3.3.4. Effect of thrombus 
Recent work has provided a constitutive model for intra-luminal thrombus (ILT) 
derived from biaxial testing but clearly the impact of ILT rupture risk is a complex one 
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and as stated by these authors, further work is required (Vande Geest et al., 2006b). 
We began our modelling before the effect of ILT on wall stress was apparent, thus 
elected not to incorporate ILT into our model. Subsequently, we wished to avoid major 
changes to the model mid study.  It is now becoming clear that ILT probably has a role 
to play in rupture risk, although this role is not without ambiguity (Malkawi et al.). 
3.3.5. Low stress versus arteriotomy samples 
The study was initially set up to test peak wall stress samples against low wall stress 
samples, and both sites were identified from Von-Mises stress diagram, and conveyed 
to the surgeon.  However due to some difficulties in theatre in harvesting AAA 
biopsies from 2 separate identified sites mainly to do with the fear of injuring adjacent 
structures and also of having to close these defects to reduce the risks of aorto-enteric 
fistulae, it was decided to take arteriotomy samples rather than low stress samples.  
This would reduce the risks high-lighted above.  The peak wall stress sample was 
essential to the study, and this was harvested as initially planned.  The change in 
biopsy site would affect the degree of difference likely to be seen between the sites, 
and would therefore increase the sample needed to avoid a type II statistical error. 
3.3.6. Sample localisation 
Sample localisation was inherently inaccurate due to problems relating to scale, and 
the difficulty in localising a position in a 3-dimensional uneven biological structure.  
The Surgeon’s stress map, and oral information given regarding position of the peak 
stress site, gave a reasonable localisation however minute accuracy was absent. 
This problem potentiates other factors such as wide variability in MMP reliability 
between runs as discussed below. 
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3.3.7. MMP / TIMP extraction & analysis 
Tissue homogenisation 
This was carried out manually with 2 scalpels on ice.  Most other studies carried this 
out with a homogeniser, but after discussions with Dr Greenman, reader, division of 
cell and molecular medicine, medical research laboratory, University of Hull, and Dr 
Madden, post-doctoral fellow, medical research laboratory, University of Hull, it was 
decided that the homogenisation could reasonably be carried out manually.  Although 
it is possible that due to this method of homogenisation, less MMP / TIMP was 
extracted, as the main object of this study was to compare matched samples, both 
obtained, and processed in the same way, this should not have been a major problem. 
Buffers 
EDTA at 10mmol/l concentration has been demonstrated to destroy MMP activity at 
pH3, reduce activity by 90% at higher pH levels, and to release active TIMP from 
TIMP/MMP complexes (Murphy et al., 1989).  Although the concentration of EDTA 
used in the buffers is less than above - 0.1%(2.7mmol/l), there is still a chance that the 
EDTA may be inhibiting MMP activity.  Vine and Powell experimented with removal 
of EDTA from the homogenizing buffer with no improvement in yield of MMPs (Vine 
and Powell, 1991).  EDTA has been used in the preparation of plasma samples for 
MMP analysis, with no obvious decrease in expected activity (Jung, 2008).  
PMSF (Phenylmethylsulfonyl Fluoride) was used at 0.1mM concentrations in both 
homogenising and dialysis buffers by Vine and Powell in their original paper (Vine 
and Powell, 1991).  Furthermore it was also used in the work of Wilson et al in his 
modified version of their MMP tissue extraction protocol (personal communication) 
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although it wasn’t specifically detailed in their paper (Wilson et al., 2006).  It was 
decided to use a cocktail of protease inhibitors (Calbiochem protease inhibitor cocktail 
set III) which included a serine inhibitor (AEBSF, 4-(2-Aminoethyl) 
benzenesulfonylfluride, HCl), related to PMSF but more stable and non-toxic, and also 
recommended as a replacement for PMSF (Calbiochem website).  This cocktail of 
inhibitors had no particular recorded activity against MMPs.  Since AEBSF 
irreversibly inhibits the same range of proteases as PMSF, it was also thought that 
further dosing in the dialysis buffer was unnecessary.   
Ammonium sulphate fractionation 
The method of extracting MMPs used in this study originated with Vine and Powell 
(Vine and Powell, 1991).  This included ammonium sulphate fractionating, where the 
proteins precipitating between 35 and 65% ammonium sulphate saturation were 
collected.  Various changes to the original protocol were apparently successfully 
carried out by Wilson et al (Wilson et al., 2006), including dropping the use of 
ammonium sulphate fractionation during the extraction process.  The fractionation 
process was carried out after centrifugation of the homogenate, and prior to dialysis 
which presumably was mainly to remove ammonium sulphate.  Since the fractionation 
was after centrifugation - where the remainder solid was discarded - this process could 
not have extracted any more MMP from the tissue, but it would have ‘cleaned up’ the 
supernatant and reduced interference from other substances.  Since the ELISA test 
used in this study relies on active MMP activating an enzyme, it is very specific, and 
there should not be much to gain by removing other substances.  Wilson et al also used 
ELISA tests, but Vine and Powell used zymography and were thus much more affected 
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by other substances, especially if these substances had similar molecular weight to the 
MMPs in question.  
Dialysis 
Dialysis was carried out to remove the 2M urea and EDTA involved in 
homogenisation process.  The urea used is at a much lower concentration than is used 
in many other extraction processes (often 10M), but could still interfere with later 
substance quantification and therefore had to be removed.  The EDTA could inhibit 
MMP function at high concentrations and therefore some removal is advised.  Dialysis 
will remove some EDTA, but will often leave a low concentration of EDTA. 
Dialysis may also however remove various protease inhibitors and may thus result in 
the recovery of function in the proteases that were not irreversible inhibited. 
ELISA plate design 
Samples to be compared together were attempted to be kept within the same ELISA 
plate in order to minimise potential inter-plate, and inter-run reliability issues.  Thus 
active MMP2 from peak wall and arteriotomy sites for subject 17 were always 
analysed in the same ELISA plates, and in general other samples that may also be 
tested against these (eg total MMP2 from peak stress and arteriotomy sites) were also 
analysed on the same plate if possible.   
ELISA kit characteristics 
Interestingly although the cross-sensitivity of the MMP2 kit was 100% for pro-MMP2, 
it was reported as only 77% for activated MMP2.  As commented on the kit insert, this 
could have simply been due to their methods (pre-activation not allowed time enough 
to achieve full activation of sample), or somehow a loss of MMP2 (eg through rapid 
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degradation), but it is possible that the ELISA tests simply does not detect 33% of 
activated MMP2.  This is an established kit, used in many previous papers, so 
comparison with these papers is valid, but there may be some discrepancy with other 
papers that did not use this test. 
The ELISA kits used in this study had significant inter-assay variability with 
coefficient of variability reported as from 5.9% (TIMP2) to 21.7% (MMP9) (kit inserts 
as supplied by Amersham Biosciences). 
Protein concentration determination 
The Bradford assay for determination of protein concentrations has a limited range of 
linear response, therefore samples often have to be diluted to be within the appropriate 
range.  The Coomassie Plus kit from Pierce seems to extend the range, but the 
microplate protocol required minute quantities (10ul) of standard, and as sample 
dilution is often still necessary, this leads to the use of even smaller quantities (3ul).  
Even with appropriate training, inexperienced laboratory staff are at risk of substantial 
titration errors at these quantities.  For this reason from run 3 onwards, protein 
quantification was carried out in triplicate, in order that obviously skew results could 
be identified, removed, and still allow protein concentration determination in order to 
work with the suite of tests carried out for that sample (MMP and TIMP tests) in that 
run. 
3.3.8. Reliability of runs 
There was generally poorer than expected correlation of results between the 2 
compared runs.  However when considering the myriad of processes contributing to an 
individual run, the variability may not be as out of place as initially thought.  Consider 
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that each sample is taken from a different area within the initially harvested peak stress 
or arteriotomy sample. Consider then the variability in the amount of MMP/TIMP that 
is successfully extracted from tissue.  Finally there are variabilities from the actual 
ELISA test, and protein concentration detection. 
More consistent results could be obtained by homogenising the entire tissue biopsy 
from the AAA in a single batch, which may be wise if the local MMP rise is extremely 
focused.  This would help to overcome the real problems in localisation this peak 
stress area.   
The coefficient of variation (CV) (ratio of standard deviation to mean) of ELISA kits 
range from 2.5% (TIMP2) to 21.7% (MMP9), and this contributes significantly to the 
overall poor consistency.   
It was not appropriate to calculate the CV for our data comparing results from these 2 
runs as a) the data was not normally distributed (failed when tested), and b) it is not 
appropriate for comparison of between subject variability (Swinscow, 1997). 
The protein concentration was higher in run 2 - 72% of times this is higher than 
expected but raises particular suspicions due to the fact that all other substances were 
lower to some extent in run 2 than in run 3.  The protein concentration is particularly 
important since all the other results are expressed in relation to unit weight of protein.  
So for example if protein concentration were to fall due to proteolysis during the 
intervening period between runs, the later run would have a lower concentration of 
overall protein, and if the MMPs have been preserved, these would appear to have a 
concentration in these later samples as the same quantity of MMP would be divided by 
a smaller quantity of protein.  This however would be surprising since a general 
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protease inhibitor cocktail was included in the homogenising buffer.  It is possible 
however to also include a protease inhibitor in the dialysis buffer which was done in 
certain previous papers, and would be again recommended.  
One of the advantages of the ELISA activity kits is that activity can be quantified in a 
more comparable format.  The results can be compared to other runs done at a late 
stage and date.  This is through comparable standards and clearly quantifiable results.  
Other methods of assessing MMP or general protease activity for example 
Zymography relay on substrate digestion and the comparative quantification is fine 
intraplate, difficult inter-plate, and almost impossible between studies even with the 
use of a densitometer.  
3.4. Conclusion 
In this study there was no demonstrated statistical difference between concentrations 
of MMP2, 8, 9 or TIMP1, or 2 in peak wall stress sites compared to areteriotomy sites 
in the aneurysm walls of patients with abdominal aortic aneurysm undergoing elective 
repair.   
Although there is a general level of agreement between the MMP and TIMP 
concentrations detected in this study and other published studies, there was enough 
discrepancy to wonder whether there was some degradation of MMP due to auto-
activation or otherwise.  This discrepancy could of course just be due to some slight 
variation in the extraction process.   
In the plasma samples, there seemed to be a relatively fast loss in MMP8 concentration 
– again presumably due to some sort of degradation.  In tissue samples MMP8 seemed 
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best preserved, perhaps due to proteases used to process the tissue.  This should be 
studied in more depth. 
There was a trend towards increased gelatinases (MMP2 & 9) in peak stress sites 
compared to arteriotomy sites, and a decrease in collagenase (MMP8) in peak stress 
sites compared to arteriotomy sites.  If this difference is true, then it may suggest that 
our hypothesis about the peak wall site being the eventual rupture site is biochemically 
further away than we thought, since in line with general agreement we would expect 
elastolysis earlier, followed by later collagenolysis at the presupposed site of rupture. 
Work continues to be carried out on patient specific biomechanical profiling in AAA, 
with improved and more rapid techniques (Malkawi et al.).  This together with a more 
detailed understanding of the background biochemical changes may result in more 
accurate determination of AAA risk with better patient selection at an appropriate time 
to achieved maximum procedural benefit. 
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4. Appendix 1: Correspondence for AAA Screening 
Study 
The following pages display correspondence and forms from the AAA screening study 
 Invitation letter 
Invitation letter from GP (sent on their behalf) to practice patients inviting them 
to join the AAA screening study. 
 Patient information sheet (on back of invitation letter) 
 Reminder letter to patient (sent at 1 month) 
 HAD scale 
This anxiety and depression scale was completed by a cohort of patients from 1 
practice only.  They completed identical forms; a) when initially carrying out 
self-examination for AAA, b) just after the ultrasound scan for AAA (at which 
time they were informed of their ultrasound result), and c) 1 month after their 
ultrasound scan (the form was mailed to them). 
 HAD scale score sheet 
 Letter to GP practice AAA 3-5cm 
 Letter to GP practice AAA ≥5cm 
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Abdominal Aortic Aneurysm Screening Study – invitation letter 
 
Date 
Title First name Surname 
Address 1 
Address 2 
Address 3 
Post Code 
Dear Title Surname 
Abdominal Aortic Aneurysm Screening Study 
There is a condition that affects men in your age group, which is completely hidden 
until it may be too late to treat: it is called an “abdominal aortic aneurysm”, and is 
when the main artery in the abdomen becomes enlarged, like a bulge, which 
occasionally and unexpectedly can burst. 
Specialists at Hull Royal Infirmary are looking for better ways to discover this 
condition, and are asking a simple question: can this be detected by feeling your own 
stomach? Early signs are that it can! We now need to test this out on a large number of 
men, and that is why I am inviting you to take part in a research study. 
If you agree to take part, could you please complete the form, and return it in the 
enclosed stamped addressed envelope.  You will then be invited to attend Alfred Bean 
Hospital Driffield for a simple ultrasound test within the next 6 months. This is similar 
to the scans done routinely on pregnant women, and is completely safe and totally 
painless!  The test will either confirm for certain that you do not have the condition, or 
will show if there is a problem for which treatment will be offered.  The specialists 
who carry out the scan will be able to answer your questions about the result. 
In order for this research to be effective, we need to enrol nine thousand men! So I do 
hope you will agree to take part: it could save your life!  There is more detailed 
information on the research study on the back of this letter, but if you have any 
further questions, you can phone me on 01482 675523 or Jennie Bryce on 01482 
674703 or Carole Tennison on 04182 675784. Please do not ring the Cranwell Road 
Surgery, as they will not be able to answer your queries. 
If you do not want to participate please tick here      and return this letter in the 
stamped addressed envelope to prevent us contacting you again. 
Thank you for your help.  Yours sincerely, 
Michael Heng 
Mr Michael Heng MB ChB MRCS 
Clinical Research Fellow 
Cranwell Road Surgery & the Academic Vascular Unit, Hull Royal Infirmary. 
Address: Vascular Laboratory, Alderson House, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ 
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Patient information sheet: detailed information 
Full Study Title: A prospective trial on a novel approach for screening clinically significant  
(>5cm) Abdominal Aortic Aneurysms 
ELSY no: 2599 
LREC no: 12/01/253 
The Academic Vascular Unit at Hull Royal Infirmary in collaboration with Cranwell Road Surgery, are initiating a 
study to detect, a condition called Abdominal Aortic Aneurysm (AAA). This is a condition that mainly affects men 
over the age of 65, with dilation (expansion) of the main artery (the aorta) in the abdomen, and the progressive 
thinning of the arterial wall leading in some cases to the artery rupturing (bursting). Most people who have a rupture 
of their aneurysm (AAA) will die (88%), with 50% of people not even getting to hospital alive. When an aneurysm 
is found specialists decide what risk it has of rupturing, and will offer surgery in certain cases. Abdominal aortic 
aneurysms often cause no symptoms until they rupture, which means that people often do not know they have this 
condition until it is too late. The aim of this study is to detect these aneurysms at a stage when we can repair  them.  
Once an aneurysm is repaired people have no further risk from it. 
A pilot project has been done involving more than 1,000 patients and the results are promising with 7 large 
aneurysms discovered. We are continuing the project and will need 8,000 more patients for the project to be 
conclusive. You have been selected by Cranwell Road Surgery from a list of men over the age of 65. 
You can choose whether or not you wish to participate in this study, and if you do decide to take part, you are still 
free to withdraw at any time without giving a reason. This will not affect any other care you receive. 
Your participation involves answering a few questions and you feeling your own tummy in the manner described by 
us. You may also ask your wife/relative/friend to feel your tummy as described by us. Once completed you can 
return the questionnaire in the self addressed envelope provided. This will be followed by an ultrasound scan of 
your tummy at a later date (usually within 6 months). Ultrasound scanning of the tummy is a painless outpatient test 
that only takes a few minutes to do. It is used to decide whether an aneurysm is present and to measure its exact 
size.  
If an aneurysm is detected you will be referred to the vascular surgical unit at Hull Royal Infirmary, and they will 
treat you according to their normal protocol (regular ultrasound scans if aneurysm <5.5cm, detailed discussion with 
vascular consultant if aneurysm >5.5cm and possible surgery). 
All information that is collected about you during the course of the research will be kept strictly confidential. The 
overall results will be published in leading scientific and medical journals in approximately 3 years. Your 
confidentiality will be preserved in all published articles. We would be happy to supply you with a copy of the 
results on request. 
The ethics behind this study have been reviewed and supported by the Hull and East Riding Local Research Ethics 
Committee. 
Thank you for taking the time to read this information sheet.  If you have any further queries or questions please 
contact; 
Mr Michael Heng, Clinical Research Fellow, Cranwell Road Surgery and the Academic Vascular Unit, Hull Royal 
Infirmary. Telephone no: 01482 675523 or Jennie Bryce on 01482 674703 or Carole Tennison on 01482 675784 
IS 4.3          12/07/2005 
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Abdominal Aortic Aneurysm Screening Study - Reminder 
Date 
Title / First name / Surname 
Address1 
Address2 
Address3 
Post code 
Dear Title Surname 
Thank you for taking the time to read this letter. 
We wrote to you a month ago regarding the above study, but have not received a 
response.  It is vitally important that you realise this study could save your life, and 
will help towards our understanding of this silent time-bomb that often kills without 
warning.   
We realise that some people will not want to take part.  If you do not want to 
participate please tick here      and return this letter in the stamped addressed envelope 
to prevent us contacting you again.  If you know that you have or have had an 
abdominal aortic aneurysm then please tick here       as you will have had treatment or 
be on surveillance and will therefore not need to take part in this study. 
We enclose another participation pack, and would be grateful if you could find the 
time to participate in this study.  Your involvement in this study will involve only 3 
things; 
You checking your own abdomen 
A simple questionnaire 
A 5 minute ultrasound scan at Eastgate Medical Group Surgery 
If you have any further questions, you can phone Jennie Bryce on 01482 674703 
or Carole Tennison on 01482 5784 or me on 01482 675523.  Please do not ring the 
Eastgate Medical Group, as they will not be able to answer your queries. 
 
Thank you for your help.  Yours sincerely, 
Michael Heng 
Mr Michael Heng MB ChB MRCS 
Clinical Research Fellow, Eastgate Medical Group Surgery & the Academic Vascular 
Unit, Hull Royal Infirmary. 
Postal Address: Vascular Laboratory, Alderson House, Hull Royal Infirmary, Anlaby 
Road, Hull, HU3 2JZ. 
MD Thesis  MST Heng 215 
 
HAD (Hospital Anxiety and Depression) Scale 
1 Month 
Instructions: Doctors are aware that emotions play an important part in most illnesses. If your doctor knows about 
these feelings he or she will be able to help you more. This questionnaire is designed to help your doctor know how 
you feel. Read each item and place a firm tick in the box opposite the reply which comes closest to how you have 
been feeling in the past week. Don’t take too long over your replies: your immediate reaction to each item will probably 
be more accurate than a long thought out response. 
Please tick only 1 box in each section 
I feel tense or ‘wound up’:  I feel as if I am slowed down:  
  
Most of the time    Nearly all of the time    
A lot of the time    Very often    
Time to time, occasionally    Sometimes    
Not at all    Not at all    
I still enjoy the things I used to enjoy:  I get a sort of frightened feeling like ‘butterflies in the 
stomach’:   
Definitely as much     Not at all     
Not quite so much     Occasionally     
Only a little     Quite often     
Not at all     Very often     
I get a sort of frightened feeling like something awful 
is about to happen:  
I have lost interest in my appearance:  
Very definitely and quite badly     Definitely     
Yes, but not too badly     I don’t take as much care as I should     
A little, but it doesn’t worry me     I may not take quite as much care     
Not at all     I take just as much care as ever     
I can laugh and see the funny side of things:  I feel restless as if I have to be on the move:   
As much as I always could     Very much indeed     
Not quite so much now     Quite a lot     
Definitely not so much now     Not very much     
Not al all     Not at all     
Worrying thoughts go through my mind:  
  
I look forward with enjoyment to things:  
  
A great deal of the time     A much as I ever did     
A lot of the time     Rather less than I used to     
From time to time but not too often     Definitely less than I used to     
Only occasionally     Hardly at all     
I feel cheerful:  I get sudden feelings of panic:  
Not at all     Very often indeed     
Not often     Quite often     
Sometimes     Not very often     
Most of the time     Not at all     
I can sit at ease and feel relaxed:  I can enjoy a good book or radio or TV programme:   
Definitely     Often     
Usually     Sometimes     
Not often     Not often     
Not at all     Very seldom     
Name: mailmerge      Date sent: mailmerge 
Date completed by patient (please complete):  
Thank you for your help in this study, your participation is now complete. Now please send this form back to the 
vascular lab in the stamped address envelope enclosed. 
2010412HM1.0         15/12/2004 
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Hospital Anxiety and Depression Scale (HADS) Score 
Doctors often need a quick, reliable method of finding out whether a patient is suffering from 
depression, or generalised anxiety disorders, and how severe their suffering may be. 
The Hospital Anxiety and Depression Scale (HADS) is an easy-to-use self-reporting 
questionnaire, that gives a measure of a person's present state of mind. It has been 
extensively researched and validated, and has a good reputation amongst psychiatrists and 
doctors. 
Choose one response for each of the questions below, clicking on the button to register your 
answer. Try not to think too long about an answer and give an immediate response. 
Questions relating to anxiety are marked "Anxiety:" and those relating to depression are 
marked "Depression:". The scores for both will be calculated separately at the bottom, along 
with guidelines to the level of any disorder. 
 
Anxiety: 
I feel tense or 
'wound up'... 
 
Most of the time 3 
 
A lot of the time 2 
 From time to time, 
occasionally 
1 
 
Not at all 0 
Depression: 
I still enjoy the 
things I used to 
enjoy... 
 
Definitely as much 0 
 
Not quite so much 1 
 
Only a little 2 
 
Hardly at all 3 
Anxiety: 
I get sort of 
frightened feeling as 
if something awful is 
about to happen... 
 Very definitely and 
quite badly 
3 
 Yes, but not too 
badly 
2 
 A little, but it doesn't 
worry me 
1 
 
Not at all 0 
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Depression: 
I can laugh and see 
the funny side of 
things...  
 As much as I always 
could  
0 
 Not quite so much 
now  
1 
 Definitely not so 
much now  
2 
 
Not at all 3 
Anxiety: 
Worrying thoughts 
go through my 
mind... 
 A great deal of the 
time 
3 
 
A lot of the time 2 
 From time to time, 
but not too often 
1 
 
Only occasionally 0 
Depression: 
I feel cheerful... 
 
Not at all 3 
 
Not often 2 
 
Sometimes 1 
 
Most of the time 0 
Anxiety: 
I can sit at ease and 
feel relaxed... 
 
Definitely 0 
 
Usually 1 
 
Not often 2 
 
Not at all 3 
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Depression: 
I feel as if I am 
slowed down... 
 
Nearly all the time 3 
 
Very often 2 
 
Sometimes 1 
 
Not at all 0 
Anxiety: 
I get a sort of 
frightened feeling 
like 'butterflies' in 
the stomach... 
 
Not at all 0 
 
Occasionally 1 
 
Quite Often 2 
 
Very Often 3 
Depression: 
I have lost interest 
in my appearance... 
 
Definitely 3 
 I don't take as much 
care as I should 
2 
 I may not take quite 
as much care 
1 
 I take just as much 
care as ever 
0 
Anxiety: 
I feel restless as I 
have to be on the 
move... 
 
Very much indeed 3 
 
Quite a lot 2 
 
Not very much 1 
 
Not at all 0 
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Depression: 
I look forward with 
enjoyment to 
things... 
 
As much as I ever did 0 
 Rather less than I 
used to 
1 
 Definitely less than I 
used to 
2 
 
Hardly at all 3 
Anxiety: 
I get sudden feelings 
of panic… 
 
Very often indeed 3 
 
Quite often 2 
 
Not very often 1 
 
Not at all 0 
Depression: 
I can enjoy a good 
book or radio or TV 
program... 
 
Often 0 
 
Sometimes 1 
 
Not often 2 
 
Very seldom 3 
Anxiety Scale: Depression Scale: 
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Score Interpretation 
0-7 Normal 
8-10 Mild 
11-14 Moderate 
15-21 Severe 
Reference 
Zigmond and Snaith (1983) 
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GP Name 
Practice address 1 
Practice address 2 
Practice address 3 
Practice address 4 
Date 
Corec ethics study number: LREC/12/01/253 
HEY Hospitals NHS Trust R & D number: ELSY 2599 
A Prospective trial on a novel approach for screening clinically significant (>5cm) 
Abdominal Aortic Aneurysms 
Dear GP Name 
Re: Patient name (forename & surname) 
Patient address 1 
Patient address 2 
Patient address 3 
Patient dob 
Patient hosp no. 
During the above patient’s involvement in the above study, an abdominal aortic 
aneurysm (AAA) was detected by abdominal ultrasonography. 
The diameter of this patient’s abdominal aortic aneurysm is:  
This patient has therefore been enrolled onto the AAA surveillance programme carried 
out by the Academic Vascular Unit, Hull and East Yorkshire Hospitals NHS Trust.  
This will entail 6 monthly to 2 yearly ultrasound scans in the vascular laboratory, Hull 
Royal Infirmary depending on the exact AAA diameter. 
Please contact me should you require any further information. 
Thank you for your help. 
Yours sincerely 
 
Mr Michael ST Heng MB ChB MRCS 
Vascular Research Fellow 
Academic Vascular Unit 
University of Hull / Hull Royal Infirmary 
Postal address: 
Vascular Laboratory 
Alderson House 
Hull Royal Infirmary 
Anlaby Road 
Hull HU3 2JZ 
Tel: 01482 675523 
Mobile: 0775 9219050 
Email: michael.heng@hey.nhs.uk 
Academic Vascular Unit 
Vascular Laboratory 
Alderson House 
Hull Royal Infirmary 
Anlaby Road 
Hull HU3 2JZ 
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GP Name 
Practice address 1 
Practice address 2 
Practice address 3 
Practice address 4 
Date 
Corec ethics study number: LREC/12/01/253 
HEY Hospitals NHS Trust R & D number: ELSY 2599 
A Prospective trial on a novel approach for screening clinically significant (>5cm) Abdominal Aortic 
Aneurysms 
Dear GP Name 
Re: Patient name (forename & surname) 
Patient address 1 
Patient address 2 
Patient address 3 
Patient dob 
Patient hosp no. 
During the above patient’s involvement in the above study, a clinically significant 
abdominal aortic aneurysm (AAA) was detected by abdominal ultrasonography. 
The diameter of this patient’s abdominal aortic aneurysm is:  
This patient has therefore been referred to a consultant within the Academic Vascular 
unit of Hull and East Yorkshire Hospitals NHS Trust.  They will write to you directly. 
Please contact me should you require any further information. 
Thank you for your help. 
Yours sincerely 
 
Mr Michael ST Heng MB ChB MRCS 
Vascular Research Fellow 
Academic Vascular Unit 
University of Hull / Hull Royal Infirmary 
Postal address: 
Vascular Laboratory 
Alderson House 
Hull Royal Infirmary 
Anlaby Road 
Hull HU3 2JZ 
Tel: 01482 675523 
Mobile: 0775 9219050 
Email: michael.heng@hey.nhs.uk 
Academic Vascular Unit 
Vascular Laboratory 
Alderson House 
Hull Royal Infirmary 
Anlaby Road 
Hull HU3 2JZ 
MD Thesis  MST Heng 223 
5. Appendix 2: Ingredients of homogenising and 
dialysis buffers 
These are the ingredients of the tissue homogenising buffer. 
Distilled water 
Urea 
Urea is often used in buffers to disrupt non-covalent bonds in proteins, and thus to 
increase protein solubility in the buffer.  Here it is used in a 2M concentration 
(molecular weight 60, therefore 120g/l or 12g in 100ml). 
Brij 35 
Brij 35 is 30% Polyoxyethyleneglycol dodecyl ether in water with preservative and 
surfactant (also known as lauryl alcohol ethylene oxide, ethoxylated lauryl alcohol, 
and polyoxyethylene lauryl ether).  It is a non-ionic detergent, commonly used in 
buffers, aiding the removal of unreacted reagents, and useful in the isolation of 
functional membrane complexes.  It also helps with the disruption of cell membranes, 
and structures and may also assist in mobilisation of MMPs from the extracellular 
matrix.  It is difficult to remove from solution by dialysis, but can be removed by 
Extracti-Gel D detergent removal gel.  It is used in this buffer at a concentration of 
0.1% (1g/l or 100mg in 100ml). 
Tris-hydrochloric acid 
Tris-hydrochloric acid acts as an acid-base buffer stabilising the overall homogenising 
buffer for pH.  It is used here in a concentration of 50mM (molecular weight 157.6, 
therefore 7.88g/l or 0.79g in 100ml) 
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EDTA 
EDTA (Ethylenediaminetetraacetic acid) (figure 35, below) is a synthetic amino acid, 
which functions as a chelating agent, widely used to sequester di- and tri- valent metal 
ions. It binds using 4 carboxylate and 2 amine groups.  EDTA also helps to disrupt cell 
membranes, and structures, thus it may assist in mobilising MMPs from the extra-
cellular matrix.  It may also be that EDTA is used here to aid extraction of MMPs from 
the tissue during homogenization through temporary chelation of the core zinc ion of 
MMP, although there is no current evidence to back this up.   
 
 
 EDTA (www.merck-chemicals.com) Figure 35.
pH 7.6 
Since low pH levels may lead to EDTA affecting MMP activity adversely, a higher pH 
was chosen. 
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Protease inhibitor 
Calbiochem protease inhibitor cocktail set III was used in this buffer (table 15, below).  
It was added on the day of buffer use.   
Table 15. Components of Calbiochem protease inhibitor cocktail set III 
(www.merckbiosciences.co.uk) 
 
 
These are the ingredients of the dialysis buffer. 
Distilled water 
Brij 35 
Brij 35 was added up to a concentration of 0.1%  
Tris-hydrochloric acid 
Tris-hydrochloric acid was added to a concentration of 25mmol/l 
Calcium Chloride 
It has been shown that calcium stabilises MMP in the presence of EDTA even at low 
pH levels.  This is added to a concentration of 10mmol/l. 
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pH 8.5 
The pH level was adjusted to 8.5 with sodium hydroxide. 
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6. Appendix 3: details of MMP kits and other laboratory 
equipment 
6.1. Matrix metalloproteinase 2 
The Matrix metalloproteinase-2 (MMP2) Biotrak activity assay system kit was used 
(Amersham code: RPN2631), produced by Amersham Biosciences.  This was a 2-day 
test including an overnight incubation period.  This kit system is specific for MMP2, 
and will measure active MMP2 directly, or total MMP2 by activation of pro-MMP2 by 
p-aminophenylmercuric acetate (APMA), in order that all MMP2 contained in the 
sample is activated and subsequently measured.  A colorimetric assay is used and has 
been validated (Capper et al., 1999).  Active MMP2 in the range 0.75 – 12ng/ml, with 
a sensitivity of 0.5ng/ml is measured.  An increased sensitivity is available through an 
altered protocol to 190pg/ml with a range of 0.19 – 3ng/ml.  42 samples can be 
analysed in each microplate (in duplicate), after allowing for the recommended number 
of standard wells for this kit. 
Mechanism of detection 
A pro detection enzyme of modified urokinase is used, which is activated by active 
MMP2, and transformed into an active detection enzyme through a single proteolytic 
event.  This active enzyme then catalyses a chromogenic peptide substrate allowing 
calculation of the level of active enzyme, through measurement of optical density at 
405nm, using a spectrophotometric plate reader (see figure 36, below).  Through 
comparison with known standards, run through the same microplate, and construction 
of a standard curve, the level of MMP2 in each of the samples can be interpolated. 
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 Protocol for MMP2 activity assay measuring endogenous active Figure 36.
MMP2 (Amersham Biosciences) 
Assay summary 
The microplate is pre-coated with anti-MMP2 antibody.  Control samples with known 
levels of human pro-MMP2, as well as unknown samples requiring quantification of 
MMP2 (active or total) are added to the microplate, with all samples being tested in 
duplicate (figure 37).  Overnight incubation at 2-8C allows MMP2 to be captured and 
bound to the microplate walls, with other components of the sample removed by 
repeated washing and aspiration.  APMA is then added to wells where the total level of 
MMP2 is required.  This activates pro-MMP2, but does not affect already active 
MMP2.  In wells where only the level of active MMP2 is required, assay buffer is 
added to ensure comparable volume, and allow both sets of tests to use the same 
controls.  The detection reagent is then added, and the microplate incubated again for a 
number of hours depending on the sensitivity required. 
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 Recommended positioning of standard and sample wells (Amersham Figure 37.
Biosciences) 
Kit contents 
This kit contained;  
 12 x 8 well microplate, pre-coated with anti-MMP2. 
 Assay buffer containing 10ml Tris-HCl buffer concentrate.  Made up with 
100ml distilled water to give 50mM Tris-HCl buffer pH7.6 containing 1.5mM 
sodium chloride, 0.5mM calcium chloride, 1M zinc chloride, 0.01% by 
volume (v/v) BRIJ 35 and 0.01% by weight (w/v) gelatin.   
 Standard contains 24ng of lyophilised (dried by freezing in a high vacuum) 
human pro MMP2.  On reconstitution with 1ml of buffer, this gives a 
concentration of 24ng/ml pro MMP2 in 50mM Tris-HCl buffer pH7.6 
containing 1.5mM sodium chloride, 0.5mM calcium chloride, 1M zinc 
chloride, 0.01% (v/v) BRIJ 35 and 0.01% (w/v) gelatin.   
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 p-Aminophenylmercuric acetate (APMA).  Bottle contains 352mg of APMA in 
powder form, made up with 1ml dimethylsulphoxide (DMSO) to 1M 
concentrated APMA solution.  This is further diluted using 5l of concentrated 
APMA (1M) to 10ml assay buffer to form a 0.5mM solution for use in the 
assay. 
 Detection enzyme.  Powdered concentrate reconstituted with assay buffer to 
100l of concentrated solution of modified urokinase in 50mM Tris-HCl buffer 
pH7.6 containing 1.5mM sodium chloride, 0.5mM calcium chloride, 1M zinc 
chloride, 0.01% (v/v) BRIJ 35 and 0.01% (w/v) gelatin.   
 Substrate.  Bottle containing lyophilised S-2444 peptide substrate , 
reconstituted with 5.1ml of assay buffer to form a ready to use solution of S-
2444 substrate in 50mM Tris-HCl buffer pH7.6 containing 1.5mM sodium 
chloride, 0.5mM calcium chloride, 1M zinc chloride, 0.01% (v/v) BRIJ 35 
and 0.01% (w/v) gelatin.   
 Wash buffer.  Bottle contains 12.5ml of phosphate buffer concentrate which 
when made up to 500ml with distilled water gives a 0.01M sodium phosphate 
buffer pH7.0 containing 0.05% Tween 20.  Tween 20 (also known as 
polysorbate 20) is a stable relatively non-toxic polysorbate surfactant used here 
as a detergent. 
The kit was stored between –15 and –30C until needed.  Kit instructions were fully 
followed as detailed including critical parameters.  Kits were equilibrated at room 
temperature, particularly the microplates, as condensation affects the performance of 
the antibody with which the plates are coated. 
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MMP2 detection procedure protocol 
The assay protocol for the assay range 0.75 – 12ng/ml of MMP2 was followed (higher 
endogenous levels).  The extended detection range (for lower endogenous levels – 
0.19-3ng/ml) involved the preparation of lower concentration standards, and a longer 
incubation time. 
Day 1 reagent preparation 
Assay buffer concentrate, anti-MMP2 coated microplate, and wash buffer concentrate 
were allowed to equilibrate to room temperature before use.  Other components were 
removed from storage just before use.  Assay buffer and wash buffer were prepared 
according to kit protocol, using distilled water.  Standard was prepared using assay 
buffer.  Both buffers were stored in a closed vessel at room temperature, and standard 
was stored on ice until needed. 
Day 1 procedure 
5 standards of known concentration of human pro-MMP2 (0.75, 1.5, 3, 6 and 12ng/ml) 
were freshly prepared by successive dilution with assay buffer and vortex mixing.  1 
sample of assay buffer only was also prepared (‘blank’ - 0ng/ml MMP2 content).  
100l of blank, all standard concentrations and unknown samples were put in wells on 
the microplate in positions as suggested (figure above), in duplicate.  The microplate 
was covered and incubated at 2-8C overnight. 
Day 2 reagent preparation 
APMA, detection enzyme, substrate, detection reagent was prepared according to kit 
protocol.  APMA was prepared as instructed using fresh dimethylsulphoxide 
(DMSO)(in a fume cupboard, with skin and eye protection), and then diluted again to 
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form the ready-to-use dilution.  Prior to use, detection enzyme was thawed and stored 
on ice.  Substrate was also stored on ice prior to use.  Detection reagent was 100l of 
detection enzyme added to the reconstituted substrate.  This was prepared immediately 
prior to addition to wells and vortex mixed.   
Day 2 procedure 
All wells were washed with wash buffer and aspirated 4 times using a microplate 
washer ensuring each well was fully filled and emptied each time.  50l of ready-to-
use APMA was pipetted into all standard wells, and wells needing the quantification of 
total MMP2.  50l of assay buffer was added to wells for quantification of active 
MMP2 only.  All wells then had 50l of detection reagent added.  The microplate was 
shaken in a microplate shaker for 20 seconds and the initial (T0) spectrophotometer 
reading at 405nm was taken.  The microplate was then covered and incubated at 37C 
for 3 hours, shaken and a subsequent spectrophotometer reading at 405nm taken (T3). 
Calculation of MMP2 activity levels 
MMP2 activity is directly proportional to the cleavage of S-2444 (substrate), so it can 
be represented by the rate of change of optical absorbance at 405nm.  The absorbance 
change is linear with respect to the square of the duration of incubation (figure 38). 
 
 
 MMP2 activity proportional to rate of change of absorbance at 405nm Figure 38.
Abs405 / h
2
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Multiplication by 1000 allows whole numbers to be plotted on the graft thus (figure 
39). 
 
 
 MMP2 activity Figure 39.
6.2. Matrix metalloproteinase 8 
The Matrix metalloproteinase-8 (MMP8) Biotrak activity assay system kit was used 
(Amersham code: RPN2635), produced by Amersham Biosciences.  This was a 2-day 
test including an overnight incubation period.  This kit system is specific for MMP8, 
and will measure active MMP8 directly, or total MMP8 by activation of pro-MMP8 by 
APMA.  Active MMP8 in the range 0.09 – 24ng/ml, with a sensitivity of 1.2ng/ml is 
measured for a 2 hour incubation.  41 samples can be analysed in each microplate (in 
duplicate).   
Details of this activity assay are similar to the activity assay for MMP2, but differences 
will be pointed out and full details of the kit will be included as an appendix. 
This assay uses a microplate that is pre-coated with goat, anti-mouse antibody, and 
subsequent exposure to mouse anti-MMP8, allows immobilisation of MMP8 within 
the microplate wells. 
Mechanism of detection 
The mechanism of detection is as for the above-described Amersham Biosciences 
MMP2 activity assay system and therefore does not need further description.   
(Abs405 / h
2
) * 1000 
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MMP8 activity assay kit contents 
The kit contents were identical to the MMP2 assay except for;  
 The microplate was pre-coated with F(ab’)2 goat anti-mouse antibody(rather 
than anti-MMP2). 
 This kit contained lyophilised mouse anti-MMP8, which on reconstitution with 
11ml of assay buffer gave mouse anti-MMP8 in 50mM Tris-HCl buffer pH7.6 
containing 1.5mM sodium chloride, 0.5mM calcium chloride, 1M zinc 
chloride, 0.01% (v/v) BRIJ 35.   
 The standard contained 48ng of lyophilised human pro MMP8 (rather than 
24ng of lyophilised human pro-MMP2), which on reconstitution gave a 
concentration of 48ng/ml pro MMP8.   
 The ready to use APMA solution was made up to 1.5mM (note concentration 
of APMA in MMP2 activity assay was 0.5mM). 
MMP8 detection procedure protocol 
The assay protocol for the assay range 0.75 – 24ng/ml of MMP8 was followed (higher 
endogenous levels).  The extended detection range (for lower endogenous levels – 
0.09-6ng/ml) was occasionally used and involved more standards, and standards of a 
lower concentration than in the normal protocol. 
The assay protocol was identical to the MMP2 activity assay protocol except for the 
following details. 
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Microplate treatment 
The microplate was pre-coated with goat anti-mouse antibody, and this was incubated 
at 37°C for 2 hours with 100µl reconstituted lyophilised mouse anti-MMP8.  The 
microplate was then aspirated and washed 4 times with wash buffer using an automatic 
microplate washer.  In contrast the microplate supplied with the MMP2 activity assay 
kit was pre-coated with anti-MMP2, and did not require this step (figure 40). 
Standards 
1 extra standard of known concentration human pro-MMP8 was used compared to the 
MMP2 activity assay (to make 6 in total) (0.75, 1.5, 3, 6, 12 and 24ng/ml).  This only 
allowed 41 samples to be analysed (compared to the 42 samples in the MMP2 activity 
assay). 
Day 2 – APMA activation of pro-MMP8 
After addition of ready-to-use APMA, the microplate was incubated at 37C for 1 hour 
prior to addition of detection reagent (In the MMP2 protocol, there was no interim 
incubation between addition of APMA and detection reagent). 
Day 2 – final incubation period 
Final incubation was at 37C for 2 hours (as opposed to 3 hours – MMP2), after which 
normal microplate shaking and spectrophotometry at 405nm was carried out. 
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 Protocol for MMP8 activity assay measuring endogenous active Figure 40.
MMP8 (Amersham Biosciences) 
Calculation of MMP8 activity levels 
The mechanism of calculation for MMP8 activity levels is as for the above-described 
Amersham Biosciences MMP2 activity assay system and therefore does not need 
further description. 
6.3. Matrix metalloproteinase 9 
The Matrix metalloproteinase-9 (MMP9) Biotrak activity assay system kit was used 
(Amersham code: RPN2634), produced by Amersham Biosciences.  This was a 2-day 
test including an overnight incubation period.  This kit system is specific for MMP9, 
and will measure active MMP9 directly, or total MMP9 by activation of pro-MMP9 by 
APMA.  Active MMP9 in the range 0.5 – 16ng/ml, with a sensitivity of 0.5ng/ml is 
measured.  A prolonged incubation period protocol is available for lower endogenous 
MMP9 levels with an assay detection range of 0.125 – 4 ng/ml.  41 samples can be 
analysed in each microplate (in duplicate). 
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Details of this activity assay are similar to the activity assay for MMP2, but differences 
will be pointed out and full details of the kit will be included as an appendix. 
Mechanism of detection 
The mechanism of detection is as for the above-described Amersham Biosciences 
MMP2 activity assay system and therefore does not need further description.   
Kit contents 
The kit contents were identical to the MMP2 assay except for;  
 12 x 8 well microplate pre-coated with anti-MMP9. 
 The standard contained 32ng of lyophilised human pro MMP9 (rather than 
24ng of pro MMP2).  On reconstitution with 1ml of buffer, this gave a 
concentration of 32ng/ml pro MMP9.   
 Ready to use APMA solution was made up to 1mM (note 0.5mM for MMP2 
assay, and 1.5mM for MMP8 assay). 
MMP9 detection procedure protocol 
The assay protocol for the assay range 0.5 – 16ng/ml of MMP9 was followed (normal 
endogenous levels).  The extended detection range (for lower endogenous levels – 
0.125-4ng/ml) was occasionally used and involved more standards, and standards of a 
lower concentration than in the normal protocol. 
The assay protocol was identical to the MMP2 activity assay protocol except for the 
following details. 
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Standards 
1 extra standard was used compared to the MMP2 assay protocol (5 standards) to make 
a total of 6 standards (0.5, 1, 2, 4, 8 and 16ng/ml).  
APMA 
After addition of ready-to-use APMA (or buffer), an interim incubation at 37C for 1.5 
hours was allowed prior to the addition of the detection reagent (no interim incubation 
for MMP2 assay). 
Detection reagent 
Incubation after addition of the detection reagent was at 37C for 1 hour (MMP2 assay 
incubation 3 hours), followed by normal plate shaking and a subsequent 
spectrophotometry at 405nm. 
Calculation of MMP9 activity levels 
The mechanism of calculation for MMP9 activity levels is as for the above-described 
Amersham Biosciences MMP2 activity assay system and therefore does not need 
further description 
6.4. Tissue inhibitor of metalloproteinase 1 
The tissue inhibitor of metalloproteinase-1 (TIMP1), human, Biotrak ELISA system 
kit was used (Amersham code: RPN2611), produced by Amersham Biosciences.  This 
was a 1-day test.  This kit system is specific for total human TIMP1, including TIMP1 
complexed with MMPs, but does not cross react with TIMP2, or MMP1.  This kit uses 
an ELISA sandwich format.  TIMP1 in the range 3.13 – 50ng/ml, with a sensitivity of 
1.25ng/ml is measured.  42 samples can be analysed in each microplate (in duplicate). 
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Mechanism of detection 
A sandwich ELISA format is used where TIMP1 is immobilised to the microplate 
walls which are coated with anti-TIMP1, and after washing, peroxidase conjugate 
(antibody to TIMP1 coupled to horseradish peroxide (HRP), sandwiches TIMP1 on the 
microplate wall (figure 41).  After washing, the amount of peroxidase bound is then 
determined by TMB substrate (3,3’, 5,5’- tetramethylbenzidine (TMB)/hydrogen 
peroxide mix), and sulphuric acid added to stop the reaction after 30mins. 
 
 TIMP1 ELISA assay design Figure 41.
Kit contents 
This kit contained;  
 12 x 8 well microplate, pre-coated with anti-TIMP1. 
 Assay buffer containing 10ml phosphate buffer concentrate.  Made up with 
100ml distilled water to give 0.1M phosphate buffer pH7.5 containing 0.9% by 
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weight (w/v) sodium chloride, 0.1% (w/v) bovine serum albumin, and 0.1% 
Tween 20.  
 Standard contains 100ng of lyophilised (dried by freezing in a high vacuum) 
TIMP1.  On reconstitution, this gives a concentration of 100ng/ml TIMP1 in 
0.1M phosphate buffer pH7.5 containing 0.9% by weight (w/v) sodium 
chloride, 0.1% (w/v) bovine serum albumin, and 0.1% Tween 20. 
 Peroxidase conjugate.  Lyophilised anti-TIMP1 horseradish peroxidase, which 
on reconstitution with 11ml of assay buffer gives anti-TIMP1 horseradish 
peroxidase in 0.1M phosphate buffer pH7.5 containing 0.9% by weight (w/v) 
sodium chloride, 0.1% (w/v) bovine serum albumin, and 0.1% Tween 20. 
 Wash buffer.  Bottle contains 12.5ml of phosphate buffer concentrate which 
when made up to 500ml with distilled water gives a 0.01M sodium phosphate 
buffer pH7.5 (note different pH to wash buffer for MMP activity kits) 
containing 0.05% Tween 20.  Tween 20 (also known as polysorbate 20) is a 
stable relatively non-toxic polysorbate surfactant used here as a detergent. 
 TMB Substrate.  3,3’, 5,5’- tetramethylbenzidine (TMB)/hydrogen peroxide 
ready for use.   
The kit was stored between –15 and –30C unit needed.  Kit instructions were fully 
followed as detailed including critical parameters.  Certain kit components were 
equilibrated at room temperature before use as instructed. 
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TIMP1 detection procedure protocol 
Reagent preparation 
Assay buffer concentrate, anti-TIMP1 coated microplate, wash buffer concentrate, 
standard, peroxidase conjugate and TMB substrate were allowed to equilibrate to room 
temperature before use as was unknown sample.  Assay buffer and wash buffer were 
prepared according to kit protocol, using distilled water.  Both buffers were stored in a 
closed vessel at room temperature. 
Procedure 
5 standards of known concentration of TIMP1 (3.13, 6.25, 12.5, 25, 50ng/ml) were 
freshly prepared by successive dilution with assay buffer and vortex mixing.  1 sample 
of assay buffer only was also prepared (‘blank’ - 0ng/ml TIMP1 content).  100l of 
blank, all standard concentrations and unknown samples were put in wells on the 
microplate in positions as suggested (figure 42 below), in duplicate.  The microplate 
was covered and incubated at 20-25C for exactly 2 hours.   
All wells were washed with wash buffer and aspirated 4 times using a microplate 
washer ensuring each well was fully filled and emptied each time.  100l of peroxidase 
conjugate was pipetted into all wells, and incubated at 20-25C for exactly 2 hours.   
All wells were washed and aspirated again 4 times, and 100l room temperature 
equilibrated TMB substrate was dispensed into all wells.  The plate was again covered 
and incubated at room temperature (15-30C) for 30 minutes on a microplate shaker.   
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100l of 1M sulphuric acid was then added to all wells, and the plate read at 450nm by 
a microplate spectrophotometer within 30minutes (note different wavelength of light to 
MMP activity kits). 
 
 Recommended positioning of standard and sample wells (Amersham Figure 42.
Biosciences) 
Calculation of TIMP1 levels 
TIMP1 is detected by peroxidase labelled antibody to TIMP1.  The excess peroxidase 
is washed away, and levels of peroxidase are then detected by TMB ready to use 
substrate.  1M sulphuric acid is used to stop the reaction and the resulting colour 
indicating concentration of peroxidase can be measured at 450nm using a microplate 
spectrophotometer.  The concentration of TIMP1 in the sample can be interpolated 
from the standard curve.  We used a polynomial equation to the graph, and calculated 
TIMP1 concentrations straight from this.  
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6.5. Tissue inhibitor of metalloproteinase 2 
The tissue inhibitor of metalloproteinase-2 (TIMP2), human, Biotrak ELISA system 
kit was used (Amersham code: RPN2618), produced by Amersham Biosciences.  This 
was a 1-day test.  This kit system recognises free TIMP2, and that complexed with 
active forms of MMPs, but not TIMP2 complexed with proMMP2.  It does not cross 
react with TIMP1, or TIMP-3.  This kit uses an ELISA sandwich format.  TIMP2 in 
the range 8 – 128ng/ml, with a sensitivity of 3ng/ml is measured.  42 samples can be 
analysed in each microplate (in duplicate). 
Details of this ELISA assay are similar to the above-described Biotrak TIMP1 ELISA 
assay, but differences will be pointed out and full details of the kit will be included as 
an appendix. 
Mechanism of detection 
A sandwich ELISA format is used (figure 43), as in the TIMP1 assay and therefore 
does not need further description.   
 
 TIMP2 ELISA assay design Figure 43.
MD Thesis  MST Heng 244 
Kit contents 
The kit contents were similar to the TIMP1 assay except for;  
 12 x 8 well microplate, pre-coated with anti-TIMP2. 
 Assay buffer containing 10ml phosphate buffer concentrate.  Made up with 
100ml distilled water to give 0.03M phosphate buffer pH7.0 containing 0.1M 
sodium chloride, 0.3% (w/v) bovine serum albumin, and 0.01M EDTA (TIMP1 
assay buffer - 0.1M phosphate buffer, with no EDTA). 
 Standard contains 256ng of lyophilised TIMP2.  On reconstitution with 1ml of 
assay buffer, this gives a concentration of 256ng/ml TIMP2 in 0.03M 
phosphate buffer pH7.0 containing 0.1M sodium chloride, 0.3% (w/v) bovine 
serum albumin, and 0.01M EDTA (TIMP1 standard contains 100ng of TIMP1, 
with different concentration of assay buffer). 
 Peroxidase conjugate.  Lyophilised anti-TIMP2 horseradish peroxidase, which 
on reconstitution with 12ml of assay buffer gives anti-TIMP2 horseradish 
peroxidase in 0.03M phosphate buffer pH7.0 containing 0.1M sodium chloride, 
0.3% (w/v) bovine serum albumin, and 0.01M EDTA. 
TIMP2 detection procedure protocol 
The assay protocol was identical to the TIMP1 ELISA assay protocol except for the 
following details. 
Standards 
5 standards of known concentration of TIMP2 (8, 16, 32, 64, 128ng/ml) were freshly 
prepared by successive dilution with assay buffer and vortex mixing.     
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Sample volume and conjugate 
50l of blank, all standard concentrations and unknown samples were put in wells on 
the microplate, together with 50l of conjugate to all wells and the microplate was 
covered and incubated at 20-27C for exactly 2 hours (in the TIMP1 protocol 100l of 
samples was added, incubated at 20-25C for 2 hours, washed, then 100l of 
peroxidase conjugate was added prior to further incubation at 20-25C for 2 hours).   
Calculation of TIMP2 levels 
Calculation of TIMP2 concentration was carried out as for TIMP1 as detailed above.   
6.6. Protein concentration 
For the truly representative and comparative MMP concentration value in tissue, many 
studies have used a MMP concentration relative to total protein concentration of the 
tissue homogenate.   
We used the modified Bradford assay to quantify the protein concentration using a test 
kit “Coomassie Plus – the better Bradford assay kit,” (product number 23236, Pierce, 
Rockford, IL). 
Mechanism of detection 
The Bradford Assay was introduced in 1976 (Bradford, 1976) and is still in use today 
with some modifications, as a rapid and sensitive method of protein concentration 
determination.  The technique is a colorimetric protein assay, and involves the binding 
of protein to dye which changes colour from red to blue (figure 44).  An optical 
reading is taken at 595nm, and the increase in absorption at this level is proportional to 
the amount of bound protein.   Known concentrations of protein are used as standards, 
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and this produces a standard curve from which protein concentration can be worked 
out for a given change in optical density (595nm), which in turn produces a reliable 
protein concentration for a particular solution. 
Other protein determination methods were quite susceptible to interference from other 
substances which could be present in protein samples.  This is less true of the Bradford 
Assay, however high concentrations of detergent which may be have been used in 
protein extraction, for example SDS (sodium dodecyl sulfate), can produce artificially 
low protein levels on testing due to detergent binding to protein, or conversely produce 
artificially high levels by binding to certain fractions of the dye, causing a change in 
equilibrium.  Buffer can also cause an over-estimation in protein concentration due to 
the depletion of free protons (which is normally taken up by the protein). 
It is often necessary to dilute protein samples in order that their concentrations lie 
within the linear section of the Bradford assay (2 – 120 µg/ml), but newer formulations 
have an extended range of linear response.  
In our study we used a modified Bradford Assay, and ‘Coomassie Plus – the better 
Bradford Assay kit’ (Pierce, Rockford, IL), which included Coomassie Plus, and 
albumin standards (bovine serum albumin 2.0mg/ml in 0.9% saline and 0.05% sodium 
azide). 
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 Reaction schematic for Coomassie Plus (Piercenet.com) Figure 44.
Assay protocol 
Sterile, 96 well flat bottom microplate, with lids (Sarstedt tissue culture plate – ref: 
83.1835) were used for protein concentration determination.  Maximum volume of 
each well 380µl. 
Protein standards were prepared according to the instructions provided with the kit for 
a working range of 100-1,500µg/ml (see table 16 below).  Diluent used was assay 
buffer for MMP kits.  The components of this buffer were fully compatible with the 
protein assay kit. 
Table 16. Preparation of diluted albumin (BSA) standards (working range 100-
1,500 µg/ml) 
Vial Volume of diluent Volume/ source of BSA Final BSA concentration 
A 0 300µl of stock 2,000 µg/ml 
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B 125µl 375µl of stock 1,500 µg/ml 
C 325µl 325µl of stock 1,000 µg/ml 
D 175µl 175µl of vial B dilution 750 µg/ml 
E 325µl 325µl of vial C dilution 500 µg/ml 
F 325µl 325µl of vial E dilution 250 µg/ml 
G 325µl 325µl of vial F dilution 125 µg/ml 
H 400µl 100µl of vial G dilution 25 µg/ml 
I 400µl 0 0 µg/ml = blank 
Abstract from instructions “Coomassie plus – the better Bradford assay kit,” Pierce product number 
23236 
Coomassie plus was allowed to equilibrate to room temperature before use, and was 
gently inverted several times to disperse any dye-dye aggregates that had formed. 
10µl of each standard and each unknown was pipetted into each well of the microplate 
(all tests were carried out in at least duplicate – some triplicate – detailed in results 
section).   
300µl of Coomassie plus was then dispensed into each well using a multi-channel 
pipette, and shaken on a plate shaker for 30 seconds.  The plate was then left at room 
temperature for 10 minutes then optical density was read at 595nm with a plate reader. 
Details were recorded on a Microsoft Excel spreadsheet.   
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Kit contents 
 Coomassie plus assay reagent, 950ml, containing Coomassie G-250 dye, 
methanol, phosphoric acid and solubilizing agents in water.   
 Albumin standard ampules 2mg/ml (10 x 1ml) with bovine serum albumin 
(BSA) at a concentration of 2.0mg/ml in a solution of 0.9% saline and 0.05% 
sodium azide. 
Calculation of protein concentration 
The average of the standard blank replicates optical density at 595nm were subtracted 
from all the other individual wells’ optical densities.   
A standard curve was produced using the known concentrations of protein in the 
standards’ wells, and blank-corrected optical density at 595nm plotted against the 
known concentration of protein in µg/ml.  A quadratic equation was fitted to the 
standard curve, and this was used to determine the protein concentration of each 
sample.  If R
2
 was <0.9 then the test was repeated and a pipetting error was assumed. 
6.7. Other lab equipment 
Pipettes 
Single and multi-channel pipettes were used – all with disposable polypropylene tips. 
Magnetic stirrer 
Magnetic stirrers were used during the preparation of buffers. 
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Centrifuge 
Centrifuge for 4 x 50ml screw-top polypropylene test tubes was used for early sample 
homogenate preparation. 
A refrigerated centrifuge for flip-top Sarstedt tube was also used for sample 
homogenate preparation.  
Microplate 
96 well flat bottom microplate (Sarstedt tissue culture plate – ref: 83.1835) used for 
protein concentration determination.  Other microplates supplied with kits as above. 
Microplate shaker 
A microplate shaker was used. Plates were covered during shaking. 
Microplate washer 
Thermo labsystems wellwash 4 Mk2 was used. 
Microplate spectrophotometer 
Anthos 2010 microplate spectrophotometer (ASYS Hitech GmbH, Austria) was used 
connected to a PC running Windows 2000 professional operating system (Microsoft, 
USA), and using Stingray ver1.1 (Dazdaq Ltd, Brighton) software.  
For 405nm spectrophotometer readings, the above spectrophotometer did not have the 
appropriate filter and therefore a different machine was used.  This was the Synergy 
HT (Bio-Tek, Vermont), using KC4 Kineticalc  for windows version 3.3 revision 10. 
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7. Appendix 4: Raw MMP / TIMP results 
The following are tables detailing results of MMP2, 8, 9, TIMP1, 2 and protein 
concentrations.  In the main thesis they are presented summarised as box and whisker 
plots. 
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Table 17. Tissue MMP2 Concentration and Ratios - active and total at peak wall 
stress and arteriotomy sites 
 MMP2 concentration (ng/mg protein) 
Subject High Act High Total Art Act Art Total High Ratio Art Ratio 
6 4.14 44.91 1.62 35.99 0.09 0.05 
7 6.15 179.92 5.74 47.43 0.03 0.12 
8       
9 2.86 35.08 2.70 29.64 0.08 0.09 
10 1.93 11.23 1.05 7.09 0.17 0.15 
11 5.65 53.41 1.10  0.11  
12 1.53 15.41 2.42 21.87 0.10 0.11 
13 4.74 30.60 1.26 25.98 0.15 0.05 
14 3.14 13.38 6.19 25.14 0.23 0.25 
15 3.07 28.85 1.30 7.64 0.11 0.17 
16 1.36 16.53 1.40 12.65 0.08 0.11 
17 2.71 24.03 2.81 18.92 0.11 0.15 
18 6.94 100.76 4.89 64.23 0.07 0.08 
19 4.46 40.55 5.99 14.03 0.11 0.43 
20 0.89 8.26 1.29 6.58 0.11 0.20 
21 2.04 15.29 2.61 26.37 0.13 0.10 
22       
23 5.99 24.78 2.48 7.50 0.24 0.33 
24       
25 1.06 23.56 4.86 58.21 0.05 0.08 
26 5.32 27.41 1.71 13.35 0.19 0.13 
27       
28       
29 2.74 28.19 6.02 70.46 0.10 0.09 
30 0.99 11.33 1.91 21.31 0.09 0.09 
31       
32       
33 1.67 10.24 2.94 29.06 0.16 0.10 
34 0.12 1.08 2.23 16.96 0.11 0.13 
35       
36       
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Mean 3.16 33.85 2.93 26.69 0.12 0.14 
Median 2.80 24.40 2.45 21.87 0.11 0.11 
Min 0.12 1.08 1.05 6.58 0.03 0.05 
Max 6.94 179.92 6.19 70.46 0.24 0.43 
Sum 69.50 744.77 64.52 560.40 2.64 2.99 
No 22 22 22 21 22 21 
High Act: Active MMP2 at peak wall stress site, High Total: Total MMP2 at peak wall stress site; Art 
Act: Active MMP2 at arteriotomy site; Art Total: Total MMP2 at arteriotomy site; High Ratio: Ratio of 
active MMP2 to total MMP2 at peak wall stress site; Art Ratio: Ratio of active MMP2 to total MMP2 at 
arteriotomy site. 
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Table 18. Tissue MMP8 Concentration and Ratios - active and total at peak wall 
stress and arteriotomy sites 
 MMP8 concentration (ng/mg protein) 
Subject High Act High Total Art Act Art Total High Ratio Art Ratio 
6 22.07 57.58 8.34 20.78 0.38 0.40 
7 30.15 85.20 56.86 71.56 0.35 0.79 
8       
9 19.62 36.44 6.66 40.35 0.54 0.16 
10 9.40 27.26 7.31 11.51 0.34 0.63 
11 2.15  0.89    
12 4.13 10.04 4.91 12.58 0.41 0.39 
13 6.74 17.55 3.18 9.36 0.38 0.34 
14 2.90 8.74 15.03 19.22 0.33 0.78 
15 1.52 4.50 4.80 11.45 0.34 0.42 
16 1.64 6.77 4.99 13.54 0.24 0.37 
17 5.76 26.24 2.75 6.32 0.22 0.43 
18 7.17 52.25 8.70 25.10 0.14 0.35 
19 2.69 14.25 11.94 8.58 0.19 1.39 
20 11.06 12.29 17.77 26.68 0.90 0.67 
21 6.06 9.59 5.26 10.16 0.63 0.52 
22       
23 3.99 20.40 3.80 16.44 0.20 0.23 
24       
25 2.65 18.80 1.72 13.97 0.14 0.12 
26 9.30 20.50 12.88 21.04 0.45 0.61 
27       
28       
29 4.63 20.58 21.01 39.27 0.22 0.54 
30 2.03 4.81 1.36 8.72 0.42 0.16 
31       
32       
33 23.34 99.80 39.57 71.69 0.23 0.55 
34 2.19 10.21 21.31 58.89 0.21 0.36 
35       
36       
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Mean 8.24 26.85 11.86 24.63 0.35 0.49 
Median 5.20 18.80 6.98 16.44 0.34 0.42 
Min 1.52 4.50 0.89 6.32 0.14 0.12 
Max 30.15 99.80 56.86 71.69 0.90 1.39 
Sum 181.22 563.80 261.02 517.21 7.29 10.22 
No 22 21 22 21 21 21 
High Act: Active MMP8 at peak wall stress site, High Total: Total MMP8 at peak wall stress site; Art 
Act: Active MMP8 at arteriotomy site; Art Total: Total MMP8 at arteriotomy site; High Ratio: Ratio of 
active MMP8 to total MMP8 at peak wall stress site; Art Ratio: Ratio of active MMP8 to total MMP8 at 
arteriotomy site 
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Table 19. Tissue MMP9 Concentration and Ratios - active and total at peak wall 
stress and arteriotomy sites 
 MMP9 concentration (ng/mg protein) 
Subject High Act High Total Art Act Art Total High Ratio Art Ratio 
6 0.67 9.33 0.43 5.19 0.072 0.083 
7 1.21 21.71 1.41 16.12 0.056 0.088 
8       
9 0.49 7.86 0.59 11.34 0.063 0.052 
10 0.74 44.93 0.32 20.69 0.016 0.015 
11 4.57  0.30    
12 0.41 15.34 0.16 20.29 0.026 0.008 
13 0.90 9.98 0.65 6.67 0.090 0.098 
14 0.21 4.22 0.41 17.15 0.050 0.024 
15 0.40 2.75 0.52 8.74 0.145 0.059 
16 0.73 34.27 0.13 19.52 0.021 0.007 
17 0.83 13.92 0.21 2.49 0.060 0.086 
18 2.56 83.12 2.02 45.84 0.031 0.044 
19 0.39 3.28 0.29 3.33 0.119 0.087 
20 0.19 3.02 0.63 10.76 0.063 0.058 
21 0.39 4.24 0.48 9.42 0.091 0.051 
22       
23 2.23 18.28 1.58 11.19 0.122 0.142 
24       
25 0.25 31.00 0.68 33.88 0.008 0.020 
26 0.47 27.22 0.44 26.65 0.017 0.016 
27       
28       
29 0.75 9.23 1.58 18.86 0.081 0.084 
30 0.33 3.68 0.55 8.36 0.088 0.066 
31       
32       
33 0.72 9.70 1.37 22.21 0.074 0.062 
34 0.12 2.26 0.83 9.96 0.053 0.083 
35       
36       
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Mean 0.89 17.11 0.71 15.65 0.064 0.059 
Median 0.58 9.70 0.53 11.34 0.063 0.059 
Min 0.12 2.26 0.13 2.49 0.008 0.007 
Max 4.57 83.12 2.02 45.84 0.145 0.142 
Sum 19.55 359.32 15.58 328.66 1.348 1.233 
No 22 21 22 21 21 21 
High Act: Active MMP9 at peak wall stress site, High Total: Total MMP9 at peak wall stress site; Art 
Act: Active MMP9 at arteriotomy site; Art Total: Total MMP9 at arteriotomy site; High Ratio: Ratio of 
active MMP9 to total MMP9 at peak wall stress site; Art Ratio: Ratio of active MMP9 to total MMP9 at 
arteriotomy site 
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Table 20. Tissue TIMP1 concentrations at peak wall stress and arteriotomy sites 
 TIMP1 concentration (ng/mg protein) 
Subject High Art Art/H Ratio 
6 903.56 288.56 0.32 
7 574.36 629.36 1.10 
8    
9 48.12 52.85 1.10 
10 371.09 176.38 0.48 
11 775.10 55.34 0.07 
12 506.23 887.31 1.75 
13 494.18 147.17 0.30 
14 483.10 144.25 0.30 
15 234.13 48.44 0.21 
16 365.53 224.07 0.61 
17 169.91 301.30 1.77 
18 1229.42 467.25 0.38 
19 145.68 158.90 1.09 
20 30.87 54.55 1.77 
21 253.89 338.85 1.33 
22    
23 799.53 97.28 0.12 
24    
25 224.02 693.51 3.10 
26 364.14 313.52 0.86 
27    
28    
29 420.12 721.16 1.72 
30 298.13 338.19 1.13 
31    
32    
33 319.94 235.60 0.74 
34 19.33 2.79 0.14 
35    
36    
    
MD Thesis  MST Heng 259 
Mean 410.47 289.85 0.93 
Median 364.84 229.84 0.80 
Min 19.33 2.79 0.07 
Max 1229.42 887.31 3.10 
Sum 9030.38 6376.62 20.38 
No 22 22 22 
High: TIMP1 at peak wall stress site, Art: TIMP1 at arteriotomy site; Art/H Ratio: Ratio of TIMP1 at 
arteriotomy site to TIMP1 at peak wall stress site  
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Table 21. Tissue TIMP2 concentration at peak wall stress and arteriotomy sites 
 TIMP2concentration (ng/mg protein) 
Subject High Art  Art/H Ratio 
6 4.67 6.33 1.35 
7 8.56 12.79 1.49 
8    
9 2.01 5.46 2.72 
10 17.14 10.08 0.59 
11 39.94 6.88 0.17 
12 13.76 18.71 1.36 
13 39.85 17.25 0.43 
14 78.16 11.91 0.15 
15 9.27 8.70 0.94 
16 22.63 39.64 1.75 
17 19.93 8.14 0.41 
18 41.28 29.53 0.72 
19 20.15 11.91 0.59 
20 2.18 31.14 14.32 
21 8.53 4.06 0.48 
22    
23 29.01 14.07 0.48 
24    
25 17.05 31.35 1.84 
26 19.18 15.20 0.79 
27    
28    
29 29.28 18.76 0.64 
30 14.54 32.55 2.24 
31    
32    
33 13.53 37.18 2.75 
34 1.34 17.62 13.11 
35    
36    
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Mean 20.55 17.69 2.24 
Median 17.09 14.63 0.87 
Min 1.34 4.06 0.15 
Max 78.16 39.64 14.32 
Sum 452.01 389.27 49.32 
No 22 22 22 
High: TIMP2 at peak wall stress site, Art: TIMP2 at arteriotomy site; Art/H Ratio: Ratio of TIMP2 at 
arteriotomy site to TIMP2 at peak wall stress site 
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Table 22. Tissue protein concentration at peak wall stress and arteriotomy sites 
 Protein concentration (mg/ml) 
Subject High Low Art/H Ratio 
6 2.09 2.83 1.35 
7 1.01 0.93 0.92 
8    
9 2.71 2.98 1.10 
10 2.27 3.95 1.74 
11 1.30 6.65 5.12 
12 2.84 1.93 0.68 
13 1.29 1.70 1.32 
14 1.98 1.16 0.59 
15 4.93 6.04 1.23 
16 2.37 2.48 1.05 
17 2.74 5.12 1.87 
18 0.84 1.22 1.45 
19 1.86 4.24 2.28 
20 6.59 3.71 0.56 
21 4.31 3.38 0.78 
22    
23  1.02  
24    
25 2.13 1.16 0.54 
26 1.44 2.39 1.66 
27    
28    
29 1.65 0.81 0.49 
30 3.71 2.06 0.56 
31    
32    
33 2.69 0.98 0.36 
34 20.92 1.54 0.07 
35    
36    
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Mean 3.41 2.65 1.22 
Median 2.27 2.23 1.05 
Min 0.84 0.81 0.07 
Max 20.92 6.65 5.12 
Sum 71.68 58.29 25.72 
No 21 22 21 
High: Protein at peak wall stress site, Art: Protein at arteriotomy site; Art/H Ratio: Ratio of Protein at 
arteriotomy site to Protein at peak wall stress site 
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Table 23. Correlations - tissue and plasma MMP2 active 
Correlations – tissue and plasma MMP2 active 
   MMP2 High 
Active 
MMP2 Art 
Active 
MMP2 Plasma 
Act 
Kendall's tau_b MMP2 High Active Correlation Coefficient 1.000 .117 -.345
*
 
Sig. (2-tailed) . .446 .039 
N 22 22 19 
MMP2 Art Active Correlation Coefficient .117 1.000 .111 
Sig. (2-tailed) .446 . .506 
N 22 22 19 
MMP2 Plasma Act Correlation Coefficient -.345
*
 .111 1.000 
Sig. (2-tailed) .039 .506 . 
N 19 19 19 
Spearman's rho MMP2 High Active Correlation Coefficient 1.000 .171 -.498
*
 
Sig. (2-tailed) . .446 .030 
N 22 22 19 
MMP2 Art Active Correlation Coefficient .171 1.000 .137 
Sig. (2-tailed) .446 . .576 
N 22 22 19 
MMP2 Plasma Act Correlation Coefficient -.498
*
 .137 1.000 
Sig. (2-tailed) .030 .576 . 
N 19 19 19 
*. Correlation is significant at the 0.05 level (2-tailed).    
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Table 24. Correlations – tissue and plasma MMP2 total 
Correlations – tissue and plasma MMP2 total 
   MMP2 High 
Total 
MMP2 Art 
Total 
MMP2 
Plasma Total 
Kendall's tau_b MMP2 High Total Correlation Coefficient 1.000 .314
*
 -.074 
Sig. (2-tailed) . .046 .650 
N 22 21 20 
MMP2 Art Total Correlation Coefficient .314
*
 1.000 -.193 
Sig. (2-tailed) .046 . .248 
N 21 21 19 
MMP2 Plasma Total Correlation Coefficient -.074 -.193 1.000 
Sig. (2-tailed) .650 .248 . 
N 20 19 20 
Spearman's rho MMP2 High Total Correlation Coefficient 1.000 .440
*
 -.050 
Sig. (2-tailed) . .046 .835 
N 22 21 20 
MMP2 Art Total Correlation Coefficient .440
*
 1.000 -.172 
Sig. (2-tailed) .046 . .482 
N 21 21 19 
MMP2 Plasma Total Correlation Coefficient -.050 -.172 1.000 
Sig. (2-tailed) .835 .482 . 
N 20 19 20 
*. Correlation is significant at the 0.05 level (2-tailed).    
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Table 25. Correlations – tissue and plasma MMP8 active 
Correlations – tissue and plasma MMP8 active 
   MMP8 High 
Active 
MMP8 Art 
Active 
MMP8 Plasma 
Active 
Kendall's tau_b MMP8 High Active Correlation Coefficient 1.000 .385
*
 -.418 
Sig. (2-tailed) . .012 .073 
N 22 22 11 
MMP8 Art Active Correlation Coefficient .385
*
 1.000 -.273 
Sig. (2-tailed) .012 . .243 
N 22 22 11 
MMP8 Plasma Active Correlation Coefficient -.418 -.273 1.000 
Sig. (2-tailed) .073 .243 . 
N 11 11 11 
Spearman's rho MMP8 High Active Correlation Coefficient 1.000 .523
*
 -.555 
Sig. (2-tailed) . .012 .077 
N 22 22 11 
MMP8 Art Active Correlation Coefficient .523
*
 1.000 -.382 
Sig. (2-tailed) .012 . .247 
N 22 22 11 
MMP8 Plasma Active Correlation Coefficient -.555 -.382 1.000 
Sig. (2-tailed) .077 .247 . 
N 11 11 11 
*. Correlation is significant at the 0.05 level (2-tailed).    
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Table 26. Correlations – tissue and plasma MMP8 total 
Correlations – tissue and plasma MMP8 total 
   MMP8 High 
Total 
MMP8 Art 
Total 
MMP8 
Plasma Total 
Kendall's tau_b MMP8 High Total Correlation Coefficient 1.000 .381
*
 -.023 
Sig. (2-tailed) . .016 .889 
N 21 21 19 
MMP8 Art Total Correlation Coefficient .381
*
 1.000 .340
*
 
Sig. (2-tailed) .016 . .042 
N 21 21 19 
MMP8 Plasma Total Correlation Coefficient -.023 .340
*
 1.000 
Sig. (2-tailed) .889 .042 . 
N 19 19 20 
Spearman's rho MMP8 High Total Correlation Coefficient 1.000 .508
*
 -.012 
Sig. (2-tailed) . .019 .960 
N 21 21 19 
MMP8 Art Total Correlation Coefficient .508
*
 1.000 .475
*
 
Sig. (2-tailed) .019 . .040 
N 21 21 19 
MMP8 Plasma Total Correlation Coefficient -.012 .475
*
 1.000 
Sig. (2-tailed) .960 .040 . 
N 19 19 20 
*. Correlation is significant at the 0.05 level (2-tailed).    
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Table 27. Correlations – tissue and plasma MMP9 active 
Correlations – tissue and plasma MMP9 active 
   MMP9 High 
Active 
MMP9 Art 
Active 
MMP9 
Plasma Active 
Kendall's tau_b MMP9 High Active Correlation Coefficient 1.000 .083 -.248 
Sig. (2-tailed) . .592 .127 
N 22 22 20 
MMP9 Art Active Correlation Coefficient .083 1.000 -.090 
Sig. (2-tailed) .592 . .581 
N 22 22 20 
MMP9 Plasma Active Correlation Coefficient -.248 -.090 1.000 
Sig. (2-tailed) .127 .581 . 
N 20 20 20 
Spearman's rho MMP9 High Active Correlation Coefficient 1.000 .154 -.320 
Sig. (2-tailed) . .493 .168 
N 22 22 20 
MMP9 Art Active Correlation Coefficient .154 1.000 -.141 
Sig. (2-tailed) .493 . .554 
N 22 22 20 
MMP9 Plasma Active Correlation Coefficient -.320 -.141 1.000 
Sig. (2-tailed) .168 .554 . 
N 20 20 20 
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Table 28. Correlations – tissue and plasma MMP9 total 
Correlations – tissue and plasma MMP9 total 
   MMP9 High 
Total 
MMP9 Art 
Total 
MMP9 
Plasma Total 
Kendall's tau_b MMP9 High Total Correlation Coefficient 1.000 .457
**
 -.053 
Sig. (2-tailed) . .004 .753 
N 21 21 19 
MMP9 Art Total Correlation Coefficient .457
**
 1.000 -.100 
Sig. (2-tailed) .004 . .552 
N 21 21 19 
MMP9 Plasma Total Correlation Coefficient -.053 -.100 1.000 
Sig. (2-tailed) .753 .552 . 
N 19 19 20 
Spearman's rho MMP9 High Total Correlation Coefficient 1.000 .629
**
 -.090 
Sig. (2-tailed) . .002 .713 
N 21 21 19 
MMP9 Art Total Correlation Coefficient .629
**
 1.000 -.033 
Sig. (2-tailed) .002 . .892 
N 21 21 19 
MMP9 Plasma Total Correlation Coefficient -.090 -.033 1.000 
Sig. (2-tailed) .713 .892 . 
N 19 19 20 
**. Correlation is significant at the 0.01 level (2-tailed).    
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Table 29. Correlations – tissue and plasma TIMP1 
Correlations – tissue and plasma TIMP1 
   
TIMP1 High TIMP1 Art 
TIMP1 
Plasma 
Kendall's tau_b TIMP1 High Correlation Coefficient 1.000 .203 -.121 
Sig. (2-tailed) . .185 .455 
N 22 22 20 
TIMP1 Art Correlation Coefficient .203 1.000 .111 
Sig. (2-tailed) .185 . .495 
N 22 22 20 
TIMP1 Plasma Correlation Coefficient -.121 .111 1.000 
Sig. (2-tailed) .455 .495 . 
N 20 20 20 
Spearman's rho TIMP1 High Correlation Coefficient 1.000 .342 -.181 
Sig. (2-tailed) . .120 .446 
N 22 22 20 
TIMP1 Art Correlation Coefficient .342 1.000 .169 
Sig. (2-tailed) .120 . .476 
N 22 22 20 
TIMP1 Plasma Correlation Coefficient -.181 .169 1.000 
Sig. (2-tailed) .446 .476 . 
N 20 20 20 
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Table 30. Correlations – tissue and plasma TIMP2 
Correlations 
   
TIMP2 High TIMP2 Art 
TIMP2 
Plasma 
Kendall's tau_b TIMP2 High Correlation Coefficient 1.000 .104 -.016 
Sig. (2-tailed) . .498 .922 
N 22 22 20 
TIMP2 Art Correlation Coefficient .104 1.000 .058 
Sig. (2-tailed) .498 . .721 
N 22 22 20 
TIMP2 Plasma Correlation Coefficient -.016 .058 1.000 
Sig. (2-tailed) .922 .721 . 
N 20 20 20 
Spearman's rho TIMP2 High Correlation Coefficient 1.000 .146 .011 
Sig. (2-tailed) . .518 .965 
N 22 22 20 
TIMP2 Art Correlation Coefficient .146 1.000 .099 
Sig. (2-tailed) .518 . .677 
N 22 22 20 
TIMP2 Plasma Correlation Coefficient .011 .099 1.000 
Sig. (2-tailed) .965 .677 . 
N 20 20 20 
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8. Appendix 5: Characteristics of MMP and TIMP ELISA 
kits 
Characteristics for MMP and TIMP detection kits as well as the protein concentration 
determinisation kit as provided by kit manufacturers are provided below. 
8.1. MMP2 test kit details 
Specificity 
The assay recognises the active form of MMP2 and the total form via activation of 
pro-MMP2.  It has no substantial cross-reactivity with other MMPs or TIMPs.   
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Table 31. Cross-reactivity of MMP2 kit 
Compound % Cross-reactivity 
Pro-MMP2 100 
Activated MMP2 77* 
ProMMP2/TIMP2 complex 43 
Active MMP2/TIMP2 complex 8.6 
Active MMP2/TIMP1 complex 21 
MMP1 0.068 
MMP9 0.64 
MMP3 <0.05 
MMP8 <0.05 
TIMP1 <0.05 
TIMP2 <0.05 
MMP2 activity assay system, Amersham Biosciences, Buckinghamshire 2004.  *pre-activated MMP2 
which was pre-activated, captured & washed. Losses may have occurred during activation or activation 
may not have followed through to completion.  
Reproducibility – within-assay precision 
The within-assay precision for duplicate determination was calculated by measuring 
controls within the same assay. 
MD Thesis  MST Heng 274 
Table 32. MMP2 kit within-assay precision 
Control Mean +/- SD % CV n 
A 4.75 +/- 0.33 7.0 10 
B 9.54 +/- 0.52 5.4 10 
C 15.63 +/- 0.68 4.4 10 
MMP2 activity assay system, Amersham Biosciences.  (mean values as ng/ml, %CV; percentage 
coefficient of variation: (sd/mean)*100) (The coefficient of variation is a way of reporting measurement 
error) 
Reproducibility – between assay precision 
This is measured by the same sample being analysed in subsequent plates. 
Table 33. MMP2 kit between assay precision 
Control Mean +/- SD % CV n 
A 2.6 +/- 0.44 16.9 12 
B 5.48 +/- 0.98 17.9 12 
C 9.49 +/- 1.76 18.5 12 
MMP2 activity assay system, Amersham Biosciences.  (mean values as ng/ml, %CV; percentage 
coefficient of variation: (sd/mean)*100) (The coefficient of variation is a way of reporting measurement 
error) 
Sensitivity 
The sensitivity was defined as 2 standard deviations above the mean optical density of 
10 zero standard replicates.  The mean zero and standard values were then used to 
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calculate the sensitivity.  This was determined as 0.5ng/ml for a 3 hour incubation 
period.   
Parallelism 
The parallelism of the kit explores the effect of dilution on the expected versus 
observed concentrations of MMP2. 
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Table 34. MMP2 kit parallelism 
Sample Dilution Observed 
(ng/ml) 
Expected 
(ng/ml) 
% Observed/ 
Expected 
Cell culture 
media 
1:4 
1:8 
1:16 
1:32 
8.07 
4.30 
2.30 
0.95 
- 
4.04 
2.02 
1.01 
- 
106.4 
113.9 
94.1 
Heparin 
plasma 
1:100 
1:200 
1:400 
1.53 
0.85 
0.44 
- 
0.77 
0.38 
- 
110.4 
115.8 
Serum 1:100 
1:200 
1:400 
1.69 
0.95 
0.49 
- 
0.85 
0.42 
- 
112.4 
116.1 
MMP2 activity assay system, Amersham Biosciences.   
Recovery 
The recovery of the kit measured the amount of MMP2 detected after various 
preparations were spiked with additional known levels of MMP2 standard.  
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Table 35. MMP2 kit recovery 
Sample type Added 
concentration 
(ng/ml) 
Measured 
(ng/ml) 
Expected 
(ng/ml) 
Recovery (%) 
Cell culture 
medium 
0 
0.38 
0.75 
1.5 
1.58 
1.68 
1.74 
1.96 
- 
1.96 
2.33 
3.08 
- 
85.7 
74.7 
63.6 
Heparin 
plasma (1:200) 
0 
0.38 
0.75 
1.5 
3 
0.95 
1.02 
1.10 
1.33 
1.74 
- 
1.33 
1.71 
2.45 
3.95 
- 
76.7 
64.7 
54.3 
44.1 
Serum (1:200) 0 
0.38 
0.75 
1.5 
3 
0.78 
1.01 
1.32 
1.74 
2.65 
- 
1.16 
1.53 
2.28 
3.78 
- 
87.1 
86.3 
76.3 
70.1 
MMP2 activity assay system, Amersham Biosciences.   
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Expected values 
Normal human MMP2 levels in serum and plasma were measured using the assay. 
Table 36. MMP2 kit normal human levels 
Sample Mean (ng/ml) Range (ng/ml) N 
Heparin plasma 139 114-170 5 
Serum 211 156-254 5 
MMP2 activity assay system, Amersham Biosciences.   
8.2. MMP8 test kit details 
MMP8 activity assay kit contents 
This kit contained;  
 12 x 8 well microplate, pre-coated with F(ab’)2 goat anti-mouse. 
 Assay buffer containing 10ml Tris-HCl buffer concentrate.  Made up with 
100ml distilled water to give 50mM Tris-HCl buffer pH7.6 containing 1.5mM 
sodium chloride, 0.5mM calcium chloride, 1M zinc chloride, 0.01% by 
volume (v/v) BRIJ 35.   
 Standard contains 48ng of lyophilised (dried by freezing in a high vacuum) 
human pro MMP8.  On reconstitution with 1ml of buffer, this gives a 
concentration of 48ng/ml pro MMP8 in 50mM Tris-HCl buffer pH7.6 
containing 1.5mM sodium chloride, 0.5mM calcium chloride, 1M zinc 
chloride, 0.01% (v/v) BRIJ 35.   
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 Antibody.  This contains lyophilised mouse anti-MMP8, which  on 
reconstitution with 11ml of assay buffer gives mouse anti-MMP8 in 50mM 
Tris-HCl buffer pH7.6 containing 1.5mM sodium chloride, 0.5mM calcium 
chloride, 1M zinc chloride, 0.01% (v/v) BRIJ 35.   
 p-Aminophenylmercuric acetate (APMA).  Bottle contains 352mg of APMA in 
powder form, made up with 1ml dimethylsulphoxide (DMSO) to 1M 
concentrated APMA solution.  This is further diluted using 15l of 
concentrated APMA (1M) added to 10ml of assay buffer to form a ready to use 
APMA solution (1.5mM) (note different concentration of APMA to MMP2 
assay). 
 Detection enzyme.  Tube containing 100l of concentrated solution of 
modified urokinase in 50mM Tris-HCl buffer pH7.6 containing 1.5mM sodium 
chloride, 0.5mM calcium chloride, 1M zinc chloride, 0.01% (v/v) BRIJ 35.   
 Substrate.  Bottle containing lyophilised S-2444 peptide substrate , 
reconstituted with 5.1ml of assay buffer to form a ready to use solution of S-
2444 substrate in 50mM Tris-HCl buffer pH7.6 containing 1.5mM sodium 
chloride, 0.5mM calcium chloride, 1M zinc chloride, 0.01% (v/v) BRIJ 35.   
 Wash buffer.  Bottle contains 12.5ml of phosphate buffer concentrate which 
when made up to 500ml with distilled water gives a 0.01M sodium phosphate 
buffer pH7.0 containing 0.05% Tween 20.  Tween 20 (also known as 
polysorbate 20) is a stable relatively non-toxic polysorbate surfactant used here 
as a detergent. 
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The kit was stored between –15 and –30C until needed.  Kit instructions were fully 
followed as detailed including critical parameters.  Kits were equilibrated at room 
temperature, particularly the microplates, as condensation affects the performance of 
the antibody with which the plates are coated.   
MMP8 detection procedure protocol 
The assay protocol for the assay range 0.75 – 24ng/ml of MMP8 was followed (higher 
endogenous levels).  The extended detection range (for lower endogenous levels – 
0.09-6ng/ml) was occasionally used and involved more standards, and standards of a 
lower concentration than in the normal protocol. 
Day 1 reagent preparation 
Assay buffer concentrate, anti-MMP8 coated microplate, and wash buffer concentrate 
were allowed to equilibrate to room temperature before use.  Other components were 
removed from storage just before use.  Assay buffer and wash buffer were prepared 
according to kit protocol, using distilled water.  Standard was prepared using assay 
buffer.  Both buffers were stored in a closed vessel at room temperature, and standard 
was stored on ice until needed. 
Day 1 procedure 
6 standards of known concentration of human pro-MMP8 (0.75, 1.5, 3, 6, 12 and 
24ng/ml)(note 1 more standard than MMP2 assay kit) were freshly prepared by 
successive dilution with assay buffer and vortex mixing.  1 sample of assay buffer only 
was also prepared (‘blank’ - 0ng/ml MMP8 content).  100l of anti-MMP8 was 
pipetted into all wells, covered and incubated at 37C for 2 hours.  The microplate was 
aspirated and washed 4 times with wash buffer.  100l of blank, all standard 
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concentrations and unknown samples were put in wells on the microplate in positions 
as suggested (figure below), in duplicate.  The microplate was covered and incubated 
at 2-8C overnight. 
 
 
 Recommended positioning of standard and sample wells (Amersham Figure 45.
Biosciences) 
Day 2 reagent preparation 
APMA, detection enzyme, substrate, detection reagent was prepared according to kit 
protocol.  APMA was prepared as instructed using fresh dimethylsulphoxide 
(DMSO)(in a fume cupboard, with skin and eye protection), and then diluted again to 
form the ready-to-use dilution.  Detection enzyme was stored on ice after thawing, but 
prior to use.  Substrate was also stored on ice prior to use.  Detection reagent was 
100l of detection enzyme added to the reconstituted substrate.  This was prepared 
immediately prior to addition to wells and vortex mixed.   
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Day 2 procedure 
All wells were washed with wash buffer and aspirated 4 times using a microplate 
washer ensuring each well was fully filled and emptied each time.  50l of ready-to-
use APMA was pipetted into all standard wells, and wells needing the quantification of 
total MMP2.  50l of assay buffer was added to wells for quantification of active 
MMP2 only.  The plate was covered and incubated at 37C for 1 hour, then all wells 
then had 50l of detection reagent added.  The microplate was shaken in a microplate 
shaker for 20 seconds and the initial (T0) spectrophotometer reading at 405nm was 
taken.  The microplate was then covered and incubated at 37C for 2 hours, shaken and 
a subsequent spectrophotometer reading at 405nm taken (T2). 
Other kit details 
Specificity 
The assay recognises the active form of MMP8 and the total form via activation of 
pro-MMP8.  It has no substantial cross-reactivity with other MMPs or TIMPs.   
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Table 37. Cross-reactivity of MMP8 kit 
Compound % Cross-reactivity 
Pro-MMP8 100 
Activated MMP8 100* 
MMP1 7.9 
MMP2 1.2 
MMP3 1.5 
MMP9 1.3 
MMP13 2.2 
TIMP1 0.5 
MMP8 activity assay system, Amersham Biosciences, Buckinghamshire 2004.  *pre-activated MMP8 
which was pre-activated, captured & washed without further APMA activation.  
Reproducibility – within-assay precision 
The within-assay precision for duplicate determination was calculated by measuring 
controls within the same assay. 
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Table 38. MMP8 kit within-assay precision 
Control Mean +/- SD % CV n 
L 4.71 +/- 0.62 13.2 9 
M 9.62 +/- 0.79 8.2 9 
H 18.69 +/- 1.37 7.3 9 
MMP8 activity assay system, Amersham Biosciences.  (mean values as ng/ml, %CV; percentage 
coefficient of variation: (sd/mean)*100) (The coefficient of variation is a way of reporting measurement 
error) 
Reproducibility – between assay precision 
This is measured by the same sample being analysed in subsequent plates. 
Table 39. MMP8 kit between assay precision 
Control Mean +/- SD % CV n 
L 3.73 +/- 0.41 19.0 18 
M 9.26 +/- 0.78 8.4 18 
H 18.7 +/- 1.41 7.5 18 
MMP8 activity assay system, Amersham Biosciences.  (mean values as ng/ml, %CV; percentage 
coefficient of variation: (sd/mean)*100) (The coefficient of variation is a way of reporting measurement 
error) 
MD Thesis  MST Heng 285 
Sensitivity 
The sensitivity was defined as 2 standard deviations above the mean optical density of 
10 zero standard replicates.  The mean zero and standard values were then used to 
calculate the sensitivity.  This was determined as 1.2ng/ml for a 2 hour incubation 
period.   
Recovery 
The recovery of the kit measured the amount of MMP8 detected after various 
preparations were spiked with additional known levels of MMP8 standard.  
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Table 40. MMP8 kit recovery 
Sample type Added 
concentration 
(ng/ml) 
Measured 
(ng/ml) 
Expected 
(ng/ml) 
Recovery (%) 
Cell culture 
medium 
0 
0.38 
0.75 
1.5 
3.0 
0.10 
0.55 
0.97 
1.95 
3.77 
- 
0.48 
0.85 
1.60 
3.10 
- 
118 
117 
123 
123 
Heparin 
plasma (1:20) 
0 
0.38 
0.75 
1.5 
3.0 
0.34 
0.56 
0.79 
1.30 
2.43 
- 
0.72 
1.09 
1.84 
3.34 
- 
57 
59 
64 
70 
Serum (1:20) 0 
0.38 
0.75 
1.5 
3.0 
3.04 
3.15 
3.40 
4.03 
5.07 
- 
3.42 
3.79 
4.54 
6.04 
- 
27 
48 
66 
68 
MMP8 activity assay system, Amersham Biosciences.   
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8.3. MMP9 test kit details 
Kit contents 
This kit contained;  
 12 x 8 well microplate, pre-coated with anti-MMP9. 
 Assay buffer containing 10ml Tris-HCl buffer concentrate.  Made up with 
100ml distilled water to give 50mM Tris-HCl buffer pH7.6 containing 1.5mM 
sodium chloride, 0.5mM calcium chloride, 1M zinc chloride, 0.01% by 
volume (v/v) BRIJ 35.   
 Standard contains 32ng of lyophilised (dried by freezing in a high vacuum) 
human pro MMP9.  On reconstitution with 1ml of buffer, this gives a 
concentration of 32ng/ml pro MMP9 in 50mM Tris-HCl buffer pH7.6 
containing 1.5mM sodium chloride, 0.5mM calcium chloride, 1M zinc 
chloride, 0.01% (v/v) BRIJ 35.   
 p-Aminophenylmercuric acetate (APMA).  Bottle contains 352mg of APMA in 
powder form, made up with 1ml dimethylsulphoxide (DMSO) to 1M 
concentrated APMA solution.  This is further diluted using 10l of 
concentrated APMA (1M) added to 10ml of assay buffer to form a ready to use 
APMA solution (1mM) (note different concentration of APMA to MMP2 & 
MMP8 assays). 
 Detection enzyme.  Tube containing 100l of concentrated solution of 
modified urokinase in 50mM Tris-HCl buffer pH7.6 containing 1.5mM sodium 
chloride, 0.5mM calcium chloride, 1M zinc chloride, 0.01% (v/v) BRIJ 35.  .   
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 Substrate.  Bottle containing lyophilised S-2444 peptide substrate , 
reconstituted with 5.1ml of assay buffer to form a ready to use solution of S-
2444 substrate in 50mM Tris-HCl buffer pH7.6 containing 1.5mM sodium 
chloride, 0.5mM calcium chloride, 1M zinc chloride, and 0.01% (v/v) BRIJ 
35.   
 Wash buffer.  Bottle contains 12.5ml of phosphate buffer concentrate which 
when made up to 500ml with distilled water gives a 0.01M sodium phosphate 
buffer pH7.0 containing 0.05% Tween 20.  Tween 20 (also known as 
polysorbate 20) is a stable relatively non-toxic polysorbate surfactant used here 
as a detergent. 
The kit was stored between –15 and –30C until needed.  Kit instructions were fully 
followed as detailed including critical parameters.  Kits were equilibrated at room 
temperature, particularly the microplates, as condensation affects the performance of 
the antibody with which the plates are coated. 
MMP9 detection procedure protocol 
The assay protocol for the assay range 0.5 – 16ng/ml of MMP9 was followed (normal 
endogenous levels).  The extended detection range (for lower endogenous levels – 
0.125-4ng/ml) was occasionally used and involved more standards, and standards of a 
lower concentration than in the normal protocol. 
Day 1 reagent preparation 
Assay buffer concentrate, anti-MMP2 coated microplate, and wash buffer concentrate 
were allowed to equilibrate to room temperature before use.  Other components were 
removed from storage just before use.  Assay buffer and wash buffer were prepared 
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according to kit protocol, using distilled water.  Standard was prepared using assay 
buffer.  Both buffers were stored in a closed vessel at room temperature, and standard 
was stored on ice until needed. 
Day 1 procedure 
6 standards of known concentration of human pro-MMP9 (0.5, 1, 2, 4, 8 and 16ng/ml) 
were freshly prepared by successive dilution with assay buffer and vortex mixing.  1 
sample of assay buffer only was also prepared (‘blank’ - 0ng/ml MMP9 content).  
100l of blank, all standard concentrations and unknown samples were put in wells on 
the microplate in positions as suggested (figure above), in duplicate.  The microplate 
was covered and incubated at 2-8C overnight. 
Day 2 reagent preparation 
APMA, detection enzyme, substrate, detection reagent was prepared according to kit 
protocol.  APMA was prepared as instructed using fresh dimethylsulphoxide 
(DMSO)(in a fume cupboard, with skin and eye protection), and then diluted again to 
form the ready-to-use dilution.  Detection enzyme was stored on ice after thawing, but 
prior to use.  Substrate was also stored on ice prior to use.  Detection reagent was 
100l of detection enzyme added to the reconstituted substrate.  This was prepared 
immediately prior to addition to wells and vortex mixed.   
Day 2 procedure 
All wells were washed with wash buffer and aspirated 4 times using a microplate 
washer ensuring each well was fully filled and emptied each time.  50l of ready-to-
use APMA was pipetted into all standard wells, and wells needing the quantification of 
total MMP9.  50l of assay buffer was added to wells for quantification of active 
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MMP9 only.  The plate was then shaken and incubated at 37C for 1.5hours.  All wells 
then had 50l of detection reagent added.  The microplate was shaken in a microplate 
shaker for 20 seconds and the initial (T0) spectrophotometer reading at 405nm was 
taken.  The microplate was then covered and incubated at 37C for 1 hour, shaken and 
a subsequent spectrophotometer reading at 405nm taken (T1). 
Other kit details 
Specificity 
The assay recognises the active form of MMP9 and the total form via activation of 
pro-MMP9.  It has no substantial cross-reactivity with other MMPs or TIMPs.  Both 
pro and active MMP9/TIMP1 complexes as well as active MMP9/TIMP2 complexes 
have shown a degree of cross-reactivity in the assay.  The non-specific protease 
inhibitor 2-macroglobulin does not interfere with the assay.  
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Table 41. Cross-reactivity of MMP9 kit 
Compound % Cross-reactivity 
Pro-MMP9 100 
Activated MMP9 65.88* 
ProMMP9/TIMP1 complex 38.53 
Active MMP9/TIMP1 complex 21.64 
Active MMP9/TIMP2 complex 7.04 
MMP1 <0.1 
MMP2 <0.1 
MMP3 <0.1 
MMP8 <0.133 
TIMP1 <0.05 
TIMP2 <0.05 
MMP9 activity assay system, Amersham Biosciences, Buckinghamshire 2004.  *pre-activated MMP9 
which was pre-activated, captured & washed. Losses may have occurred during activation or activation 
may not have followed through to completion.  
Reproducibility – within-assay precision 
The within-assay precision for duplicate determination was calculated by measuring 
controls within the same assay. 
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Table 42. MMP9 kit within-assay precision 
Control Mean +/- SD % CV n 
A 6.03 +/- 0.26 4.3 10 
B 13.00 +/- 0.4 3.1 10 
C 21.15 +/- 5.11 3.4 10 
MMP9 activity assay system, Amersham Biosciences.  (mean values as ng/ml, %CV; percentage 
coefficient of variation: (sd/mean)*100) (The coefficient of variation is a way of reporting measurement 
error) 
Reproducibility – between assay precision 
This is measured by the same sample being analysed in subsequent plates. 
Table 43. MMP9 kit between assay precision 
Control Mean +/- SD % CV n 
A 3.59 +/- 0.73 20.2 10 
B 12.51 +/- 2.72 21.7 10 
C 24.75 +/- 5.11 20.7 10 
MMP9 activity assay system, Amersham Biosciences.  (mean values as ng/ml, %CV; percentage 
coefficient of variation: (sd/mean)*100) (The coefficient of variation is a way of reporting measurement 
error) 
Sensitivity 
The sensitivity was defined as 2 standard deviations above the mean optical density of 
10 zero standard replicates.  The mean zero and standard values were then used to 
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calculate the sensitivity.  This was determined as 0.5ng/ml for the 1 hour incubation 
period.   
Parallelism 
The parallelism of the kit explores the effect of dilution on the expected versus 
observed concentrations of MMP9. 
Table 44. MMP9 kit parallelism 
Sample Dilution Observed 
(ng/ml) 
Expected 
(ng/ml) 
% Observed/ 
Expected 
Cell culture 
media 
1:32 
1:64 
14.1 
9.4 
- 
7.1 
- 
132 
Heparin 
plasma 
1:16 
1:32 
1.35 
0.95 
- 
0.68 
- 
140 
Serum 1:16 
1:32 
2.72 
1.66 
- 
1.36 
- 
122 
MMP9 activity assay system, Amersham Biosciences.   
Recovery 
The recovery of the kit measured the amount of MMP9 detected after various 
preparations were spiked with additional known levels of MMP9 standard.  
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Table 45. MMP9 kit recovery 
Sample type Added 
concentration 
(ng/ml) 
Measured 
(ng/ml) 
Expected 
(ng/ml) 
Recovery (%) 
Cell culture 
medium 
0 
0.5 
1 
2 
4 
8 
0 
0.4 
0.6 
1.4 
2.9 
6.3 
- 
0.3 
0.6 
1.4 
2.9 
6.3 
- 
133 
100 
108 
112 
121 
Heparin 
plasma (1:32) 
0 
0.5 
1 
2 
4 
8 
1.0 
1.4 
1.8 
2.6 
4.3 
7.2 
- 
1.5 
2.0 
3.0 
5.0 
9.0 
- 
93.3 
90.0 
86.7 
86.0 
80.0 
Serum (1:32) 0 
0.5 
1 
1.0 
1.3 
1.6 
- 
1.5 
2.0 
- 
86.7 
80.0 
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2 
4 
8 
2.4 
4.2 
7.9 
3.0 
5.0 
9.0 
80.0 
84.0 
87.8 
MMP9 activity assay system, Amersham Biosciences.   
Expected values 
Normal human MMP9 levels in serum and plasma were measured using the assay. 
Table 46. MMP9 kit normal human levels 
Sample Mean (ng/ml) Range (ng/ml) N 
Heparin plasma 18.7 4.4-27.2 9 
Serum 43.8 - 1 
MMP9 activity assay system, Amersham Biosciences.   
8.4. TIMP1 test kit details 
Specificity 
The assay recognises total TIMP1, ie free TIMP1 and that complexed to MMPs.  The 
assay will cross react with TIMP1 in complexes with MMP1, MMP2, MMP3, and 
MMP9.  It does not cross-react with TIMP2.   
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 Cross-reactivity of TIMP1 assay with MMP1 and MMP1/TIMP1 Figure 46.
complex. Amersham Biosciences. 
 
 Non-interference of MMP1 in TIMP1 assay. Amersham Biosciences.  Figure 47.
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Reproducibility – within-assay precision 
The within-assay precision for duplicate determination was calculated by measuring 
controls within the same assay. 
Table 47. TIMP1 kit within-assay precision 
Control Mean +/- SD % CV n 
A 10.3 +/- 1.18 11.4 11 
B 23.1 +/- 2.14 9.3 11 
C 39.4 +/- 3.50 8.9 11 
TIMP1 ELISA system, Amersham Biosciences.  (mean values as ng/ml, %CV; percentage coefficient of 
variation: (sd/mean)*100) (The coefficient of variation is a way of reporting measurement error) 
Reproducibility – between assay precision 
This is measured by the same sample being analysed in subsequent plates. 
Table 48. TIMP1 kit between assay precision 
Control Mean +/- SD % CV n 
A 12.5 +/- 1.9 15.2 24 
B 24.9 +/- 3.1 12.4 24 
C 47.3 +/- 6.2 13.1 24 
TIMP1 ELISA system, Amersham Biosciences.  (mean values as ng/ml, %CV; percentage coefficient of 
variation: (sd/mean)*100) (The coefficient of variation is a way of reporting measurement error) 
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Sensitivity 
The sensitivity was defined as 2 standard deviations above the mean optical density of 
10 zero standard replicates was determined for each of 4 batches of reagents.  The 
corresponding concentration was calculated from a standard curve set up in 
quadruplicate for each batch.  The grand mean zero and standard values were then used 
to calculate the sensitivity.  This was determined as 1.25ng/ml.   
Parallelism 
The parallelism of the kit explores the effect of dilution on the expected versus 
observed concentrations of TIMP1. 
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Table 49. TIMP1 kit parallelism 
Sample Dilution Observed 
(ng/ml) 
Expected 
(ng/ml) 
% Observed/ 
Expected 
Cell culture 
media 
Neat 
1:5 
1:10 
1:20 
39.0 
9.3 
4.7 
2.8 
- 
7.8 
3.9 
1.95 
- 
119 
120 
143 
Heparin 
plasma 
1:10 
1:20 
1:40 
1:80 
10.7 
5.5 
3.4 
2.2 
- 
5.4 
2.7 
1.4 
- 
102 
126 
157 
Serum 1:10 
1:20 
1:40 
1:80 
11.0 
7.2 
4.8 
3.1 
- 
5.5 
2.8 
1.4 
- 
131 
171 
221 
TIMP1 ELISA system, Amersham Biosciences.   
Recovery 
The recovery of the kit measured the amount of TIMP1 detected after various 
preparations were spiked with additional known levels of TIMP1 standard.  
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Table 50. TIMP1 kit recovery 
Sample type Added 
concentration 
(ng/ml) 
Measured 
(ng/ml) 
Expected 
(ng/ml) 
Recovery (%) 
Cell culture 
medium (1:10) 
0 
46 
22 
11 
0.37 
40.78 
18.05 
8.40 
- 
46.37 
22.37 
11.37 
- 
88 
81 
74 
Heparin 
plasma (1:40) 
0 
46 
22 
11 
4.2 
42.4 
22.6 
13.7 
- 
50.0 
26.2 
15.2 
- 
85 
86 
90 
Serum (1:40) 0 
46 
22 
11 
5.0 
41.9 
22.2 
13.6 
- 
51.0 
27.0 
16.0 
- 
82 
82 
85 
TIMP1 ELISA system, Amersham Biosciences.   
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8.5. TIMP2 test kit details 
Specificity 
The assay recognises free TIMP2, and TIMP2 complexed with active MMPs, but not 
TIMP2 complexed with pro-MMP2.  The immunoreactivity is shown in the table 
below. 
Table 51. Immunoreactivity of TIMP2 ELISA system 
Form Immunoreactivity (%) 
Free TIMP2 100 
TIMP2 / proMMP2 ~5 
TIMP2 / active MMP1 330 
TIMP2 / active MMP2 450 
TIMP2 / active MMP3 105 
TIMP2 / active MMP7 100 
TIMP2 / active MMP8 ~33 
TIMP2 / active MMP9 300 
TIMP2 ELISA system. Amersham Biosciences. 
The cross-reactivity of the ELISA system with other TIMPs is as detailed in the table 
below. 
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Table 52. Specificity towards TIMPs (TIMP2 ELISA system) 
Standard (ng/ml) TIMP2 TIMP1 TIMP3 
0 0.036 0.036 0.036 
8 0.087 0.049 0.049 
16 0.142 0.043 0.045 
32 0.352 0.040 0.029 
64 1.145 0.041 0.028 
128 3.576 0.034 0.024 
TIMP2 ELISA system. Amersham Biosciences. (values as optical density) 
The assay also detects TIMP2 from other species including mouse, rat, guinea pig, 
rabbit, and calf.  The immunoreactivity between human and rat purified TIMP2 is 
equivalent. 
Reproducibility – within-assay precision 
The within-assay precision for duplicate determination was calculated by measuring 
controls within the same assay. 
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Table 53. TIMP2 kit within-assay precision 
Control Mean +/- SD % CV n 
A 16.3 +/- 0.88 5.4 12 
B 31.6 +/- 1.10 3.5 12 
C 50.9 +/- 1.36 2.8 12 
TIMP2 ELISA system, Amersham Biosciences.  (mean values as ng/ml, %CV; percentage coefficient of 
variation: (sd/mean)*100) (The coefficient of variation is a way of reporting measurement error) 
Reproducibility – between assay precision 
This is measured by the same sample being analysed in subsequent plates. 
Table 54. TIMP2 kit between assay precision 
Control Mean +/- SD % CV n 
A 16.0 +/- 0.94 5.9 12 
B 29.5 +/- 1.76 6.0 12 
C 50.1 +/- 1.25 2.5 12 
TIMP2 ELISA system, Amersham Biosciences.  (mean values as ng/ml, %CV; percentage coefficient of 
variation: (sd/mean)*100) (The coefficient of variation is a way of reporting measurement error) 
Sensitivity 
The sensitivity was defined as 2 standard deviations above the mean optical density of 
20 zero standard replicates was determined.  The corresponding concentration was 
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calculated from a standard curve.  The mean zero and standard values were then used 
to calculate the sensitivity.  This was determined as 3.0ng/ml.   
Parallelism 
The parallelism of the kit explores the effect of dilution on the expected versus 
observed concentrations of TIMP2. 
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Table 55. TIMP2 kit parallelism 
Sample Dilution Observed 
(ng/ml) 
Expected 
(ng/ml) 
% Observed/ 
Expected 
Cell culture 
media 
1:2 
1:4 
1:8 
1:16 
109 
53.8 
27.3 
15.8 
- 
54.5 
27.3 
13.6 
- 
98.7 
100 
116 
EDTA plasma 1:2 
1:4 
1:8 
1:16 
104 
57.8 
28.1 
14.3 
- 
52.0 
26.0 
13.0 
- 
111 
108 
110 
Serum 1:4 
1:8 
1:16 
1:32 
91.9 
48.3 
25.7 
13.5 
- 
46.0 
23.0 
11.5 
- 
105 
112 
118 
TIMP2 ELISA system, Amersham Biosciences.   
Recovery 
The recovery of the kit measured the amount of TIMP2 detected after various 
preparations were spiked with additional known levels of TIMP2 standard.  
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Table 56. TIMP2 kit recovery 
Sample type Added 
concentration 
(ng/ml) 
Measured 
(ng/ml) 
Expected 
(ng/ml) 
Recovery (%) 
Cell culture 
medium 
0 
8 
16 
32 
64 
49.0 
59.6 
66.2 
85.0 
118 
- 
57.0 
65.0 
81.0 
113 
- 
105 
102 
105 
104 
Heparin 
plasma 
0 
8 
16 
32 
64 
50.4 
60.9 
65.8 
90.3 
117 
- 
58.4 
66.4 
82.4 
114 
- 
104 
99.1 
110 
102 
Heparin 
plasma 
0 
8 
16 
32 
64 
17.3 
22.6 
31.9 
47.4 
88.8 
- 
25.3 
33.3 
49.3 
81.3 
- 
89.3 
95.8 
96.1 
109 
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Serum 0 
8 
16 
32 
64 
49.5 
58.5 
67.1 
82.7 
118 
- 
57.5 
65.5 
81.5 
114 
- 
102 
102 
101 
104 
Serum 0 
8 
16 
32 
64 
20.1 
26.3 
35.1 
52.1 
88.2 
- 
28.1 
36.1 
52.1 
84.1 
- 
93.6 
97.2 
100 
105 
TIMP2 ELISA system, Amersham Biosciences. 
Expected values 
Normal serum and plasma samples were evaluated in the assay. 
Table 57. Normal levels of TIMP2 
Sample Mean (ng/ml) Range (ng/ml) n 
Plasma (EDTA) 50 21-108 40 
Serum 56 29-108 127 
TIMP2 ELISA system, Amersham Biosciences. 
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8.6. Protein concentration test kit details 
Typical standard curve 
 
 Coomassie plus reagent typical standard curve (Piercenet.com) Figure 48.
MD Thesis  MST Heng 309 
Compatible substances 
Table 58. Compatible substances with Coomassie plus reagent 
 
Pierce, Rockford, IL, USA (Piercenet.com) 
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Protein to protein variation 
Table 59. Protein-to-protein variation  
 
Absorbance at 595nm relative to BSA (Bovine serum albumin) with standard test tube protocol with 
Coomassie plus (Pierce, Rockford, IL, USA) 
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